Retrieve available abstracts of 1298 articles: HTML format
Single Articles
July 2025
MARANGOU J, Beaton A, Fulurija A, Carapetis J, et al Cardiac monitoring safety assessment framework for early phase group a
streptococcal vaccine trials.
Vaccine. 2025;60:127334. PubMedAbstract available
NJOH AA, Dinga JN, Kongnyuy EJ, Ndoula TS, et al Malaria vaccine acceptance and associated factors in cameroon: A nationwide
cross-sectional survey.
Vaccine. 2025;60:127323. PubMedAbstract available
STOUTEN V, Van Evercooren I, Vernemmen C, Braeye T, et al Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023.
Vaccine. 2025;60:127290. PubMedAbstract available
PIAL RH, Capeding MR, Song KR, Park EL, et al Immune persistence after 5 years of vaccination by Vi-DT vaccine among children
below 2 years: Result from long-term observational study.
Vaccine. 2025;60:127304. PubMedAbstract available
LI H, Zhang J, Guo R, Li J, et al Immunogenicity evaluation of a recombinant pseudorabies virus co-expressing PCV2
and PCV3 capsid proteins in mice and piglets.
Vaccine. 2025;60:127307. PubMedAbstract available
June 2025
YI Z, Owusu-Edusei K, Elbasha EH Economic evaluation of PCV21 in PCV-naive adults aged 50-64 years in the United
States.
Vaccine. 2025;59:127264. PubMedAbstract available
ESPARZA J The illness of empress Maria Theresa as a trigger for the adoption of variolation
in Austria (1768).
Vaccine. 2025;58:127253. PubMedAbstract available
CHAIWONG W, Takheaw N, Laopajon W, Nisoong C, et al Low-dose intradermal mRNA-1273 boosting vaccine following BBiBP-CorV vaccination
during the omicron pandemics.
Vaccine. 2025;61:127330. PubMedAbstract available
ROUX K, Roux F, Burns S, Guy R, et al Effective strategies in human papillomavirus (HPV) vaccination interventions to
increase uptake in rural, low socioeconomic, indigenous and migrant populations:
A scoping review.
Vaccine. 2025;61:127359. PubMedAbstract available
MOHAMMADI S, Sisay MM, Saraswati PW, Osman AK, et al COVID-19 vaccine safety studies among special populations: A systematic review
and meta-analysis of 120 observational studies and randomized clinical trials.
Vaccine. 2025;61:127342. PubMedAbstract available
COSTELLO LM, Kerns EK, McCulloh RJ, Roberts JR, et al Hesitancy and confidence in pediatric COVID-19 vaccination among diverse
caregivers of unvaccinated children.
Vaccine. 2025;61:127245. PubMedAbstract available
KIM C, Lee D, Oh YW, Jung SJ, et al Association between parental and child influenza vaccination: A national health
survey analysis.
Vaccine. 2025;61:127345. PubMedAbstract available
KOBAYASHI K, Masuda K, Wu JT, Lin L, et al Impact of digital communication message on HPV vaccine decision-making among
Japanese mothers: A randomized controlled trial.
Vaccine. 2025;61:127327. PubMedAbstract available
HALONEN A, Fan HSL, Masina S, Chooniedass R, et al Understanding COVID-19 vaccine hesitancy during parenthood in British Columbia.
Vaccine. 2025;61:127305. PubMedAbstract available
HU XX, Qin ZZ, Mo ZY, Wang R, et al Timeliness and completeness of serial routine vaccinations among 8062 rural
children in southwest China during the COVID-19 pandemic: A multi-stage
stratified cluster sampling survey in 1094 villages.
Vaccine. 2025;61:127346. PubMedAbstract available
ANASTASSOPOULOU C, Panagiotopoulos AP, Ferous S, Poland GA, et al RSV vaccines and Guillain-Barre syndrome: Insights into an emerging concern.
Vaccine. 2025;61:127338. PubMedAbstract available
AKTHER A, Laurie C, Elton-Marshall T, Ly V, et al Healthcare workers' current practices, knowledge/awareness, barriers, and
attitudes/perceptions related to pneumococcal vaccination of older adults: A
mixed-methods systematic review.
Vaccine. 2025;61:127331. PubMedAbstract available
JOLFAYI AG, Alipour S, Aminizadeh S, Yaghoubi SM, et al Dendritic cell-based vaccines, a promising prospect for ending AIDS and
eradication of HIV worldwide: A narrative review on the latest updates.
Vaccine. 2025;61:127340. PubMedAbstract available
WAN JIA AARON H, Yuan R, Chan SCS Socio-demographic and behavioral predictors of multiple-dose COVID-19 vaccine
uptake among older adults in Hong Kong: A community-based cross-sectional study
of the generations connect project.
Vaccine. 2025;61:127308. PubMedAbstract available
May 2025
NG YF, Lockhart K, Dawar M, Vigor D, et al Assessing measles immunity among healthcare workers, a systematic review of
peer-reviewed literature (2013-2023). Where do we go from here?
Vaccine. 2025;57:127214. PubMedAbstract available
STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort
study.
Vaccine. 2025;57:127232. PubMedAbstract available
SIDORENKO SV, Rennert W, Zhdanov KV, Lobzin YV, et al Serotype dynamics of Streptococcus pneumoniae in some countries in Eastern Europe
and Central Asia.
Vaccine. 2025;57:127213. PubMedAbstract available
LIEN SB, Yang QW, Huang HW, Chiu KC, et al A novel immunogen comprising a bc loop and mutant fusion loop epitopes generates
potent neutralization and protective abilities against flaviviruses without risk
of disease enhancement.
Vaccine. 2025;57:127219. PubMedAbstract available
BREWER NT, Rockwell EM, Tomar A, Fisher EB, et al Covid-19 vaccine incentives' effectiveness and differential impact on high-risk
groups: A prospective cohort study.
Vaccine. 2025;61:127302. PubMedAbstract available
SAYEM ASM, Musuka G, Atuhebwe PL, Dadari I, et al Childhood vaccination catch-up and recovery plans for mitigating immunity gap
post the COVID-19 pandemic: A case study of selected African countries.
Vaccine. 2025;61:127328. PubMedAbstract available
HARTON PE, Chamberlain AT, Moore A, Fletcher G, et al Estimating COVID-19 vaccine effectiveness among children and adolescents using
data from a school-based weekly COVID-19 testing program.
Vaccine. 2025;61:127292. PubMedAbstract available
COBELENS F, Pelzer PT, Churchyard GJ, Garcia-Basteiro A, et al Sample size efficiency of restricting participation in tuberculosis vaccine
trials to interferon-gamma release assay-positive participants.
Vaccine. 2025;61:127301. PubMedAbstract available
DAVE E, Culhane JF, Lundsberg LS, Partridge C, et al Trends in Tdap and influenza vaccination in pregnancy relative to the coronavirus
disease-19 pandemic.
Vaccine. 2025;61:127329. PubMedAbstract available
YADAV G, Dandu H, Malhotra HS, Jain A, et al COVID-19 vaccination and utility of booster dose: A community-based
cross-sectional study.
Vaccine. 2025;60:127325. PubMedAbstract available
HUNG CT, Wang LM, Liu DC National trends and disparities in herpes zoster vaccination coverage among U.S.
older adults with cancer, 2008-2023.
Vaccine. 2025;60:127326. PubMedAbstract available
NASREEN S, Jiang Y, Lu H, Lee A, et al Risk of Guillain-Barre syndrome after COVID-19 vaccination or SARS-CoV-2
infection: A multinational self-controlled case series study.
Vaccine. 2025;60:127291. PubMedAbstract available
ESCOBAR-ZIEDE P, Borras-Bermejo B, Pinos-Tella L, Vivet-Escale M, et al Real-world effectiveness of MBA-VN vaccine against mpox, a test-negative
case-control study.
Vaccine. 2025;59:127295. PubMedAbstract available
ABE M, Shinmura Y, Tokieda Y, Mitsuhiro Y, et al A phase I, randomized, placebo-controlled, double-blind, ascending-dose and
single-center study to evaluate immunogenicity and safety of a live attenuated
tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naive healthy adults.
Vaccine. 2025;60:127313. PubMedAbstract available
ABU-RAYA B, Giles ML, Kollmann T Co-administration of vaccines in pregnancy: unique challenges and knowledge gaps.
Vaccine. 2025;60:127309. PubMedAbstract available
SEILER P, Kaplan BS, Brice DC, Duan S, et al Altered germinal center responses in mice vaccinated with highly pathogenic avian
influenza A(H5N1) virus.
Vaccine. 2025;60:127311. PubMedAbstract available
BHATIA D, Crowcroft N, Antoni S, Danovaro-Holliday MC, et al Prediction of subnational-level vaccination coverage estimates using routine
surveillance data and survey data.
Vaccine. 2025;60:127277. PubMedAbstract available
SENPUKU K, Kunishima Y, Taniguchi K, Ito T, et al Development and characterization of MRC-5 and Vero cell-adapted enterovirus D68
strains for vaccine production.
Vaccine. 2025;60:127314. PubMedAbstract available
LEE N, Nguyen L, Nasreen S, Austin PC, et al Limited durability of protection conferred by XBB.1.5 vaccines against
omicron-associated severe outcomes among community-dwelling adults, Ontario,
Canada.
Vaccine. 2025;60:127300. PubMedAbstract available
KATSEFF AS, Toumanios C, Barahim E, McCormick AA, et al PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates
protection from Pseudomonas aeruginosa via an early Th1/Th17 skewed localized and
systemic immune response.
Vaccine. 2025;60:127306. PubMedAbstract available
DEVKOTA B, Lal BK, Gautam A, Poudel L, et al Nationwide rollout of HPV vaccination in Nepal: Early key insights.
Vaccine. 2025;60:127312. PubMed
KROEGER M, Fano E, Sponheim A, Schwartz KJ, et al Assessment of homologous and heterologous PCV2 vaccine efficacy in a PCV2d/PRRSV
co-challenge model.
Vaccine. 2025;60:127303. PubMedAbstract available
MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al Influenza vaccination during early pregnancy and risk of major birth defects, US
Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
Vaccine. 2025;59:127297. PubMedAbstract available
ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al Understanding the shift in COVID-19 vaccine hesitancy and its associated factors
for primary and booster doses among university students: A cross-sectional study.
Vaccine. 2025;59:127296. PubMedAbstract available
LI M, Cai W, Chandrasekhar A, Hu H, et al Factors associated with primary care providers' recommendation of HPV vaccination
for adolescent males in China: A mixed-methods study.
Vaccine. 2025;59:127299. PubMedAbstract available
LAI SW, Liao KF Breakthrough herpes zoster risk after recombinant zoster vaccination.
Vaccine. 2025 May 23:127294. doi: 10.1016/j.vaccine.2025.127294. PubMed
BAKHT P, Hussain A, Pandey S, Pathania R, et al Live attenuated hfq-deleted Acinetobacter baumannii vaccine provides protection
against systemic infection.
Vaccine. 2025;59:127298. PubMedAbstract available
MOHAMED Y, Luey E, Kata ', Tukia O, et al "The only vaccine that we really question is the new vaccine": A qualitative
exploration of the social and behavioural drivers of human papillomavirus (HPV)
vaccination in Tonga.
Vaccine. 2025;59:127280. PubMedAbstract available
RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al Immunogenicity and adverse effects of pneumococcal vaccines co-administered with
influenza or SARS-CoV-2 vaccines in adults: A systematic review and
Meta-analysis.
Vaccine. 2025;59:127293. PubMedAbstract available
SHAHI N, Singh B, Pande A, Chandra S, et al Safe and efficacious inactivated immersion vaccine against KG+ phenotype of
emerging bacterial pathogen Lactococcus garvieae for early developmental stage of
rainbow trout (Oncorhynchus mykiss) in India.
Vaccine. 2025;59:127266. PubMedAbstract available
KIBETI DM, Hoff NA, Merritt S, Lulebo AM, et al Quality and usability of home-based record photos to assess vaccine coverage: A
case study from the 2022 Democratic Republic of the Congo Vaccine Coverage
Survey.
Vaccine. 2025;59:127248. PubMedAbstract available
GANDHI K, Vijay Y, Page K, Dahari H, et al Challenges in coverage of future hepatitis C vaccines: Review and potential
solutions.
Vaccine. 2025;59:127256. PubMedAbstract available
SURI RK, Maugeais D, Maithal K COVID-19 pandemic: A multidimensional analysis and the strategic role played by
developing countries vaccine manufacturers.
Vaccine. 2025;59:127271. PubMedAbstract available
GIANNINI F, Hogan AB, Cameron E, Le H, et al Estimating the impact of Western Australia's first respiratory syncytial virus
immunisation program for all infants: A mathematical modelling study.
Vaccine. 2025;56:127155. PubMedAbstract available
MANDVIWALA AS, Munje AK, Huckriede ALW, Arankalle VA, et al Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based
virus-like-particles consisting of G and M proteins in mice.
Vaccine. 2025;56:127203. PubMedAbstract available
KISLAYA I, Caserta M, Faye SLB, Dia OK, et al Evaluating the effects of a multisectoral dialogue-based COVID-19
awareness-raising intervention in a limited-resource setting: A
quasi-experimental study in Senegal.
Vaccine. 2025;56:127168. PubMedAbstract available
ISLAM MD, Islam MM, Inoue A, Yesmin S, et al Neutralizing antibodies against the Japanese encephalitis virus are produced by a
12 kDa E. coli- expressed envelope protein domain III (EDIII) tagged with a
solubility-controlling peptide.
Vaccine. 2025;56:127143. PubMedAbstract available
XU P, Lu J, Chen L, Chen X, et al Development of a chicken egg yolk antibody (IgY) could effectively prevent and
treat goose astrovirus infection.
Vaccine. 2025;56:127167. PubMedAbstract available
HASAN Z, Masood KI, Qaiser S, Kanji A, et al Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by
different COVID-19 vaccine types: Insights into protection against wildtype,
Delta and JN.1 omicron strains.
Vaccine. 2025;59:127270. PubMedAbstract available
KEUTLER A, Lainka E, Hudert C, Bufler P, et al Safety and immunogenicity of the measles-mumps-rubella vaccine in
immunocompromised children with inflammatory bowel disease, or after liver
transplantation: An observational study.
Vaccine. 2025;59:127288. PubMedAbstract available
TIAN X, Zhou Y, Deng P, Xu N, et al Effectiveness and safety of a novel intranasal influenza vaccine in Chinese
children: A phase IV multi-Center, randomized, double-blind, placebo-controlled
clinical trial.
Vaccine. 2025;59:127268. PubMedAbstract available
QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake
Using the National Healthcare data System.
Vaccine. 2025;58:127223. PubMedAbstract available
FITZPATRICK T, Yamoah P, Summerby-Murray D, Cowan J, et al Neurological adverse events following COVID-19 vaccination among Canadians
referred to the special immunization clinic network.
Vaccine. 2025;59:127254. PubMedAbstract available
BUSSINK-VOOREND D, Hulscher MEJL, Akkermans R, Krom A, et al Vaccine hesitancy among Dutch parents of newborn children and its associated
characteristics, values and uptake of vaccines.
Vaccine. 2025;59:127244. PubMedAbstract available
NHAM E, Song JY, Sohn JW, Choi WS, et al Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis
over nine months.
Vaccine. 2025;59:127275. PubMedAbstract available
SCHAFFER AL, Hulme WJ, Horne E, Parker EPK, et al Effect of the 2022 COVID-19 booster vaccination campaign in people aged 50 years
in England: Regression discontinuity analysis in OpenSAFELY-TPP.
Vaccine. 2025;59:127257. PubMedAbstract available
MYBURGH L, van Loon K, Huijbers EJM, van Beijnum JR, et al Guided design for the development of an evolution-proof influenza vaccine.
Vaccine. 2025;59:127281. PubMedAbstract available
HATTORI F, Higashimoto Y, Miura H, Kawamura Y, et al Epidemiology and clinical features of breakthrough varicella in the 9 years after
universal vaccination began in Japan.
Vaccine. 2025;59:127274. PubMedAbstract available
FURUSE Y, Tabuchi T Impact of COVID-19 vaccination by implementation timing and coverage rate in
relation to misinformation prevalence in Japan.
Vaccine. 2025;59:127273. PubMedAbstract available
LIAW K, Konrath KM, Trachtman AR, Tursi NJ, et al DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with
chemokine adjuvant CTACK induces potent immunogenicity for heterologous
protection in vivo.
Vaccine. 2025;59:127231. PubMedAbstract available
MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al Routine vaccination rates globally: A continuing and alarming situation.
Vaccine. 2025;59:127269. PubMed
SOARES LMC, de Medonca AEO, de Souza DLB, Carvalho AV, et al Factors associated with HPV vaccine hesitancy: A nationally representative
cross-sectional study.
Vaccine. 2025;59:127278. PubMedAbstract available
LUPTON D, Whitten T, Tay AK, Beek K, et al Mental health and psychosocial factors predicting concerns about the COVID-19
vaccine among refugee background and Australian-born women.
Vaccine. 2025;58:127251. PubMedAbstract available
NUNEZ IA, Ross TM Corrigendum to "Human COBRA 2 vaccine contains two major epitopes that are
responsible for eliciting neutralizing antibody responses against heterologous
clades of viruses" [Vaccine 38 (4) (2020) 830-839].
Vaccine. 2025;58:127205. PubMed
AVERIN A, Quinn E, Atwood M, Weycker D, et al Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF)
maternal vaccine among infants in the United States.
Vaccine. 2025;58:127191. PubMedAbstract available
SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al Establishment of a novel adjuvant screening system for the development of
intranasal vaccine adjuvants.
Vaccine. 2025;58:127267. PubMedAbstract available
NIINIKOSKI V, Barkoff AM, Mertsola J, Holubova J, et al Alterations in the expression of Bordetella pertussis antigens in relation to the
use of acellular pertussis vaccine in Finland.
Vaccine. 2025;58:127279. PubMedAbstract available
EINARSON TA, Musana E, Balonde J, Lorentzen KB, et al Corrigendum to "Human papillomavirus awareness, vaccination rate, and
sociodemographic covariates of vaccination status in a low-income country: A
cross-sectional study in the rural Busoga region of Uganda" [Vaccine 53 (2025)
127089].
Vaccine. 2025;58:127204. PubMed
HUNG SH, Torres JL, Chen F, Giang E, et al Antigenic and EM characterization of the Chiron experimental hepatitis C virus
vaccine.
Vaccine. 2025;58:127239. PubMedAbstract available
BUHL E, Vedel JO, Nanque LM, Correia C, et al Does timing of the Bacillus Calmette-Guerin vaccine affect weight in children
under the age of 5 years? An observational study in Guinea-Bissau.
Vaccine. 2025;58:127246. PubMedAbstract available
SOBLE A, Malhame M, Malvolti S, Mantel C, et al Identification and sizing of the current use cases for seasonal influenza
vaccines.
Vaccine. 2025 May 15:127233. doi: 10.1016/j.vaccine.2025.127233. PubMedAbstract available
MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al Childhood vaccine hesitancy: The power of metaphors.
Vaccine. 2025;58:127221. PubMedAbstract available
PATTYN J, Hanning N, Valckx S, Claessens T, et al Investigating the state of vaccine confidence among the general public and
parents with children up to 13 years in Flanders (Belgium).
Vaccine. 2025;58:127250. PubMedAbstract available
MERRITT A, Bansal S Prison Vaccination in a pandemic: Geographic disparities and policy insights.
Vaccine. 2025;58:127218. PubMedAbstract available
ELLIS JT, Kennedy PJ Multi-criteria decision making and its application to in silico discovery of
vaccine candidates for Toxoplasma gondii.
Vaccine. 2025;58:127242. PubMedAbstract available
VARMA A, Bolotin S, De Serres G, Didierlaurent AM, et al What is the current evidence base for measles vaccination earlier than 9 months
of age?: Report from an informal technical consultation of the World Health
Organization.
Vaccine. 2025;57:127187. PubMedAbstract available
KUMARI M, Su SC, Lin HT, Ko SH, et al Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with
modified key residue.
Vaccine. 2025;57:127216. PubMedAbstract available
PEARCE A, Henery P, Dundas R, Katikireddi SV, et al Socio-economic inequalities in uptake and timing of childhood vaccination: Taking
a life course approach in an administrative cohort in Scotland.
Vaccine. 2025;57:127222. PubMedAbstract available
MOU J, LaSalle G, Pflugeisen C, Sherls-Jones J, et al Practice, beliefs and intent in influenza vaccination among Hispanic patients
during the pandemic: An interventional study.
Vaccine. 2025;58:127207. PubMedAbstract available
LE DOARE K, Benassi V, Cavaleri M, Enwere G, et al Clinical and regulatory development strategies for GBS vaccines intended for
maternal immunisation in low- and middle-income countries.
Vaccine. 2025;58:127131. PubMedAbstract available
SPURGERS K, Wynn M, Charles L, Hamm S, et al A Brighton Collaboration standardized template with key considerations for a
benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral
vector vaccine for Lassa fever.
Vaccine. 2025;58:127137. PubMedAbstract available
WANG-LU H, Valerio Mendoza OM, Chen S, Geldsetzer P, et al Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.
Vaccine. 2025;58:127179. PubMedAbstract available
GELLERT FR, Gonzalez C, Mokdad AH Bridging the gap: A mixed-methods analysis of Canadian and U.S. immunization
programs for enhancing racial equity in childhood vaccinations.
Vaccine. 2025;57:127249. PubMedAbstract available
ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients
with severe respiratory illness (SRI): Findings from the COVID-19 vaccine
effectiveness evaluation in Kenya and Mali, 2022-2023.
Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234. PubMedAbstract available
PATRICK E, Iuliano A, Bakare D, Salako J, et al Non-specific effects of routine vaccinations on child survival between
12-59 months of age in Jigawa, Nigeria: A secondary analysis of the INSPIRING
Jigawa trial.
Vaccine. 2025;57:127211. PubMedAbstract available
NAVARRETE JAY, Rodriguez D, Kanno AI, de Cerqueira Leite LC, et al Modulation of immune responses induced by recombinant BCG expressing LTAK63
adjuvant in an immunotherapeutic model vaccine.
Vaccine. 2025;57:127215. PubMedAbstract available
NTAKIYISUMBA E, Tanveer M, Won G A comprehensive analysis of the current strategy for developing live attenuated
vaccines against African swine fever: A systematic review and meta-analysis.
Vaccine. 2025;57:127243. PubMedAbstract available
CARTER DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, et al Corrigendum to "Cross-protection against H7N9 influenza strains using a
live-attenuated H7N3 virus vaccine" [Vaccine (2015) 33(1) 108-16].
Vaccine. 2025;57:127174. PubMed
SAXTON P, Hollingshead BM, Rich J, Saini S, et al Mpox vaccine eligibility, uptake and coverage among gay, bisexual and other men
who have sex with men in Aotearoa New Zealand.
Vaccine. 2025;57:127247. PubMedAbstract available
HU J, Cao H, Luan N, Zhang X, et al Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no
effect on vaccine immunogenicity.
Vaccine. 2025;57:127241. PubMedAbstract available
ANGULO M, Ramos-Vega A, Angulo C Trained immunity-based Adjuvated vaccines (TIbAV) approach: beta-glucans as example.
Vaccine. 2025;57:127240. PubMedAbstract available
MACLENNAN CA, Cunningham AF, Dean JE, Pope S, et al BactiVac, the Bacterial Vaccines Network.
Vaccine. 2025;57:127210. PubMedAbstract available
XIONG Y, Wu C, Zhang Y, Guo D, et al Can levels of HPV vaccine knowledge mitigate HPV vaccine hesitation among
guardians of children aged 9-14 years? A moderated mediation model.
Vaccine. 2025;57:127208. PubMedAbstract available
MEESTERS K, Sadarangani M, Clark SA, Borrow R, et al Characterization of Canadian Neisseria meningitidis serogroup B isolates and
factor-H binding protein expression, data from the Canadian Immunization
Monitoring Program Active (IMPACT), 2013-2020.
Vaccine. 2025;55:127030. PubMedAbstract available
GAGNON D, Gubany C, Ouakki M, Malo B, et al Factors influencing acceptance of RSV immunization for newborns among pregnant
individuals: A mixed-methods study.
Vaccine. 2025;55:127062. PubMedAbstract available
SOTO-NOGUERON A, Carnalla-Barajas MN, Sanchez-Gonzalez G, Solorzano-Santos F, et al Distribution of pneumococcal serotypes causing invasive and non-invasive diseases
in children in Mexico after introduction of PCV13 (2012-2023). Results from the
GIVEBPVac group.
Vaccine. 2025;55:127031. PubMedAbstract available
XIE F, Du K, Li J, Zhong S, et al Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in
Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
Vaccine. 2025;55:127015. PubMedAbstract available
PUTZ EJ, Andreasen CB, Stasko JA, Hamond C, et al Circulating foamy macrophages and other features of bacillus Calmette-Guerin
challenge in Golden Syrian hamsters.
Vaccine. 2025;55:127037. PubMedAbstract available
HAO T, Ryan GE, Lydeamore MJ, Cromer D, et al Predicting immune protection against outcomes of infectious disease from
population-level effectiveness data with application to COVID-19.
Vaccine. 2025;55:126987. PubMedAbstract available
KIM GL, Pyo SW, Kim SH, Song HJ, et al Serological correlates of protection and long-term efficacy of a novel
recombinant protective antigen-based anthrax vaccine in a rabbit model.
Vaccine. 2025;57:127212. PubMedAbstract available
ADAME BJ, Corman SR, Von Feldt PA, Meneses CM, et al Reactance as a cause of COVID-19 vaccination hesitancy.
Vaccine. 2025;57:127209. PubMedAbstract available
ROULEAU I, Issa Kana KDN, Zafack JG, Viger YB, et al New-onset anesthesia/paresthesia following the administration of COVID-19
vaccines in Quebec, Canada.
Vaccine. 2025;57:127217. PubMedAbstract available
GEORGIADIS N, Katsimpris A, Tzanakaki G, Tsiodras S, et al Cross-protection of meningococcal B vaccines against gonorrhea: A systematic
review and Meta-analysis.
Vaccine. 2025;56:127180. PubMedAbstract available
MASHAMBA M, Msibi T, Tshabalala G, Tsotetsi L, et al Factors influencing influenza vaccine uptake among adults in Johannesburg, South
Africa: A qualitative study.
Vaccine. 2025;57:127133. PubMedAbstract available
RAHA JR, Kim KH, Le CTT, Bhatnagar N, et al Intranasal vaccination with multi-neuraminidase and M2e virus-like particle
vaccine results in greater mucosal immunity and protection against influenza than
intramuscular injection.
Vaccine. 2025;57:127206. PubMedAbstract available
GUMASING MJJ Rebuilding Public Trust: Factors Influencing Dengue Vaccine Uptake in the
Aftermath of the Dengvaxia Controversy in the Philippines: A Partial Least
Structural Equation Modeling Approach.
Vaccine. 2025;57:127220. PubMedAbstract available
VIETHS S, Waibler Z, Schumann GG Opting for the appropriate methodology for quantification of residual DNA
impurities in mRNA vaccines.
Vaccine. 2025;56:127186. PubMed
SZONDY I, Lorincz K, Walter A, Mohammed AA, et al Evaluating cross-protection: Meningococcal vaccines show effectiveness in
gonorrhoea prevention - A systematic review and meta-analysis.
Vaccine. 2025;56:127188. PubMedAbstract available
PADRON-REGALADO E, Escudero Gonzalez NA, Del Carmen Selvera HN Morbidity of viral vaccine preventable diseases in the Mexican states bordering
the U.S., 2014-2023.
Vaccine. 2025;56:127192. PubMedAbstract available
ASHRAF U, Lee A, Gao Q, Gonzalez JC, et al Impact of age and prior COVID-19 on the response to influenza a components in the
2020-2021 Fluzone vaccine.
Vaccine. 2025;56:127171. PubMedAbstract available
BOUADDI O, Khalis M, Abdellatifi M, Seedat F, et al Behavioural and social drivers of vaccination among child and adult migrants in
Morocco: A qualitative interview study.
Vaccine. 2025;56:127166. PubMedAbstract available
PITTER JG, Mihajlovic J, Nagy D, van der Schans J, et al Underreported influenza mortality in Central and Eastern Europe hinders the
extension of seasonal influenza vaccination programs in older adults.
Vaccine. 2025;56:127184. PubMedAbstract available
ANNEQUIN M, Mora M, Fressard L, Cogordan C, et al The relationship between men who have sex with men on PrEP and care providers is
essential for HPV vaccination: A mixed-methods study in France.
Vaccine. 2025;56:127190. PubMedAbstract available
ALGREN MH, Timmermann A, Valentiner-Branth P, Thygesen LC, et al Comparing Risk Behaviour among 14,614 Human Papillomavirus Vaccinated and
Unvaccinated Danish Young Women.
Vaccine. 2025;56:127202. PubMedAbstract available
SEFAT KMSR, Kulkarni R, Trinh J, Leekha A, et al Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV
(respiratory syncytial virus) replication in cotton rats.
Vaccine. 2025;56:127183. PubMedAbstract available
ZHANG Z, Yildirim M, Keskinocak P, Dasthagirisaheb YBS, et al Serotype specific pneumococcal vaccine effectiveness in children with sickle cell
disease: A two-decade analysis.
Vaccine. 2025;56:127193. PubMedAbstract available
WHELDRAKE K, Sisnowski J, AHoure M, Anagnostou N, et al Surveillance of adverse events following immunisation with meningococcal B
vaccine (4CMenB), South Australia, 2018-2022.
Vaccine. 2025;56:127158. PubMedAbstract available
CHAN YT, Chair SY, Gao RT, Ng MH, et al Effect of vaccine education intervention on vaccine uptake and vaccine knowledge
among older adults: A systematic review with meta-analysis.
Vaccine. 2025;56:127182. PubMedAbstract available
IBARZ-PAVON AB, Bielsky MC, Bose R, Cavaleri M, et al Consultation report - considerations for a regulatory pathway for bivalent
Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.
Vaccine. 2025;56:127189. PubMedAbstract available
AKMATOVA R, Otorbaeva D, Ebama MS Impact of the COVID-19 pandemic on influenza knowledge, attitudes, and
vaccination practices in at-risk groups in the Kyrgyz Republic: A comparative
study.
Vaccine. 2025;56:127159. PubMedAbstract available
OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al Corrigendum to "Post-introduction evaluation (PIE) of the seasonal influenza
vaccination program in Kyrgyzstan in 2023" Vaccine 55 (2025) 127052.
Vaccine. 2025;56:127123. PubMed
BADZI CD, Modey E, Apreku A, Guure C, et al Factors influencing COVID-19 vaccine uptake among pregnant women in Greater Accra
Region, Ghana.
Vaccine. 2025 May 1:127073. doi: 10.1016/j.vaccine.2025.127073. PubMedAbstract available
KANESHITA S, Chambers CD, Johnson D, Kavanaugh A, et al Short-term side effects following COVID-19 vaccination in pregnancies complicated
by autoimmune inflammatory rheumatic diseases: A prospective cohort study.
Vaccine. 2025;56:127194. PubMedAbstract available
April 2025
MOTTA M, Callaghan T, Ross JC, Gargano L, et al Promoting RSV vaccine confidence through reversal narrative (RN) messaging.
Vaccine. 2025;56:127178. PubMedAbstract available
PAUL MJ, Hudda MT, Pallett S, Groppelli E, et al Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination.
Vaccine. 2025;56:127175. PubMedAbstract available
WAN J, Wu M, Zhu Z, Liu X, et al Vaccination of a CdrA fragment conferred protection against Pseudomonas
aeruginosa in wound infection via inhibition of biofilm formation.
Vaccine. 2025;56:127185. PubMedAbstract available
ZHENG F, Zhu M, Ran H, He J, et al Assessment of recombinant Lactobacillus vector-based expressing IFITM3 protein
anti-PRV infection in mice.
Vaccine. 2025;54:127093. PubMedAbstract available
JAROVSKY D, Cereda RF, Figueiredo LM, Berezin EN, et al Epidemiology and clinical burden of invasive pneumococcal disease in older adults
in the city of Sao Paulo, Brazil.
Vaccine. 2025;54:126992. PubMedAbstract available
BOLOTIN S, Wright J, McLachlan E, Severini A, et al Investigating the measles susceptibility gap in Ontario infants.
Vaccine. 2025;54:126908. PubMedAbstract available
WIBOWO DP, Chalid MT, Rasyak MR, El Khobar KE, et al Characteristics of hepatitis B virus surface protein and occult hepatitis B
infection in infants with immunoprophylaxis failure from Indonesia.
Vaccine. 2025;56:127130. PubMedAbstract available
SHANKER A, Vlaev I The social influence of the corrections of vaccine misinformation on social
media.
Vaccine. 2025;56:127177. PubMedAbstract available
OSEI I, Mendy E, van Zandvoort K, Sarwar G, et al Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage
in rural Gambia 10 years after its introduction: A population-based
cross-sectional study.
Vaccine. 2025;56:127181. PubMedAbstract available
BAYSAC DJ, Guay M, Chen R, Dube E, et al Did inequalities in COVID-19 vaccination resolve over time? Insights from the
Canadian Community Health Survey.
Vaccine. 2025;56:127153. PubMedAbstract available
LONG Q, Wang H, He Q, Liu W, et al Effectiveness of rBS/WC cholera vaccine against bacterial infectious diarrhea: A
test-negative study on children aged 2-6 years in Guangzhou China.
Vaccine. 2025;56:127139. PubMedAbstract available
MELN I, Van Molle W, Velez MP, Abrahamsen G, et al Advancing regulatory dialogue: In silico models for improved vaccine
biomanufacturing - an expert meeting report.
Vaccine. 2025;56:127170. PubMedAbstract available
HANSEN BT, Kristoffersen AB, Stecher M Vaccination readiness among adults in Norway: A cross-sectional survey using the
7C model.
Vaccine. 2025;56:127169. PubMedAbstract available
SINGLETON KL, Post DJ, Augustine AD, Ison MG, et al Collaborative influenza vaccine innovation centers (CIVICs) program.
Vaccine. 2025;54:127118. PubMedAbstract available
ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a
MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine
(aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.
Vaccine. 2025;56:127127. PubMed
FATIMAH MNN, Thian BYZ, Wong CL, Ong HK, et al Chimeric virus-like particles of nodavirus displaying M2e of human and avian
influenza A viruses as a potential dual-use vaccine: Inducing a broader immune
response and protecting mice against viral infections.
Vaccine. 2025;56:127165. PubMedAbstract available
OHNO M, Sekiya T, Obeng-Kyeremeh R, Handabile C, et al Optimization of the preparation method of inactivated intact virus particle
vaccine for COVID-19.
Vaccine. 2025;56:127173. PubMedAbstract available
MELCHINGER H, Khemsara M, Ahmed N, Belgaumi SM, et al Assessment of mpox awareness, attitudes, and vaccination intent among the United
States public following an outbreak of mpox clade Ib in Africa.
Vaccine. 2025;56:127141. PubMedAbstract available
JACOVETTY J, Wagner AL, Ichsan I, Yufika A, et al Associations between parental vaccine hesitancy, religion-based vaccine
hesitancy, and childhood full vaccination in a cross-sectional study in Aceh,
Indonesia, 2023.
Vaccine. 2025;56:127154. PubMedAbstract available
SUH TY, Park JH, Hwang SY, Park CR, et al Safety and efficacy of a Vero-adapted live attenuated vaccine candidate for
African swine fever.
Vaccine. 2025;56:127172. PubMedAbstract available
LANATA CF, Ochoa TJ, Bancalari EM, Baylor NW, et al Testing an experimental vaccine during a public health emergency: Lessons from a
Peruvian case.
Vaccine. 2025;56:127176. PubMedAbstract available
BUSTAMANTE Q, Sparkes D, Findlater L, Munro K, et al Understanding occupational and attitudinal factors influencing UK healthcare
worker decisions for COVID-19 and influenza vaccination: A cross-sectional survey
within SIREN.
Vaccine. 2025;56:127160. PubMedAbstract available
AGRUPIS KA, Crisostomo MV, Daag JV, Sarol J Jr, et al Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines:
Final results of a 5-year case-control study.
Vaccine. 2025;56:127142. PubMedAbstract available
MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al 2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US
states.
Vaccine. 2025;56:127120. PubMedAbstract available
HONDA-OKUBO Y, Sakala IG, Li L, Bielefeldt-Ohmann H, et al Advax(R)-adjuvanted inactivated influenza vaccine provides accelerated protection
of mice via early induction of an influenza-specific IgM response.
Vaccine. 2025;56:127144. PubMedAbstract available
ZHANG X, Shi H, Ross TM Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in
a pre-immune elderly ferret model.
Vaccine. 2025;56:127156. PubMedAbstract available
LUKA MM, Ferguson EA, Rees E, Hoffu H, et al Optimising human rabies vaccine supply chains: A modelling study.
Vaccine. 2025 Apr 21:127108. doi: 10.1016/j.vaccine.2025.127108. PubMedAbstract available
JURADO-MARTIN I, Tomas-Cortazar J, Rezk N, Hou Y, et al The novel antigen, lipopolysaccharide export protein LptH, protects mice against
Pseudomonas aeruginosa acute pneumonia in monovalent and multivalent vaccines.
Vaccine. 2025;56:127145. PubMedAbstract available
KAHN R, Moiane B, Lessa FC, Massora S, et al Corrigendum to "Nasopharyngeal carriage of Streptococcus pneumoniae among
children and their household members in southern Mozambique five years after
PCV10 introduction" Vaccine, Volume 47, 15 February 2025, 126,691.
Vaccine. 2025;56:127124. PubMed
FINNEY J, Kuraoka M, Song S, Watanabe A, et al Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza
neuraminidases.
Vaccine. 2025;56:127157. PubMedAbstract available
XIA Y, Zhu W, Shi Z, Shen Y, et al Herpes zoster vaccination coverage and factors associated among adults aged 40
and older in China: A population-based survey.
Vaccine. 2025;56:127122. PubMedAbstract available
FERRERAS-COLINO E, de la Fuente J, Couto J, Golovchenko M, et al Immunostimulant effect of heat-inactivated Mycobacterium bovis in mice challenged
with vector-borne pathogens.
Vaccine. 2025;53:127076. PubMedAbstract available
LUN J, Zheng P, Liang X, Hu Y, et al Identification of a conserved cryptic epitope with cross-immunoreactivity in
outer membrane protein K (OmpK) from Vibrio species.
Vaccine. 2025;53:126964. PubMedAbstract available
TAKEUCHI N, Chang B, Ishiwada N, Cho Y, et al Nationwide population-based surveillance of invasive pneumococcal disease in
children in Japan (2014-2022): Impact of 13-valent pneumococcal conjugate vaccine
and COVID-19 pandemic.
Vaccine. 2025;54:127138. PubMedAbstract available
DE MELO ARAUJO AC, Oliveira TM, Souza JFA, da Fonseca Victer TN, et al Incorporating vaccines into vaccination schedules around the world: A scoping
review.
Vaccine. 2025;54:127132. PubMedAbstract available
MANTLO EK, Huang YS Knowledge-based mitigation of the environmental risk of Orthoflavivirus
live-attenuated vaccines by targeting viral encoded determinants for the mosquito
attenuated phenotype.
Vaccine. 2025;54:127114. PubMedAbstract available
MO AX, McGugan G, Pesce JT Meeting report: Expert consultation on late arresting replication competent
(LARC) malaria sporozoite vaccine research & development.
Vaccine. 2025;54:127009. PubMedAbstract available
ARSENAULT C, Ravishankar S, Lewis T, Armeni P, et al The role of health systems in shaping vaccine decisions: Insights from Italy,
Mexico, the United Kingdom, and the United States.
Vaccine. 2025;54:127134. PubMedAbstract available
STONER MCD, Michaels J, Stocks JB, Mancuso N, et al Evaluating concurrency and gaps between self-report and vaccine card data for
COVID-19 vaccination.
Vaccine. 2025;54:127136. PubMedAbstract available
WANG Z, Wang M, Wang F, Luo Y, et al Corrigendum to "Dendritic cell targeting peptide plus Salmonella FliCd flagellin
fused outer membrane protein H (OmpH) demonstrated increased efficacy against
infections caused by different Pasteurella multocida serogroups in mouse models"
[Vaccine 42
Vaccine. 2025;54:127126. PubMed
URIU K, Kaku Y, Kihara M, Sato K, et al Antiviral humoral immunity against SARS-CoV-2 omicron JN.1 subvariants induced by
JN.1 recombinant protein vaccine.
Vaccine. 2025;54:127129. PubMed
TONG F, Zhou T, Tang L, Wu X, et al Evaluating the impact of influenza vaccine on preventing stroke hospitalization
and death in Chinese elderly hypertensive patients: A retrospective cohort study.
Vaccine. 2025;54:127004. PubMedAbstract available
WEETS CM, Wilson R, Swadley H, Katz R, et al Strengthening health security through routine vaccination policy: A comprehensive
analysis of childhood vaccination laws across 194 countries.
Vaccine. 2025;54:127121. PubMedAbstract available
ENTRICAN G, Bredell H, Charlier J, Cunningham AF, et al Opportunities and challenges for the adoption of novel platform technologies to
develop veterinary bacterial vaccines.
Vaccine. 2025;54:127117. PubMedAbstract available
YE Q, Li H, Xie Z, Gao X, et al Corrigendum to "Antibody persistence in Chinese toddlers at 1 year and 2 years
after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate
vaccine (PCV13-TT)" [Vaccine 49 (7) (2025) 126815].
Vaccine. 2025;54:127125. PubMed
WANG F, Zheng J, Qiu F, Yang Y, et al Long-term effectiveness of vaccination for prevention of hepatitis B virus
mother-to-child transmission in Yunnan, China.
Vaccine. 2025;54:127128. PubMedAbstract available
LEYNS C, McClenaghan E, Rodriguez P, Nguipdop-Djomo P, et al Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional
food markets in Bolivia (2020-2022): A cross-sectional analysis of a serological
survey.
Vaccine. 2025;54:127104. PubMedAbstract available
SYROGIANNOPOULOS GA, Michoula AN, Moriondo M, Nieddu F, et al Childhood invasive pneumococcal disease and acute otitis media in Central Greece
during 2005-2024 - A report at the doorstep of the new multivalent PCV era.
Vaccine. 2025;52:126765. PubMedAbstract available
OLIVEIRA LMA, Prasad N, Lynfield R, Ip M, et al WHO defeating meningitis symposium, 3rd international symposium on Streptococcus
agalactiae disease (ISSAD) in Rio de Janeiro, Brazil: State-of-the-art overview
of S. agalactiae meningitis.
Vaccine. 2025;52:126895. PubMedAbstract available
RESIK S, Lopez Cavestany R, Tejeda A, Diaz M, et al Tropis needle-free injector for fractional-dose IPV administration: A pilot study
for integration into routine immunization services in Cuba.
Vaccine. 2025;52:126903. PubMedAbstract available
DEY A, Jackson J, Wang H, Lambert SB, et al Australia's rotavirus immunisation program: Impact on acute gastroenteritis and
intussusception hospitalisations over 13 years.
Vaccine. 2025;52:126789. PubMedAbstract available
JOSHI R, Ayele HT, Johnson KD, Velentgas P, et al Anticipated impact of novel adult-specific pneumococcal conjugate vaccine.
Vaccine. 2025;53:127080. PubMedAbstract available
JOHN TJ, Dharmapalan D, Steinglass R, Hirschhorn N, et al Lessons for polio eradication from the geographic variations of vaccine efficacy
of oral polio.
Vaccine. 2025;53:127115. PubMed
WALTENBURG MA, Kainulainen MH, Whitesell A, Nyakarahuka L, et al Corrigendum to "Knowledge, attitudes, and practices and long-term immune response
after rVSVDeltaG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk
districts in Uganda" [Vaccine 24 (22) (2024) 126031].
Vaccine. 2025;54:127119. PubMed
CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al Regional cooperation on pandemic preparedness and vaccine equity from an
economic, regulatory and legal perspective.
Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107. PubMedAbstract available
BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al Development and validation of a clinical prediction tool for non-receipt of
updated COVID-19 vaccines.
Vaccine. 2025;53:127074. PubMedAbstract available
DYMOCK M, Marsh JA, Murray K, Snelling TL, et al What is the quality of evidence informing vaccine clinical practice
recommendations in Australia?
Vaccine. 2025;53:127105. PubMedAbstract available
ZHANG L, Xia Y, Chu L, Sundaram ME, et al Differences in seasonal influenza vaccine hesitancy profiles between clinicians
practicing traditional Chinese medicine and modern Western medicine: A national
cross-sectional survey.
Vaccine. 2025;53:127106. PubMedAbstract available
JANI B, Hokororo A, Mchomvu J, Cortese MM, et al Corrigendum to "Detection of rotavirus before and after monovalent rotavirus
vaccine introduction and vaccine effectiveness among children in mainland
tanzania" [Vaccine 36(47) (2018 Nov 12) 7149-7156].
Vaccine. 2025;53:127103. PubMed
NA EJ, Chae SB, Oh B, Jeong CG, et al A novel approach using IFNAR1 KO mice for assessing Akabane virus pathogenicity
and vaccine efficacy.
Vaccine. 2025;53:127094. PubMedAbstract available
EINARSON TA, Musana E, Balonde J, Lorentzen KB, et al Human papillomavirus awareness, vaccination rate, and sociodemographic covariates
of vaccination status in a low-income country: A cross-sectional study in the
rural Busoga region of Uganda.
Vaccine. 2025;53:127089. PubMedAbstract available
SHARIF E, Mobasheri T, Mohit E Bioengineered ClearColi-derived outer membrane vesicles displaying CT26
neoepitopes as potent vaccine adjuvants against colon carcinoma in a preventive
mouse model.
Vaccine. 2025;53:127088. PubMedAbstract available
LA EM, Sweeney C, Davenport E, Bunniran S, et al Pharmacy and healthcare provider offices as convenient adult vaccination settings
in the US: Patient experiences from a survey of recently-vaccinated adults.
Vaccine. 2025;54:127057. PubMedAbstract available
SASANKAN S, Gathers D, Bellerose A, Pankratz VS, et al Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on
oncology patients in New Mexico with substantial representation of racial
minorities and rural residents.
Vaccine. 2025;53:127091. PubMedAbstract available
ZASZTOWT-STERNICKA M, Jagielska A, Rzad M, Szymusik I, et al Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women,
including the level of postvaccination antibodies in umbilical cord blood.
Vaccine. 2025;53:127047. PubMedAbstract available
LLOYD PC, Acharya G, Zhao H, Shah N, et al Safety monitoring of health outcomes following influenza vaccination during the
2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older.
Vaccine. 2025;53:127069. PubMedAbstract available
YUILL S, Hall MT, Caruana M, Lui G, et al Erratum to "Predicted impact of HPV vaccination and primary HPV screening on
precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070:
Modelling in a high income, high vaccination coverage country with HPV-based
cervical screeni
Vaccine. 2025;53:127079. PubMed
ASSONI L, Valim V, Couto AJM, Trentini M, et al In-silico and experimental analysis of Klebsiella pneumoniae fimbriae subunits
for vaccine development.
Vaccine. 2025;53:127075. PubMedAbstract available
PRALL S, Lopes A "Better to die trying": Vaccine perceptions and COVID-19 experiences in rural
Namibian pastoralists.
Vaccine. 2025;55:127061. PubMedAbstract available
MOLLO A, Peri M, Lodi L, Gissi A, et al Considering recombinant herpes zoster vaccine for fragile pediatric patients: A
new opportunity.
Vaccine. 2025;53:127072. PubMedAbstract available
FROSTH S, Reddick D, Righetti F, Bjerketorp J, et al Sow vaccination with a novel recombinant protein vaccine protects piglets against
Streptococcus suis infection.
Vaccine. 2025;53:127077. PubMedAbstract available
DIEZ A, Arrieta-Aguirre I, Carrano G, Bregon-Villahoz M, et al A synthetic peptide vaccine induces protective immune responses against Candida
albicans infection in immunocompromised mice.
Vaccine. 2025;53:127102. PubMedAbstract available
SHEARN C, Postavaru GI, Hylton L, Morris H, et al COVID-19 vaccine decision-making and the role of institutions across the pandemic
in UK Black African and Black Caribbean communities.
Vaccine. 2025;53:127071. PubMedAbstract available
LI G, Cao S, Xu B, Hu J, et al Safety, immunogenicity and immune persistence of a lyophilized purified human
diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A
randomized, blinded controlled phase 3 trial in healthy participants aged
10-60 years old.
Vaccine. 2025;53:127082. PubMedAbstract available
LEADER AE, Burke-Garcia A, Afanaseva D, Cutroneo E, et al Partnering with social media influencers to promote HPV vaccination in diverse
communities.
Vaccine. 2025;53:127085. PubMedAbstract available
SHALASH AO, Wang W, Xia Y, Hussein WM, et al Evaluation of novel single-dose vaccine candidates against gonadotropin-releasing
hormone (GnRH) in mice.
Vaccine. 2025;53:127092. PubMedAbstract available
BERNARD C, Drouin J, Le Vu S, Botton J, et al COVID-19 vaccination rates among pregnant women in France: A nationwide cohort
study.
Vaccine. 2025;53:127070. PubMedAbstract available
FISHER KA, Goldthwait L, Desrochers O, Zemel M, et al Reasons for COVID-19 vaccination late in the pandemic: A qualitative study.
Vaccine. 2025;53:127084. PubMedAbstract available
FLYNN PM, Stull C, Jain VM, Evans MD, et al A national cross-sectional study of dentists' vaccine hesitancy and intention to
provide HPV vaccines following emergency COVID-19 vaccination authorization.
Vaccine. 2025;53:127035. PubMedAbstract available
CHEN PL, Richardson RA, Rovito S, Yang G, et al Live-attenuated pandemic H1N1 influenza vaccines expressing computationally
optimized broadly reactive antigens (COBRAs) are immunogenic and protective in
mice and ferrets.
Vaccine. 2025;53:127090. PubMedAbstract available
PAYNE AB, Novosad S, Sung HM, Zhang Y, et al Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated
hospitalizations among adults aged >/=18 years with end stage kidney disease -
United States, September 2023-April 2024.
Vaccine. 2025;55:127010. PubMedAbstract available
EIDEN AL, Mackie DS, Modi K, Drakeley S, et al Corrigendum to the article titled, "Attitudes and beliefs about vaccination among
adults in the United States: A real-world, cross-sectional, web-based survey
study" [Vaccine 50 (2025) 126807].
Vaccine. 2025;53:127053. PubMed
FELIX P, Melo AA, Costa JP, Colaco M, et al Exploring TLR agonists as adjuvants for COVID-19 oral vaccines.
Vaccine. 2025;53:127078. PubMedAbstract available
MCCOSKER LK, Dyer B, Sudarmana T, Seale H, et al COVID-19 vaccination uptake in people experiencing homelessness during the first
three years of the global COVID-19 vaccination effort: A systematic review and
meta-analysis.
Vaccine. 2025;53:127050. PubMedAbstract available
ANTILLON M, Verjans A, El Sheikh F, Scarna T, et al Microarray patch vaccines for typhoid conjugate vaccines: A global
cost-effectiveness analysis.
Vaccine. 2025;53:127055. PubMedAbstract available
DAVIDSON N, Fisher J "If I know about it of course I would give my son and daughter", barriers to and
enablers of accessing human papillomavirus vaccination among women from refugee
and asylum-seeking backgrounds resettling in Melbourne, Australia - A qualitative
study.
Vaccine. 2025;53:127064. PubMedAbstract available
EIDEN AL, Drakeley S, Modi K, Mackie DS, et al Corrigendum to, "Attitudes and beliefs of healthcare providers toward vaccination
in the United States: A cross-sectional online survey" [Vaccine (2024) Dec 2
42(26) 126437].
Vaccine. 2025;53:127054. PubMed
MCKECHNIE JL, Kepl E, Louth J, Sun CJ, et al Nanoparticles displaying fHbp elicit an enhanced antibody response against
meningococcal B isolates compared to low valency fHbp antigens.
Vaccine. 2025;51:126885. PubMedAbstract available
CARNALLA M, Gaspar-Castillo C, Dimas-Gonzalez J, Aparicio-Antonio R, et al A population-based measles serosurvey in Mexico: Implications for re-emergence.
Vaccine. 2025;51:126886. PubMedAbstract available
MONCHAUSSE T, Launay T, Rossignol L, Ait El Belghiti F, et al Clinical characteristics of cases during the 2024 pertussis epidemic in France,
January 2024 to December 2024.
Vaccine. 2025;51:126862. PubMedAbstract available
OLIVIERI G, Amodio D, Manno EC, Santilli V, et al Shielding the immunocompromised: COVID-19 prevention strategies for patients with
primary and secondary immunodeficiencies.
Vaccine. 2025;51:126853. PubMedAbstract available
JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related
hospitalisation amongst adult members of a private health insurance plan in South
Africa during the Delta and Omicron periods: A test-negative case-control study.
Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068. PubMedAbstract available
PEREZ MARC G, Coria LM, Ceballos A, Rodriguez JM, et al Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted
RBD-based protein booster vaccines in adults previously immunized with different
vaccine platforms: A phase II/III, randomized clinical trial.
Vaccine. 2025;54:127045. PubMedAbstract available
HE X, Pu Y, Li Z, Huan S, et al The global regulatory landscape for combined vaccines: A comparative case study
of registration strategies for diphtheria-tetanus-pertussis-containing vaccines.
Vaccine. 2025;54:127017. PubMedAbstract available
PATRICK R, Mahale P, Ackerson BK, Hong V, et al Respiratory syncytial virus vaccine uptake among adults aged >/=60 years in a
large, integrated healthcare system in Southern California 2023-2024.
Vaccine. 2025;53:127033. PubMedAbstract available
FORAN AM, Jetten J, Muldoon OT Religious group membership and conspiracy beliefs influence vaccine uptake:
Insights from 20 European countries.
Vaccine. 2025;53:127086. PubMedAbstract available
ALVES K, Kouassi A, Plested JS, Kalkeri R, et al Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant
spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive
participants: Primary day-28 analysis of a phase 2/3 open-label study.
Vaccine. 2025;55:127046. PubMedAbstract available
STRONG C, Joson P, Chu IY, Chuang TT, et al Prioritization and barriers of mpox vaccination uptake among gay, bisexual and
other men who have sex with men in Taiwan: 2023 HEART survey.
Vaccine. 2025;53:127059. PubMedAbstract available
VADREVU KM, Chavan A, Chawla A, Chakravarthy BS, et al A double-blind, randomised phase III clinical trial to evaluate safety,
immunogenicity, non-inferiority & lot to lot consistency of single component oral
cholera vaccine BBV131 (Hillchol(R)) in comparison to Shanchol.
Vaccine. 2025;55:126998. PubMedAbstract available
OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al Post-introduction evaluation (PIE) of the seasonal influenza vaccination program
in Kyrgyzstan in 2023.
Vaccine. 2025;55:127052. PubMedAbstract available
March 2025
KARAN S, Opdensteinen P, Ma Y, De Oliveira JFA, et al A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic
virus-like particles.
Vaccine. 2025;53:127063. PubMedAbstract available
DA SILVA TMR, de Sa ACMGN, Prates EJS, Veloso GA, et al Trends and spatial distribution of the burden of vaccine-preventable diseases in
children under five in Brazil from 2000 to 2019.
Vaccine. 2025;55:127060. PubMedAbstract available
JIANG J, Lam KF, Lau EHY, Yin G, et al Estimation of trajectory of COVID-19 vaccines effectiveness against infection.
Vaccine. 2025;55:127067. PubMedAbstract available
NEWBERN EC, Shoaibi A, Haynes K, Blacketer C, et al A rapid cycle analytics framework for vaccine safety surveillance within a
real-world data network: Experience with enhanced surveillance of the Janssen
COVID-19 vaccine.
Vaccine. 2025;55:127044. PubMedAbstract available
LEE JW, Lee DY, Baek S, Jeong JY, et al Sensitive detection of pertussis toxin in acellular pertussis vaccines using
HRH1-mediated calcium signaling.
Vaccine. 2025;54:127056. PubMedAbstract available
CENAT JM, Moshirian Farahi SMM, Dalexis RD, Xu Y, et al Vaccine hesitancy among racially diverse parents in Canada: The important role of
health literacy, conspiracy beliefs and racial discrimination.
Vaccine. 2025;55:127049. PubMedAbstract available
TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al Sociodemographic and health-related predictors of COVID-19 booster uptake among
fully vaccinated adults.
Vaccine. 2025;54:127048. PubMedAbstract available
OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al Hepatitis B vaccination initiation and vaccination series completion: An in-depth
systematic evidence review, with meta-analysis of associations with individual
socioeconomic and health-related factors.
Vaccine. 2025;55:127051. PubMedAbstract available
STRAVORAVDI AS, Ladas AI, Frantzidis CA, Papazisis G, et al HAVI: A novel tool to explore vaccine hesitancy among adults in Greece.
Vaccine. 2025;55:127042. PubMedAbstract available
VYSOTSKAYA V, Gassowski M, Kasper A, Gasich E, et al Hepatitis B serosurvey to validate the achievement of regional hepatitis B
control targets in Belarus.
Vaccine. 2025;55:127058. PubMedAbstract available
MOUCHERAUD C, Ochieng E, Kweka A, Wang P, et al Parent-daughter agreement about HPV vaccination status in Kenya and Malawi.
Vaccine. 2025;55:127025. PubMedAbstract available
KANG M, Marks KM, Cox AL, Sherman KE, et al An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in
persons with HIV.
Vaccine. 2025;55:127028. PubMedAbstract available
FUNK T, Norgaard SK, Hallundbaek L, Grau J, et al Effect of a proactive childhood vaccination reminder system on vaccination
coverage and uptake in Denmark: A register-based cohort study.
Vaccine. 2025;54:126934. PubMedAbstract available
ZHANG Y, Sullivan N, Abraham M, Haley HD, et al Evaluation of HPV-loaded PLGA microparticles as single-dose HPV vaccine: Insights
for sustained-release vaccine development.
Vaccine. 2025;55:127024. PubMedAbstract available
VEDEL JO, Furtado O, Almeida LL, Martins JSD, et al Refresher training in administering intradermal BCG-vaccine increased
BCG-scarring rates in rural Guinea-Bissau.
Vaccine. 2025;55:127039. PubMedAbstract available
EMARY K, Bentsi-Enchill AD, Giersing BK, Gordon M, et al Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS
vaccine use case and demand: Report of a WHO expert consultation.
Vaccine. 2025;55:127008. PubMedAbstract available
BAKARE AA, Gobbo E, Akinsola KO, King C, et al "It's easier to deal with the vaccines you know than the ones you don't know": A
qualitative study on healthcare workers' vaccine confidence in Nigeria.
Vaccine. 2025;55:127020. PubMed
FRIVOLD C, Giersing B, Amorij JP, Mvundura M, et al Identification of potential vaccines for use with microarray patches in low- and
middle-income countries: An assessment from the Vaccine Innovation Prioritisation
Strategy Alliance.
Vaccine. 2025;55:126996. PubMedAbstract available
BLACKWELL CK, Bekelman T, Bakre S, Jacobson LP, et al Sociodemographic differences in parental hesitancy to the COVID-19 vaccine.
Vaccine. 2025;55:127041. PubMedAbstract available
GOEDERS N, Vanneste K, Roosens NHC, Bogaerts B, et al Molecular and WGS-based characterization of invasive Neisseria meningitidis
isolates collected in Belgium (2016-2022) and MenB-FHbp vaccine coverage
estimation of serogroup B.
Vaccine. 2025;55:127026. PubMedAbstract available
MELOT L, Thyfault E, Hester K, Prausnitz MR, et al Perceptions of non-needle-based vaccination devices in the state of Georgia.
Vaccine. 2025;55:127038. PubMedAbstract available
HARALAMBIEVA IH, Ratishvili T, Goergen KM, Grill DE, et al Effect of lymphocyte miRNA expression on influenza vaccine-induced immunity.
Vaccine. 2025;55:127023. PubMedAbstract available
FRANCIS MJ A rapid human vaccine process development map outlining lessons learnt from
ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic.
Vaccine. 2025;55:127040. PubMedAbstract available
AHMAD I, Burton R, Arshad R, Younis BB, et al Humoral immune response to 10-valent pneumococcal conjugate vaccine (PCV10) in
individuals with type 2 diabetes mellitus.
Vaccine. 2025;55:127029. PubMedAbstract available
YAN K, Xu S, Fang H, Yang H, et al Next-generation immunotherapeutic strategy and clinical advances of vaccines
against nicotine addiction.
Vaccine. 2025;55:127036. PubMedAbstract available
GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al Adverse events among early caregivers' COVID-19 vaccination correlated inversely
with intention to vaccinate their children.
Vaccine. 2025;55:127001. PubMedAbstract available
SALLOUM M, Lariviere Y, Bikioli Bolombo F, Zola Matuvanga T, et al The exclusion of pregnant women from an Ebola vaccine trial in Boende, western
DRC: Perceptions of female participants who became pregnant and community
members.
Vaccine. 2025;55:127000. PubMedAbstract available
VACHON A, Keeshan A, Galipeau Y, Crawley AM, et al Alcohol consumption does not influence SARS-CoV-2 vaccine immunogenicity: A stop
the spread Ottawa cohort analysis.
Vaccine. 2025;55:127034. PubMedAbstract available
KAISER S, Kaiser S, Reis J, Marschalek R, et al Quantification of objective concentrations of DNA impurities in mRNA vaccines.
Vaccine. 2025;55:127022. PubMedAbstract available
CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in
the World Health Organization Africa region: A mixed-methods evaluation of the
African region monitoring vaccine effectiveness (AFRO-MoVE) network.
Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823. PubMedAbstract available
HAMID S, Simeone RM, Newhams MM, Halasa N, et al Concordance between parent-reported and documented COVID-19 vaccination status
among hospitalized children and adolescents: Implications for vaccine
effectiveness estimates, May 2021-October 2023.
Vaccine. 2025;54:126891. PubMedAbstract available
SHINO MY, Ibarrondo FJ, Yang OO SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the
spectrum in non-immunocompromised persons.
Vaccine. 2025;50:126851. PubMedAbstract available
HAGEDORN B, Frey K, Scarna T, El Sheikh F, et al Microarray patches likely to reduce the operational costs of immunization: A
Monte Carlo simulation study.
Vaccine. 2025;50:126840. PubMedAbstract available
ILIYASU Z, Danzomo AA, Jeyaseelan V, Gofama MM, et al Impact of novel Oral Poliovirus Type 2 vaccination campaigns: A seroprevalence
survey in Nigeria, 2022.
Vaccine. 2025;54:126978. PubMed
THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
Vaccine. 2025;55:126981. PubMedAbstract available
RASKIN N, Hiligsmann M, Luyten J, Tubeuf S, et al Socio-demographic differences in citizen' preferences for distributing a scarce,
lifesaving resource: A case study using COVID-19 vaccine distribution in Belgium.
Vaccine. 2025;55:126997. PubMedAbstract available
NAZIAT H, Rahman MH, Das RC, Islam M, et al Impact of 10-valent pneumococcal conjugate vaccine on the epidemiology of otitis
media with otorrhea among Bangladeshi children.
Vaccine. 2025;55:126995. PubMedAbstract available
CHOI J, Feelemyer J, Choe K, Lynch K, et al Anti-vaccine attitudes and COVID-19 vaccine status at the end of the U.S. public
health emergency.
Vaccine. 2025;55:127003. PubMedAbstract available
BALDOLLI A, Fournier A, Roger H, Piednoir E, et al Implementation of school-based vaccination in French middle schools: Efficient or
not?
Vaccine. 2025;55:127007. PubMedAbstract available
MPABALWANI EM, Sakala C, Kamiji E, Simwaka J, et al Challenges and lessons learned during the switching of rotavirus vaccine from
Rotarix to Rotavac in Zambia.
Vaccine. 2025;55:127012. PubMedAbstract available
HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al A phase I study of the safety, reactogenicity and immunogenicity of two
quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without
one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of
age.
Vaccine. 2025;54:126991. PubMedAbstract available
GHARPURE R, Vegvari C, Abdissa A, Alimi Y, et al Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to
inform human vaccine development, Nairobi, 4-5 June 2024.
Vaccine. 2025;54:126860. PubMedAbstract available
MACGIBBON J, Storer D, Bavinton BR, Cornelisse VJ, et al Mpox vaccination coverage among Australian gay and bisexual men and non-binary
people: Results of behavioural surveillance in early 2024.
Vaccine. 2025;55:127014. PubMedAbstract available
YANAI T, Yoshida S, Kawakami K Gastroenteritis hospitalizations over 19 years before and after introduction of
rotavirus vaccine in Japan: A nationwide claims database.
Vaccine. 2025;55:127027. PubMedAbstract available
YUILL S, Hall MT, Caruana M, Lui G, et al Predicted impact of HPV vaccination and primary HPV screening on precancer
treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling
in a high income, high vaccination coverage country with HPV-based cervical
screening.
Vaccine. 2025;54:126986. PubMedAbstract available
ZHANG X, Zhao T, Cai X, Zhang W, et al Are health education effective to improve herpes zoster vaccine willingness in
vulnerable elderly.
Vaccine. 2025;54:126975. PubMedAbstract available
XU J, Davoudpour S, Phillips G 2nd Applying the health belief model (HBM) to understand COVID-19 vaccine uptake
among youth and young adults: Findings from a 6-month follow-up study in the
United States.
Vaccine. 2025;54:127002. PubMedAbstract available
PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al Factors associated with influenza and COVID-19 vaccination among health workers
in Lao PDR, 2023.
Vaccine. 2025;54:127006. PubMedAbstract available
RICCI L, Fery C, Tubach F, Agrinier N, et al Health care institutions and their physicians are the greatest promoters of
COVID-19 vaccine acceptance among health care workers.
Vaccine. 2025;54:127005. PubMedAbstract available
MYBURGH L, Karsjens H, Blanas A, de Ligt A, et al Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate
vaccine.
Vaccine. 2025;54:126989. PubMedAbstract available
LU H Generative AI for vaccine misbelief correction: Insights from targeting
extraversion and pseudoscientific beliefs.
Vaccine. 2025;54:127018. PubMedAbstract available
FIRTH C, Emary K, Stuart A, Browne R, et al Acceptability of the gonorrhoea human challenge model to accelerate vaccine
development in UK men.
Vaccine. 2025;54:127013. PubMedAbstract available
SKOCZYNSKA A, Golebiewska A, Wrobel-Pawelczyk I, Ronkiewicz P, et al The direct impact of mandatory PCV10 vaccination on invasive pneumococcal disease
in Polish children.
Vaccine. 2025;54:126999. PubMedAbstract available
TAMIR TT, Tekeba B, Techane MA, Alemu TG, et al Coverage of complete basic childhood vaccination and its variation by basic
characteristics among children aged 12-23 months in 41 low- and middle-income
countries: A Meta-analysis of demographic and health survey reports between 2015
and 2025.
Vaccine. 2025;54:127019. PubMedAbstract available
VEDEL JO, Furtado O, Almeida LL, Nehal KR, et al Childhood vaccination coverages in rural Guinea-Bissau before and during the
early COVID-19 pandemic, a cohort study.
Vaccine. 2025;54:127011. PubMedAbstract available
MARTINON-TORRES F, Martinez SN, Kline MJ, Drozd J, et al A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers
previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine.
Vaccine. 2025;53:126931. PubMedAbstract available
DAVIS P, Montroy J, Warshawsky B, Abrams EM, et al Immunogenicity of pre-exposure rabies vaccination comparing number of doses and
routes of administration: A systematic review and meta-analyses.
Vaccine. 2025;53:126878. PubMedAbstract available
SIKUVI K, Nghitukwa N, Kakehongo N, Katjitae I, et al Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2
infection amongst health workers, Windhoek, Namibia.
Vaccine. 2025 Mar 11:126977. doi: 10.1016/j.vaccine.2025.126977. PubMedAbstract available
BOLU O, Alo OD, Iwara E, Longley AT, et al Feasibility of cohort event monitoring and assessment of reactogenicity and
adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine
recipients in Nigeria, 2021.
Vaccine. 2025;52:126907. PubMedAbstract available
DI CHIARA C, Karimi-Shahrbabak E, Peresin J, Farrar DS, et al A review of Canadian online resources providing information on COVID-19
vaccination for caregivers of children aged 5-11 years.
Vaccine. 2025;54:126990. PubMedAbstract available
MEERAUS W, Postema A, Gray CM, Lee A, et al Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase
protection against COVID-19 hospitalization: Final analysis from the
REFORCO-Brazil real-world effectiveness study during Omicron.
Vaccine. 2025;53:126955. PubMedAbstract available
KRAMMER F Next-generation seasonal influenza virus vaccines need a neuraminidase component.
Vaccine. 2025;54:126994. PubMed
OTIENO NA, Kalani R, Ayugi J, Nyawanda BO, et al Seasonal influenza vaccination in Kenya: What determines healthcare Workers'
willingness to accept and recommend vaccination?
Vaccine. 2025;54:126963. PubMedAbstract available
DE SOUZA RA, Barreto FR, de Jesus Lima CCO, da Natividade MS, et al Efficacy of BCG vaccination on incidence, severity and clinical progression of
COVID-19: A BCG-REVAC population analysis.
Vaccine. 2025;54:126911. PubMedAbstract available
JI C, Senthinathan A, Apajee J, Dubey V, et al Impact of the COVID-19 pandemic on routine immunization coverage of children and
teenagers in Ontario, Canada.
Vaccine. 2025;49:126811. PubMedAbstract available
FORZY T, Tesfaye L, Getnet F, Misganew A, et al Assessing the geographic and socioeconomic determinants of vaccine coverage in
Ethiopia: A spatial and multistage analysis at the district level.
Vaccine. 2025;53:126834. PubMedAbstract available
DESILVA MB, Vazquez-Benitez G, Seburg EM, Henderson MSG, et al Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota,
2023-2024.
Vaccine. 2025;54:126958. PubMedAbstract available
DOWGIER G, Hobbs A, Greenwood D, Shawe-Taylor M, et al Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1
in the assessment of vaccination and therapeutics.
Vaccine. 2025;54:126960. PubMedAbstract available
NAVAEISEDDIGHI Z, Schmit T, Wang Z, Ahamed N, et al The vaccine dosing effect overcomes the reduced immunogenic potential and in vivo
efficacy of 33F pneumococcal serotype.
Vaccine. 2025;54:126983. PubMedAbstract available
LEE DW, Nasir A, Elbashir S, Jani H, et al mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses
against the JN.1 sublineages of SARS-CoV-2 in mice.
Vaccine. 2025;54:126961. PubMedAbstract available
ABAASA AM, Kusemererwa S, Ankunda V, Ongaria TA, et al Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic
COVID-19 patients in Uganda.
Vaccine. 2025 Mar 6:126976. doi: 10.1016/j.vaccine.2025.126976. PubMedAbstract available
KUSEMERERWA S, Ankunda V, Ongaria TA, Abaasa A, et al COVID-19 vaccination status and associated factors among patients presenting with
COVID-19-like symptoms in Uganda.
Vaccine. 2025 Mar 6:126984. doi: 10.1016/j.vaccine.2025.126984. PubMedAbstract available
CARTER JJ, Smith RA, Scherer EM, Skibinski DAG, et al Corrigendum to "Long-Term immune memory responses to human papillomavirus (HPV)
vaccination following 2 versus 3 doses of HPV vaccine" [Vaccine, Volume 50, 19
March 2025, 126,817].
Vaccine. 2025;54:126974. PubMed
TILLYA R, Abdallah G, Msuya H, Bajaria S, et al Associated factors for dropout of first versus third doses of pentavalent
vaccination in Tanzania.
Vaccine. 2025;54:126962. PubMedAbstract available
XIMENES R, Simmons AE, Gebretekle GB, Nam A, et al Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among
adults in Canada.
Vaccine. 2025;54:126985. PubMedAbstract available
MINUTTI AF, Sasse JP, Dos Santos Silva AC, Martins TA, et al Evaluation of a DNA vector plasmid encoding a partial rop18 gene from toxoplasma
gondii in domestic cats as a vaccine candidate.
Vaccine. 2025;54:126965. PubMedAbstract available
GORDON JL, Boespflug EL, Coleman A, Taylor K, et al Development of broadly protective coronavirus vaccines: A joint NIAID-CEPI
workshop report.
Vaccine. 2025;54:126909. PubMed
CARROLL M, Fox HB, Tran A, Chellappan G, et al SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect
against evolving variants.
Vaccine. 2025;54:126988. PubMedAbstract available
PROCTOR RA, Jackson AM, Fowler VG The lack of a biorepository during vaccine trials: A lost opportunity to
understand staphylococcal immunity.
Vaccine. 2025;53:126896. PubMedAbstract available
GATES CJ, Brazel EB, Kennedy EV, Brown JS, et al A gamma-irradiated pneumococcal vaccine elicits superior immunogenicity in
comparison to heat or chemically inactivated whole-cell vaccines.
Vaccine. 2025;54:126982. PubMedAbstract available
MOORE M, Anderson L, Schiffer JT, Matrajt L, et al Durability of COVID-19 vaccine and infection induced immunity: A systematic
review and meta-regression analysis.
Vaccine. 2025;54:126966. PubMedAbstract available
CHISNALL G, Letley L, Mounier-Jack S, Bedford H, et al Parents' experiences of accessing childhood vaccination services in England: A
qualitative longitudinal cohort study.
Vaccine. 2025;52:126921. PubMedAbstract available
RAMIREZ-BENCOMO F, Thistlethwaite A, Viviani V, Bartolini E, et al Identification of immunogenic outer membrane vesicle vaccine antigen components
using a meningococcal protein microarray.
Vaccine. 2025;53:126953. PubMedAbstract available
PEIXOTO DE MIRANDA EJF, Calado RT, Boulos FC, de Sousa Moreira JA, et al Safety and immunogenicity of an inactivated recombinant Newcastle disease virus
vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled
phase I ADAPTCOV trial in Brazil.
Vaccine. 2025;52:126680. PubMedAbstract available
CHU CF, Chang TH, Ho JJ Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and
claim approval rates.
Vaccine. 2025;52:126830. PubMedAbstract available
HAMIDI A, Willemsen M, Robert T, Drugmand JC, et al Sabin inactivated polio vaccine upstream process development using fixed-bed
bioreactor technology.
Vaccine. 2025;53:126950. PubMedAbstract available
ZHAO T, Xu Q, Cai X, Wang M, et al Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy
between 2020 and 2022: A meta-analysis.
Vaccine. 2025;53:126933. PubMedAbstract available
MAFUTA EM, Lulebo AM, Kasonga JN, Mvuama NM, et al Designing a National Rapid Vaccine Coverage Survey in low-resource settings:
Experiences from the Democratic Republic of the Congo 2018-2023.
Vaccine. 2025;53:126956. PubMedAbstract available
FRANCA AP, Domingues CMAS, Domingues RAS, Barata RB, et al Vaccine hesitancy in the vaccination of children in Brazil.
Vaccine. 2025;53:126905. PubMedAbstract available
COTTER LM, Hopkins-Sheets M, Yang S, Passmore SR, et al Increasing confidence for pediatric COVID-19 and influenza vaccines using
messages affirming parental autonomy: A randomized online experiment.
Vaccine. 2025;53:126947. PubMedAbstract available
AYAD C, Porter D, Lambert E, Libeau P, et al An LNP-mRNA vaccine protects fish against rhabdovirus infection.
Vaccine. 2025;53:126957. PubMedAbstract available
TENGATTINI S, Bavaro T, Rinaldi F, Temporini C, et al Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy
for good practices.
Vaccine. 2025;53:126932. PubMedAbstract available
ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al Factors associated with mortality among patients aged 12 years and above
requiring hospitalization for severe respiratory illness (SRI): Findings from the
COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910. PubMedAbstract available
DAVIES A, Schreiber D, Carey C, Tucker SB, et al Community pharmacists' pneumococcal vaccine knowledge and perceived barriers to
vaccination.
Vaccine. 2025;53:126930. PubMedAbstract available
KEELING MJ, Hill EM, Petrou S, Tran PB, et al Cost-effectiveness of routine COVID-19 adult vaccination programmes in England.
Vaccine. 2025;53:126948. PubMedAbstract available
NIU Y, Yan Y, Hu Y, Yang X, et al A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector.
Vaccine. 2025;53:126959. PubMedAbstract available
February 2025
SHAO Q Corrigendum to The origin of vaccine nationalism [Vaccine 51 (2025) 126897].
Vaccine. 2025;53:126935. PubMed
RIGAMONTI V, Torri V, Morris SK, Ieva F, et al Real-world effectiveness of influenza vaccination in preventing influenza and
influenza-like illness in children.
Vaccine. 2025;53:126946. PubMedAbstract available
WANG B, Lassi Z, Andraweera P, Chen G, et al Pregnant women's choices for preventing respiratory syncytial virus (RSV).
Vaccine. 2025;48:126790. PubMedAbstract available
ZHOU S, Wang J, Lv M, Lan W, et al Long-term antibody trajectories after PPSV23 in elderly: Results from a 4-year
follow-up study.
Vaccine. 2025;48:126737. PubMedAbstract available
ADU P, Popoola T, Iqbal N, Roemer A, et al A cross-country network analysis of disease infodemics: Looking through the lens
of the COVID-19 pandemic.
Vaccine. 2025;48:126733. PubMedAbstract available
AN SJ, Yang JS, Chae MH, Woo JS, et al Development of invasive non-typhoidal Salmonella conjugate vaccines and their
evaluation in a trivalent formulation with typhoid conjugate vaccine.
Vaccine. 2025;52:126913. PubMedAbstract available
GUTTIERES D, Van Riet C, Vandaele N, Decouttere C, et al Dynamics of global emergency vaccine stockpiles: A systems analysis and
application to cholera.
Vaccine. 2025;52:126889. PubMedAbstract available
KIM HJ, Lee SH, Park YS, Seo DW, et al Utility of edible plant-derived exosome-like nanovesicles as a novel delivery
platform for vaccine antigen delivery.
Vaccine. 2025;52:126902. PubMedAbstract available
SHEERAH HA, Al-Jedai AH, Al-Jerian NA, Al-Otaiby MA, et al COVID-19 and influenza hospitalizations and the role of COVID-19 vaccination in
the post-pandemic period: A cross-sectional study from Saudi Arabia.
Vaccine. 2025;52:126937. PubMedAbstract available
SINGER D, Salem A, Stempniewicz N, Ma S, et al Corrigendum to "The potential impact of increased recombinant zoster vaccine
coverage on the burden of herpes zoster among adults aged 50-59 years" [Vaccine
41 (37) (23 August 2023) 5360-5367].
Vaccine. 2025;52:126805. PubMed
MATHUR I, Ruisch A, Conlin M, Oyatoye I, et al COVID-19 vaccination integration, innovations and key populations: Results from a
global survey.
Vaccine. 2025;52:126863. PubMedAbstract available
ARABIAN S, Sadr M, Ayati MH, Ince F, et al The earliest report of smallpox oral vaccination by Baha' al-Dawlah Razi in the
16th century.
Vaccine. 2025;52:126949. PubMedAbstract available
PEREZ-PEREZ A, Vallejo JR Francisco Oller y Ferrer (1758-1831). The surgeon who performed the first
smallpox vaccination in a Hispanic American territory.
Vaccine. 2025;51:126875. PubMedAbstract available
GRIFFIN LB, Polnaszek BE, Shin J, Clark MA, et al Parental status and gender are associated with differences in Tdap vaccination
rates among United States adults.
Vaccine. 2025;52:126901. PubMedAbstract available
BENDERA A, Nakamura K, Tran XMT, Kapologwe NA, et al Persistent socioeconomic disparities in childhood vaccination coverage in
Tanzania: Insights from multiple rounds of demographic and health surveys.
Vaccine. 2025;52:126904. PubMedAbstract available
DHINGRA MS, Peterson J, Hedrick J, Pan J, et al Corrigendum to "Immunogenicity, safety and inter-lot consistency of a
meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase
III randomized study" [Vaccine (38) (2020) 5194-5201].
Vaccine. 2025;52:126912. PubMed
DIYA O, Gayed J, Lowry FS, Ma H, et al A phase 2/3 trial to investigate the safety and immunogenicity of monovalent
Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old.
Vaccine. 2025;52:126869. PubMedAbstract available
LEBLANG D, Smith MD, Wesselbaum D Global perspectives on COVID-19 vaccination: Impacts on well-being and
inequality.
Vaccine. 2025;52:126906. PubMedAbstract available
ANDERSEN KM, Allen KE, Nepal RM, Mateus JS, et al Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using
tokenization in two U.S. states.
Vaccine. 2025;52:126881. PubMedAbstract available
DUDLEY MZ, Zapf AJ, Delamater P, Proveaux TM, et al Attitudes of California school personnel on potential COVID-19 vaccine mandates
and state law SB277 to remove nonmedical vaccine exemptions.
Vaccine. 2025;52:126888. PubMedAbstract available
GARLING A, Goursat C, Seguy C, Martin P, et al Development of intimin-enriched outer membrane vesicles (OMVs) as a vaccine to
control intestinal carriage of Enterohemorrhagic Escherichia coli.
Vaccine. 2025;52:126899. PubMedAbstract available
FARAH Z, Bazant ES, Basha I, Saleh N, et al Determinants of seasonal influenza vaccination uptake, intention and
recommendations among Lebanese physicians.
Vaccine. 2025;52:126890. PubMedAbstract available
CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al Correction to "Recombinant Spike protein vaccines coupled with adjuvants that
have different modes of action induce protective immunity against SARS-CoV-2"
[Vaccine 2023 Sep 22 41(41) 6025-6035. Doi: 10.1016/j.vaccine.2023.08.054].
Vaccine. 2025;52:126880. PubMedAbstract available
YE Q, Xiao Z, Bai C, Yao H, et al Unveiling the multi-characteristic potential of hyper-productive suspension MDCK
cells for advanced influenza A virus propagation.
Vaccine. 2025;52:126900. PubMedAbstract available
MACKENZIE LJ, Bousie JA, Newman P, Cunningham J, et al What three years of COVID-19 vaccine administration reveals about the incidence
of shoulder injury related to vaccine administration (SIRVA).
Vaccine. 2025;51:126892. PubMedAbstract available
VAN BEEK LF, van der Gaast-de Jongh C, Platenburg PP, Hilgers L, et al Improving the immunogenicity of the pneumococcal conjugate vaccine using a
synthetic carbohydrate fatty acid monosulphate squalane-in-water adjuvant.
Vaccine. 2025;51:126893. PubMedAbstract available
ATTI A, England A, Sung J, Foulkes S, et al Estimating neutralising antibody responses against emerging SARS-CoV-2 variants
utilising convalescent sera before the roll-out of XBB-lineage vaccines.
Vaccine. 2025;51:126898. PubMedAbstract available
MEYERS E, De Rop L, Deschepper E, Duysburgh E, et al SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and
staff post-primary course vaccination in Belgium between February and December
2021.
Vaccine. 2025;51:126865. PubMedAbstract available
BERGSTROM F, Gunther F, Britton T A counterfactual analysis quantifying the COVID-19 vaccination impact in Sweden.
Vaccine. 2025;52:126870. PubMedAbstract available
DERBISE A, Guillas C, Echenique-Rivera H, Carniel E, et al Contribution of the type 3 secretion system to adaptive and innate immunity
induced by a live Yersinia pseudotuberculosis plague vaccine.
Vaccine. 2025;51:126887. PubMedAbstract available
SHAO Q The origin of vaccine nationalism.
Vaccine. 2025;51:126897. PubMed
HALL C, Lanning J, Romano CJ, Bukowinski AT, et al COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes
among United States military service members, January-December 2021.
Vaccine. 2025;51:126894. PubMedAbstract available
ZHAO T, Liu X, Huang X, Wang L, et al Development and evaluation of mosaic VLPs vaccine for enhanced broad-Spectrum
immunity against influenza B virus lineages in mice.
Vaccine. 2025;51:126882. PubMedAbstract available
TAAFFE J, Goldin S, Lambach P, Sparrow E, et al Global production capacity of seasonal and pandemic influenza vaccines in 2023.
Vaccine. 2025;51:126839. PubMedAbstract available
DARWAR R, Huang X, Abayeneh A, Alemayehu Beshah S, et al Costing approaches for vaccine-preventable disease surveillance: Lessons from
Ethiopia and Nepal.
Vaccine. 2025;50:126776. PubMedAbstract available
SIERRA MS, Carvajal LJ, Dull P, Herrero R, et al Human papillomavirus type 16 and 18 viral clearance and progression to precancer
among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine
trial (CVT).
Vaccine. 2025;50:126841. PubMedAbstract available
APPEL AM, Janbek J, Laursen TM, Gasse C, et al Dementia and influenza vaccination: Time trends and predictors of vaccine uptake
among older adults.
Vaccine. 2025;51:126864. PubMedAbstract available
MONTROY J, Yan C, Khan F, Forbes N, et al Post-exposure prophylaxis for the prevention of measles: A systematic review.
Vaccine. 2025;47:126706. PubMedAbstract available
KAHN R, Moiane B, Lessa FC, Massora S, et al Nasopharyngeal carriage of Streptococcus pneumoniae among children and their
household members in southern Mozambique five years after PCV10 introduction.
Vaccine. 2025;47:126691. PubMedAbstract available
YILDIRIM M, Keskinocak P, Hinderstein S, Tran K, et al A comprehensive analysis of serotype-specific invasive capacity, clinical
presentations, and mortality trends of invasive pneumococcal disease.
Vaccine. 2025;47:126692. PubMedAbstract available
KEMP M, Capriola A, Schauer S RSV immunization uptake among infants and pregnant persons - Wisconsin, October
1, 2023-March 31, 2024.
Vaccine. 2025;47:126674. PubMedAbstract available
YE Q, Li H, Xie Z, Gao X, et al Antibody persistence in Chinese toddlers at 1 year and 2 years after two
different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine
(PCV13-TT).
Vaccine. 2025 Feb 15:126815. doi: 10.1016/j.vaccine.2025.126815. PubMedAbstract available
CHANG C, Patel H, Ferrari A, Scalzo T, et al sa-mRNA influenza vaccine raises a higher and more durable immune response than
mRNA vaccine in preclinical models.
Vaccine. 2025;51:126883. PubMedAbstract available
BENN CS Non-specific effects of vaccines: The status and the future.
Vaccine. 2025;51:126884. PubMed
THOMPSON EL, Akpan IN, Alkhatib S, Grace J, et al Implementation of mid-adult HPV vaccination guidelines into clinical practice.
Vaccine. 2025;51:126867. PubMedAbstract available
SMITH DS, Postma M, Fisman D, Mould-Quevedo J, et al Cost-effectiveness models assessing COVID-19 booster vaccines across eight
countries: A review of methods and data inputs.
Vaccine. 2025;51:126879. PubMedAbstract available
DEANE A, White C, Morrissey Y, Jessop L, et al The impact of HPV vaccine disinformation and misinformation in disadvantaged
educational settings in Ireland: A multi-year analysis of a school immunisation
system.
Vaccine. 2025;51:126868. PubMedAbstract available
BERRYMAN S, Asfor A, Benham E, Howe N, et al Foot-and-mouth disease vaccine quality: A universal test for intact viral capsids
based on detection of VP4.
Vaccine. 2025;51:126845. PubMedAbstract available
VAN DIEMEN PM, Lean FZX, Ramsay A, Mollett BC, et al Evaluation of a nanoparticle influenza vaccine in the pig model.
Vaccine. 2025;49:126844. PubMedAbstract available
KIM SY, Song M, Kwon SL Impact of caregiver vaccination status on child influenza vaccination hesitancy:
A time-to-vaccination analysis for 2023-2024 season in the Republic of Korea.
Vaccine. 2025;49:126852. PubMedAbstract available
COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in
vulnerable groups - The CONVERS project, report from a pediatric tertiary
hospital.
Vaccine. 2025;49:126778. PubMedAbstract available
SHERMAN ME, Michalski J, Das S, Yang H, et al BECC-engineered live-attenuated Shigella vaccine candidates display reduced
endotoxicity with robust immunogenicity in mice.
Vaccine. 2025;50:126779. PubMedAbstract available
ADAMS L, Karachaliou Prasinou A, Trotter C Modelling the impact and cost effectiveness of universal varicella vaccination in
England.
Vaccine. 2025;50:126831. PubMedAbstract available
ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted
quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults
aged 50 years and older.
Vaccine. 2025;51:126791. PubMedAbstract available
WILLIAMS JTB, Johnson D, Weinshenker D, O'Leary ST, et al Co-creation of pediatric influenza digital stories via rapid community
translation.
Vaccine. 2025;51:126866. PubMedAbstract available
O'KENNEDY MM, Reedy SE, Abolnik C, Khan A, et al Protective efficacy of a bivalent equine influenza H3N8 virus-like particle
vaccine in horses.
Vaccine. 2025;50:126861. PubMedAbstract available
CAPAO A, Araujo MF, Tort LFL, Toledo TS, et al Impact in the humoral and cellular immune response to SARS-CoV-2 variants after
primary vaccination with AZD1222/COVISHIELD protocol in healthy adults.
Vaccine. 2025;50:126785. PubMedAbstract available
HOULE SKD, Constantinescu C, Dube E Navigating the 'sea of Cs' in vaccine hesitancy: Where does collaboration fit?
Vaccine. 2025;51:126876. PubMed
SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al Intention to receive new vaccines post-COVID-19 pandemic among adults and health
workers in Lusaka, Zambia.
Vaccine. 2025;50:126846. PubMedAbstract available
GEIGER M, Betsch C, Bohm R Mind the jingle: A call to consider construct validity of the 7C of vaccination
readiness.
Vaccine. 2025 Feb 8:126843. doi: 10.1016/j.vaccine.2025.126843. PubMed
FAUSTINI SE, Backhouse C, Duggal NA, Toellner KM, et al Time of day of vaccination does not influence antibody responses to pneumococcal
and annual influenza vaccination in a cohort of healthy older adults.
Vaccine. 2025;49:126770. PubMedAbstract available
NAFICY A, Chugh Y, Tariq M, Hawksworth H, et al Immune response and safety of the adjuvanted recombinant zoster vaccine in adults
50 years of age and older in India: A randomized phase 3 trial.
Vaccine. 2025;50:126819. PubMedAbstract available
SCALSKY R, Dwivedi A, Stabler TC, Mbambo G, et al Whole-genome sieve analysis: Identification of protective malaria antigens by
leveraging allele-specific vaccine efficacy.
Vaccine. 2025;50:126783. PubMedAbstract available
FU Y, Xu Z, Wang Q, Zhang J, et al Effectiveness and coverage of COVID-19 vaccination among the infection-naive
population: A community-based retrospective cohort study in China.
Vaccine. 2025;50:126836. PubMedAbstract available
FRITSCHI N, Heininger U Pertussis vaccination campaign among health care workers and validity of recall
of previous adverse events following immunization.
Vaccine. 2025;50:126850. PubMedAbstract available
ABBAD A, Yueh J, Yellin T, Singh G, et al Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads
to enhanced immune responses to influenza virus and reduced immune responses to
SARS-CoV-2 in naive mice.
Vaccine. 2025;50:126825. PubMedAbstract available
KRAJCAR N, Trkulja V, Butic I, Tesovic G, et al Impact of the 10-valent pneumococcal conjugate vaccine (PCV10) on pneumococcal
carriage in healthy children and children with acute otitis media and pneumonia:
emergence of serotypes 3, 6C and 19A in Croatia.
Vaccine. 2025;50:126848. PubMedAbstract available
GEBREAL A, Ashmawy R, Ahmed MJ, Khattab M, et al A systematic review and meta-analysis on parental uptake and willingness to
vaccinate children against human papillomavirus in the Eastern Mediterranean
Region.
Vaccine. 2025 Feb 6:126832. doi: 10.1016/j.vaccine.2025.126832. PubMedAbstract available
NAKAYAMA T, Hamada S, Kawamura A, Sogawa Y, et al Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001;
measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy
1-year-old Japanese children.
Vaccine. 2025 Feb 6:126698. doi: 10.1016/j.vaccine.2024.126698. PubMedAbstract available
VAHORA MS, Leao O, da Silveira MF, Domingues MR, et al Impacts of vaccination, school attendance, and nutrition on SARS-CoV-2 antibody
titer in a prospective birth cohort in Brazil.
Vaccine. 2025;49:126838. PubMedAbstract available
MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al Acceptance and preference between respiratory syncytial virus vaccination during
pregnancy and infant monoclonal antibody among pregnant and postpartum persons in
Canada.
Vaccine. 2025;50:126818. PubMedAbstract available
KANG HS, Kim SY, De Gagne JC, Chae SM, et al Pregnant women's experiences of and attitudes toward COVID-19 vaccination: A
qualitative descriptive study.
Vaccine. 2025;50:126835. PubMedAbstract available
SOENS M, Ananworanich J, Hicks B, Lucas KJ, et al A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal
influenza vaccine in adults.
Vaccine. 2025;50:126847. PubMedAbstract available
JENNINGS MC, Nabia S, Morgan C, Nduka CC, et al Realist review of low- to upper-middle-income country experiences on integration
of HPV vaccination with other adolescent health services.
Vaccine. 2025;50:126833. PubMedAbstract available
HONDA-OKUBO Y, Sajkov D, Wauchope B, Turner JV, et al Immunogenicity and safety study of a single dose of SpikoGen(R) vaccine as a
heterologous or homologous intramuscular booster following a primary course of
mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory
adults.
Vaccine. 2025;49:126744. PubMedAbstract available
PORTER RM, Bednarczyk RA Better, worse, or holding the course? Analysis of HPV vaccination patterns in the
US, 2008-2020.
Vaccine. 2025;50:126824. PubMedAbstract available
DOUA J, Ndembi N, Auerbach J, Kaseya J, et al Advancing local manufacturing capacities for vaccines within Africa -
Opportunities, priorities and challenges.
Vaccine. 2025;50:126829. PubMedAbstract available
CARTER JJ, Smith RA, Scherer EM, Skibinski DAG, et al Term immune memory responses to human papillomavirus (HPV) vaccination following
2 versus 3 doses of HPV vaccine.
Vaccine. 2025;50:126817. PubMedAbstract available
WALKER RI Conserved antigens for enteric vaccines.
Vaccine. 2025;50:126828. PubMedAbstract available
SORENSEN JK, Jensen A, Zimakoff AC, Vittrup DM, et al Genetic associations with measles PRNT and IgG antibody response to MMR
vaccination in 6- and 15-month-old children.
Vaccine. 2025;50:126788. PubMedAbstract available
GAO MZ, Awonusi OO, Ramkumar SP, Myint JA, et al The Affordable Care Act and change in human papillomavirus (HPV) vaccine uptake
in the United States.
Vaccine. 2025;50:126842. PubMedAbstract available
KAN AKC, Mak HWF, Chiang V, Yim JSH, et al Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy
delabelling: Effectiveness and impact on quality of life.
Vaccine. 2025;50:126849. PubMedAbstract available
URSELLI F, Gomez A, Gray MD, Cameron CE, et al Identification of antibodies induced by immunization with the syphilis vaccine
candidate Tp0751.
Vaccine. 2025;50:126804. PubMedAbstract available
POWELL A, Jones A, Van Hout MC, Montgomery C, et al Influenza vaccine uptake in socially deprived areas: A multilevel retrospective
population-based cross-sectional study using electronic health records in
Liverpool, United Kingdom.
Vaccine. 2025;50:126837. PubMedAbstract available
VAN ENTER BJD, de Zeeuw J, Bakar O, Bakhlakh S, et al Health system barriers to HPV-vaccination in adolescent females with a Moroccan
or Turkish migration background in the Netherlands: A qualitative study.
Vaccine. 2025;50:126827. PubMedAbstract available
GE Y, Handel A, Giabbanelli PJ, Lemacks J, et al Exploring bias due to below-limit-of-detection values in influenza vaccine
antibody modeling: A case study and instructional guide for the CIVIC study.
Vaccine. 2025;49:126802. PubMedAbstract available
PIGHI L, Salvagno GL, Lippi G Correlation between basal humoral immunogenicity and side effects after receiving
the bivalent formulation of a mRNA-based vaccine.
Vaccine. 2025 Feb 1:126803. doi: 10.1016/j.vaccine.2025.126803. PubMed
CHUNG H, Krishnasamy M, Joyce T, Dryden T, et al "It's a risk-benefit analysis": Qualitative perspectives on barriers and enablers
to post-treatment vaccination from adults affected by a haematological malignancy
in Australia.
Vaccine. 2025;50:126826. PubMedAbstract available
EIDEN AL, Mackie DS, Modi K, Drakeley S, et al Attitudes and beliefs about vaccination among adults in the United States: A
real-world, cross-sectional, web-based survey study.
Vaccine. 2025;50:126807. PubMedAbstract available
January 2025
MCGOLDRICK M, Truong TBQ, Campa C, Ali M, et al How to accelerate the supply of vaccines to all populations worldwide? Part III:
Reflections after the pandemic.
Vaccine. 2025;49:126782. PubMedAbstract available
GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in
immunocompromised patients: A targeted literature review.
Vaccine. 2025;49:126777. PubMedAbstract available
GRAILEY K, Crespo RF, Woldmann L, Chisambi M, et al Implementing behavioural science-informed letter interventions to increase
COVID-19 vaccination uptake in London residents. A difference-in-difference study
in London, United Kingdom.
Vaccine. 2025;49:126781. PubMedAbstract available
FETENSA G, Tolossa T, Besho M, Yadesa G, et al Willingness to take Mpox vaccine and associated factors among health
professionals in Ethiopia: A cross-sectional study.
Vaccine. 2025;49:126822. PubMedAbstract available
BARAL R, Amponsa-Achiano K, Barros I, Cofie P, et al What will introducing and delivering new maternal vaccines cost in Ghana and
Mozambique? A prospective analysis.
Vaccine. 2025;49:126769. PubMedAbstract available
DALE KD, Denholm JT Optimising the M72/AS01E tuberculosis vaccine candidate phase 3 trial based on
the phase 2b trial results.
Vaccine. 2025;49:126816. PubMed
ONO S, Nakajima M, Yamana H, Michihata N, et al Tetanus toxoid vaccination uptake by trauma patients in Japan: A retrospective
cohort study using large administrative claims data.
Vaccine. 2025;49:126812. PubMedAbstract available
YILMAZ IC, Ipekoglu EM, Golcuklu BS, Bildik T, et al A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen
carrying virus-like particle COVID-19 vaccine.
Vaccine. 2025;49:126787. PubMedAbstract available
MWENDA JM, Mandomando I, Worwui AK, Gacic-Dobo M, et al A decade of rotavirus vaccination in the World Health Organization African
Region: An in-depth analysis of vaccine coverage from 2012 to 2023.
Vaccine. 2025 Jan 30:126768. doi: 10.1016/j.vaccine.2025.126768. PubMedAbstract available
JIANG Y, Luo Y, Xiao X, Li X, et al Global, regional, and national burdens of vaccine-preventable infectious diseases
with high incidence among middle-aged and older adults aged 55-89 years from 1990
to 2021: Results from the global burden of disease study 2021.
Vaccine. 2025;49:126786. PubMedAbstract available
HASHIMOTO M, Tsujii K, Nakajima-Yoshida H, Akiyama N, et al A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune
responses of quadrivalent influenza vaccine in ferrets.
Vaccine. 2025;49:126780. PubMedAbstract available
VIGEZZI GP, Vecchio R, Barbati C, Bonazza G, et al Historical analysis of the first smallpox vaccination campaigns in early
19-century northern Italy: organisation and communication insights for
contemporary epidemics' prevention and control.
Vaccine. 2025;49:126764. PubMedAbstract available
WIEGAND RE, Devine O, Wallace M, Ortega-Sanchez IR, et al Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital
deaths averted in the United States by 2023-2024 COVID-19 vaccination: A
conditional probability, causal inference, and multiplier-based approach.
Vaccine. 2025;49:126808. PubMedAbstract available
KHAN A, Zhu Y, Babcock HM, Busse LW, et al COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United
States, 2019-2022.
Vaccine. 2025 Jan 29:126806. doi: 10.1016/j.vaccine.2025.126806. PubMedAbstract available
STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al Corrigendum to "General vaccination willingness and current vaccination status in
relation to clinical and psychological variables in patients with multiple
sclerosis" [Vaccine 40 (23) (2022 May 20) 3236-3243].
Vaccine. 2025;48:126741. PubMed
FLECK-VIDAL C, Doubell A, Gerke C, Lamichhane U, et al Vaccines and AMR: An analysis of the funding landscape for human bacterial
vaccines in low-and middle-income countries.
Vaccine. 2025;49:126771. PubMedAbstract available
ITO S, Tsuchida N, Kusunoki S, Kaneko Y, et al Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca
AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe
acute respiratory syndrome coronavirus 2 vaccination in Japan.
Vaccine. 2025;49:126754. PubMedAbstract available
LAO G, Feng J, Wu L, Su W, et al Development of a genetically modified full-length human respiratory syncytial
virus preF protein vaccine.
Vaccine. 2025;49:126799. PubMedAbstract available
ROPER LE, Link-Gelles R, Surie D, DeCuir J, et al A framework for monitoring RSV prevention product effectiveness in the United
States.
Vaccine. 2025;45:126633. PubMedAbstract available
EURICH DT, Weaver O, McDermott C, Soprovich A, et al Describing COVID-19 immunizations for First Nations people on-reserve in Alberta
using real-time integration of point of care and provincial data.
Vaccine. 2025;45:126614. PubMedAbstract available
CONLIN K, Jenkin D, de Whalley P, Weckx LY, et al Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a
randomised controlled trial.
Vaccine. 2025;45:126582. PubMedAbstract available
WEI Y, Wang J, Wang L, Liu B, et al Comparative study on the inactivation and immunogenicity of Mycoplasma
hyopneumoniae and Mycoplasma hyorhinis vaccines prepared using different
inactivants.
Vaccine. 2025 Jan 24:126766. doi: 10.1016/j.vaccine.2025.126766. PubMedAbstract available
KHETSURIANI N, Tursunova D, Kasimova R, Sharapov S, et al Prevalence of chronic hepatitis B virus infection among children in Uzbekistan:
Impact of vaccination.
Vaccine. 2025;48:126743. PubMedAbstract available
GLOANEC N, Guyard-Nicodeme M, Chemaly M, Dory D, et al Reverse vaccinology: A strategy also used for identifying potential vaccine
antigens in poultry.
Vaccine. 2025;48:126756. PubMedAbstract available
OKA E, Ueda Y, Yagi A, Machida M, et al Challenges to promoting maternal respiratory syncytial virus vaccination in
Japan.
Vaccine. 2025;48:126767. PubMedAbstract available
FARNSWORTH MG, Khanipov K, Botnar K, Weaver SC, et al Real-world evidence of yellow Fever vaccination data-driven study.
Vaccine. 2025;48:126758. PubMedAbstract available
SATO R Closing the gap on vaccine uptake in developing countries: Is there a role for
cash incentives?
Vaccine. 2025;48:126763. PubMedAbstract available
BJERKHAUG AU, Ramalingham S, Mboizi R, Le Doare K, et al Corrigendum to "The immunogenicity and safety of Group B Streptococcal maternal
vaccines: A systematic review" [Vaccine 42 (2024) 84-98].
Vaccine. 2025;48:126732. PubMed
PROSSER LA, Perroud J, Chung GS, Gebremariam A, et al The cost-effectiveness of vaccination against COVID-19 illness during the initial
year of vaccination.
Vaccine. 2025;48:126725. PubMedAbstract available
NGOCHO JS, de Jongh CEVG, Sebba J, Mtei M, et al Emerging of non-vaccine Streptococcus pneumoniae serotypes colonizing the
nasopharynx of children under the age of five years in the 13-vallent
pneumococcal conjugate vaccine era in Moshi district, Tanzania. A short
communication.
Vaccine. 2025;48:126724. PubMedAbstract available
HINMAN AR, Banerjee E, Brewer NT, Hayes ES, et al Corrigendum to "Sustainability of measles, rubella, and congenital rubella
syndrome (CRS) elimination in the United States, January 2022 - June 2024"
[Vaccine 46C (2025) 126681].
Vaccine. 2025;48:126739. PubMed
GIOVANETTI M, Cella E, Sampaio SC, Elias MC, et al Dengue vaccination and outbreaks: Bridging clinical diagnosis with genomic
surveillance.
Vaccine. 2025 Jan 20:126755. doi: 10.1016/j.vaccine.2025.126755. PubMed
CLAESSENS T, Eagan RL, Hendrickx G, Van Damme P, et al Navigating vaccine confidence: A mixed methods study investigating healthcare
providers' perspectives across four non-EU European regions.
Vaccine. 2025;47:126694. PubMedAbstract available
MARTINON-TORRES F, Wysocki J, Szenborn L, Carmona-Martinez A, et al Corrigendum to "A Phase III, multicenter, randomized, double-blind, active
comparator-controlled study to evaluate the safety, tolerability, and
immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)"
[Vaccine 41 (2023) 3387-339
Vaccine. 2025;48:126628. PubMed
LIAO Z, Deng L, Luo J, Shi M, et al Association between adults' vaccine literacy and their intention to recommend
older family members for influenza vaccine.
Vaccine. 2025;48:126757. PubMedAbstract available
RAINERI D, Mazzucca CB, Moia R, Bruna R, et al Impairment of the T cell memory response in chronic lymphocytic leukemia patients
after SARS-CoV-2 vaccination.
Vaccine. 2025;48:126723. PubMedAbstract available
BANU S, Kishor PV, Krishnappa S, Ramasamy Periyasamy TS, et al Effect of vaccination against foot-and-mouth disease during mid-pregnancy on the
neutralizing antibody response in the cow.
Vaccine. 2025;48:126738. PubMedAbstract available
MADESH S, McGill J, Jaworski DC, Ferm J, et al Prolonged immune response to tick-borne Ehrlichia chaffeensis infection using a
genetically modified live vaccine.
Vaccine. 2025;48:126730. PubMedAbstract available
SILVA-FERNANDES AT, Moreira SB, Gaspar LP, Cajaraville ACDRA, et al Safety and immunogenicity of different 17DD yellow fever vaccines in
golden-headed tamarins (Leontopithecus chrysomelas): Inhibition of viremia and
RNAemia after homologous live-attenuated vaccination.
Vaccine. 2025;48:126721. PubMedAbstract available
TRANTER I, Judd D, Stickley M, Vasant B, et al Promoting aged care COVID-19 and influenza vaccination through education of
Australian residential aged care staff: A mixed methods project evaluation.
Vaccine. 2025;48:126742. PubMedAbstract available
SHAH RM, Parzen-Johnson S, Sun S, Patel SJ, et al Childhood opportunity index and vaccine uptake in pediatric COVID-19
hospitalizations.
Vaccine. 2025;48:126734. PubMedAbstract available
DOS SANTOS CVB, Coelho LE, de Noronha TG, Goedert GT, et al The impact of vaccination on the length of stay of hospitalized COVID-19 patients
in Brazil.
Vaccine. 2025;48:126735. PubMedAbstract available
POURAKBARI B, Mahmoudi S, Sajedi Moghaddam S, Jafari E, et al Evaluation of anti-Pertussis antibody levels in Iranian infants and children: Is
it time to include booster acellular Pertussis Vaccines in the immunization
schedule?
Vaccine. 2025;48:126736. PubMedAbstract available
KUMAR S, Hazlett K, Bai G Mucosal immunity elicited by a human-Fcgamma receptor-I targeted intranasal vaccine
platform enhances resistance against nasopharyngeal colonization of Streptococcus
pneumoniae and induces broadly protective immunity against respiratory pathogens.
Vaccine. 2025;48:126729. PubMedAbstract available
SONG H, Jin S, Yang GJ, Lim NWH, et al Modelling the impact and cost-effectiveness of upcoming Zika virus vaccines on
congenital Zika syndrome.
Vaccine. 2025;48:126728. PubMedAbstract available
SANTANA AP, Soborg B, Jacobsen SU, Zettler I, et al Danish parents' vaccination readiness is associated with their children's
officially registered vaccination history.
Vaccine. 2025;47:126693. PubMedAbstract available
ISLAM EA, Fegan JE, Zeppa JJ, Ahn SK, et al Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in
preclinical models of nasal and genital colonization by pathogenic Neisseria.
Vaccine. 2025;48:126709. PubMedAbstract available
AANYU HT, Nalunkuma C, Kaudha E, Nalumansi E, et al Effectiveness of monovalent rotavirus vaccine against hospital-attended rotavirus
gastroenteritis among children in Uganda.
Vaccine. 2025;48:126726. PubMedAbstract available
DE OLIVEIRA PMN, Hartmann K, Bhamare C, Lucchesi MBB, et al Active vaccine safety surveillance in low- and middle-income countries:
Challenges for vaccine manufacturers from emerging countries.
Vaccine. 2025;48:126727. PubMedAbstract available
ZHANG Y, Li X, Yang Y, Yin Y, et al Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant
breakthrough infection.
Vaccine. 2025;48:126722. PubMedAbstract available
COROMINAS J, Garriga C, Prenafeta A, Moros A, et al Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2
booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Vaccine. 2025;47:126685. PubMedAbstract available
XIE W, Luo D, Soni V, Wang Z, et al Functional characterization of MMAR_1296 in Mycobacterium marinum and its
potential as a vaccine candidate.
Vaccine. 2025;48:126720. PubMedAbstract available
GONG X, Huang Z, Zheng Y, Xiao W, et al Rotavirus vaccine effectiveness and coverage among children younger than 5 years
old in Shanghai, China: A test-negative case control study.
Vaccine. 2025;48:126731. PubMedAbstract available
ROSENTHAL M, Stoecker C, Leidner AJ, Cho BH, et al Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for
U.S. adults aged 65 years and older and adults 19 years and older with underlying
conditions.
Vaccine. 2025;44:126567. PubMedAbstract available
ESCABI-WOJNA E, Alvelo-Fernandez PM, Suarez E, Colon-Lopez V, et al Sex differences in parental reasons for lack of intent to initiate HPV
vaccination among adolescents ages 13-17 years: National Immunization Survey -
Teen 2019-2021.
Vaccine. 2025;44:126584. PubMedAbstract available
MARCHESE AM, Beyhaghi H, Rousculp MD, Huang V, et al Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines
compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2
trial (COV-BOOST).
Vaccine. 2025;44:126569. PubMedAbstract available
FILIMONOVIC J, Stosic M, Gazibara T, Dotlic J, et al The trend in national childhood immunization program coverage throughout Serbian
communities in Kosovo and Metohija from 2003 to 2022: pre-COVID-19 period vs.
COVID-19 pandemic.
Vaccine. 2025;44:126576. PubMedAbstract available
CARNEIRO GB, Yerneni SS, Chinaia K, Araujo AP, et al Protection induced by Streptococcus pneumoniae extracellular vesicles against
nasal colonization and invasive infection in mice and the role of PspA.
Vaccine. 2025;44:126566. PubMedAbstract available
OLIVERO-DEIBE N, Frigini EN, Ramos N, Carrion F, et al The stability of PCV2 virus-like particles from mammalian cells and challenges
for biotechnological applications.
Vaccine. 2025;44:126549. PubMedAbstract available
HARTEVELD LM, van Leeuwen LM, Euser SM, Smit LJ, et al Respiratory syncytial virus (RSV) prevention: Perception and willingness of
expectant parents in the Netherlands.
Vaccine. 2025;44:126541. PubMedAbstract available
LI Y, Chen L, Xiao J, Feng K, et al Immunoprotective efficacy of Escherichia coli-derived outer membrane vesicles
displaying PlpE protein of Pasteurella multocida.
Vaccine. 2025;44:126532. PubMedAbstract available
DE LIMA EDS, Antunes MOB, de Souza JS, Jones MH, et al Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes
among children and adolescents: A Brazilian nationwide cohort study.
Vaccine. 2025;44:126550. PubMedAbstract available
SILVA HM Return of poliomyelitis: A real risk in a country afflicted by scientific
denialism.
Vaccine. 2025;44:126449. PubMedAbstract available
DAVIES C, Baker B, Berger MN, Knox SL, et al Vaccine microarray patch self-administration: A preliminary study in adults
50 years of age and over.
Vaccine. 2025 Jan 12:126699. doi: 10.1016/j.vaccine.2024.126699. PubMedAbstract available
VITTRUP DM, Charabi S, Jensen A, Stensballe LG, et al A systematic review and meta-analysis of adverse events following
measles-containing vaccines in infants less than 12 months of age.
Vaccine. 2025;47:126687. PubMedAbstract available
RITCHIE AJ, Meeyai A, Trotter C, Douglas AD, et al Routine childhood rabies pre-exposure prophylaxis can be cost effective in low-
and middle-income countries.
Vaccine. 2025;47:126703. PubMedAbstract available
OSEI I, Schmidt-Chanasit J, Licciardi PV, Secka O, et al Immunogenicity of yellow fever vaccine co-administered with 13-valent
pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial.
Vaccine. 2025;47:126712. PubMedAbstract available
FREY SE, Brady R, Jackson L, Goepfert P, et al Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated
vaccine with or without MF59(R).
Vaccine. 2025;47:126702. PubMedAbstract available
HONDA-OKUBO Y, Vaghasiya U, Petrovsky N Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted
recombinant hemagglutinin seasonal quadrivalent influenza vaccine.
Vaccine. 2025;47:126707. PubMedAbstract available
GENDLER Y, Ofri L, Videl H Understanding factors contributing to vaccination underutilization among Jewish
ultra-orthodox communities in Israel: A cross-sectional study.
Vaccine. 2025;47:126711. PubMedAbstract available
SHIELDS T, King KD, Cripps S, Edwards SA, et al Perspectives on vaccination among unvaccinated members of a Canadian indigenous
population.
Vaccine. 2025;47:126665. PubMedAbstract available
CHIU CY, Sampathkumar P, Brumble LM, Vikram HR, et al Optimizing hepatitis B virus seroprotection in thoracic organ transplantation:
The role of HepB-CpG (Heplisav-B) vaccination schedule.
Vaccine. 2025;47:126705. PubMedAbstract available
NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al Corrigendum to How has post-implementation surveillance of high-coverage
vaccination with HPV16/18-AS04 vaccine in England added to evidence about its
cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi:
10.1016/j.vaccine.2024.126215. Ep
Vaccine. 2025;47:126701. PubMed
CASPERSEN IH, Skodvin SN, Blix K, Robertson AH, et al Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster
vaccination: A population-based cohort study.
Vaccine. 2025;47:126664. PubMedAbstract available
CAO Y, da Silva Araujo M, Lorang CG, Dos Santos NAC, et al Distinct immunogenicity outcomes of DNA vaccines encoding malaria
transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
Vaccine. 2025;47:126696. PubMedAbstract available
LE N, McMann TJ, Wenzel C, Li Z, et al COVID-19 pediatric vaccine Hesitancy: Themes and interactions with verified
twitter accounts.
Vaccine. 2025;47:126688. PubMedAbstract available
SEO H, Kim BJ, Oh J, Jung S, et al Protection against tuberculosis by vaccination of secreted chorismate mutase
(Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and
alum adjuvants.
Vaccine. 2025;47:126710. PubMedAbstract available
SU Q, Qiu F, Gao Z, Zhao Y, et al Long-term efficacy and anamnestic response of hepatitis B vaccine derived from
Chinese hamster ovary cell after 18-20 years.
Vaccine. 2025;47:126655. PubMedAbstract available
ZHANG S, Liu G, Wang C, Guo A, et al Enhanced immunogenicity of a BoHV-1 gG-/tk- vaccine.
Vaccine. 2025;47:126704. PubMedAbstract available
LI W, Li YA, Wang S, Shi H, et al A universal live vaccine platform against multiple serotypes Streptococcus suis
based on polyvalent antigen protein.
Vaccine. 2025;47:126700. PubMedAbstract available
DE LA FUENTE J, Gortazar C, Contreras M, Kabi F, et al Anti-tick vaccine in Uganda - from bench to field.
Vaccine. 2025 Jan 6:126695. doi: 10.1016/j.vaccine.2024.126695. PubMed
EL SAHLY HM, Anderson EJ, Jackson LA, Neuzil KM, et al Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza
a(H7N9) vaccine regimens.
Vaccine. 2025;47:126689. PubMedAbstract available
NAKANO T, Tanaka T Looking back at the 27th Academic Conference of the Japanese Society for
Vaccinology.
Vaccine. 2025;47:126697. PubMed
DUAN Y, Suo L, Li X, Bai C, et al Association between underlying conditions, multimorbidity, and COVID-19
vaccination status of adults aged >/=80 years old in Beijing, China.
Vaccine. 2025;47:126677. PubMedAbstract available
ALVARADO-FACUNDO E, Herrup R, Wang W, Colombo RE, et al Comparison of neuraminidase inhibiting antibody responses elicited by egg- and
cell-derived influenza vaccines.
Vaccine. 2025;46:126669. PubMedAbstract available
ANSELEM O, Charlier C, Viaud M, Lelong N, et al Barriers to influenza vaccination during pregnancy in France: A national
population-based study.
Vaccine. 2025;47:126671. PubMedAbstract available
KAUL R, Leidner AJ, Chesson HW Trends in costs of routinely recommended vaccines in the United States,
2001-2023.
Vaccine. 2025;47:126667. PubMedAbstract available
POLAND GA, de la Fuente J Quantum vaccinology: A new science and epistemological abstraction framework for
developing new vaccines and understanding the generation of the immune response.
Vaccine. 2025;46:126641. PubMed
GALETTI SC, Gadoth A, Halbrook M, Tobin NH, et al Historic smallpox vaccination and Mpox cross-reactive immunity: Evidence from
healthcare workers with childhood and adulthood exposures.
Vaccine. 2025;46:126661. PubMedAbstract available
GIERSING B, Mo AX, Hwang A, Baqar S, et al Meeting summary: Global vaccine and immunization research forum, 2023.
Vaccine. 2025;46:126686. PubMedAbstract available
POSTON TB, Girardi J, Kim M, Zwarycz P, et al Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4
T cell response and reduces bacterial burden following intravaginal infection
with Chlamydia muridarum.
Vaccine. 2025;43. PubMedAbstract available
LANG BALIJA M, Jagusic M, Forcic D, Ivancic-Jelecki J, et al Mumps virus neurovirulence assessment-impact of viral doses, animal sex and age
on results dispersion.
Vaccine. 2025;43. PubMedAbstract available
CHAUDHARY M, Cutland CL, Bonet M, Gentile A, et al Burden of Lassa fever disease in pregnant women and children and options for
prevention.
Vaccine. 2025;43. PubMedAbstract available
DERMENCHYAN A, Choi KR, Bokhoor PR, Cho DJ, et al Receipt of respiratory vaccines among patients with heart failure in a
multicenter health system registry.
Vaccine. 2025;46:126682. PubMedAbstract available
FLORES-VALDEZ MA Intravenous vaccination with BCG against tuberculosis: Strengths and questions
deserving further research.
Vaccine. 2025 Jan 1:126666. doi: 10.1016/j.vaccine.2024.126666. PubMed
December 2024
GURRY CE, Mwenda JM, Nardone A, Cohuet S, et al Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE)
network for respiratory pathogens.
Vaccine. 2024 Dec 31:126616. doi: 10.1016/j.vaccine.2024.126616. PubMedAbstract available
FERNANDEZ A, Askenazy F, Thummler S Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with
neurodevelopmental or psychiatric disorders.
Vaccine. 2024 Dec 30:126679. doi: 10.1016/j.vaccine.2024.126679. PubMed
HUSSEIN I, Valiverronen E, Nohynek H, Lamsa R, et al What makes an expert in childhood vaccinations? Perceptions of parents in
Finland.
Vaccine. 2024;46:126645. PubMedAbstract available
PILAPITIYA D, Lee WS, Vu MN, Kelly A, et al Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses
delivering self-assembling nanoparticles.
Vaccine. 2024;46:126668. PubMedAbstract available
CHOI YJ, Jung J, Kang M, Choi MJ, et al Corrigendum to The risk of pregnancy-related adverse outcomes after COVID-19
vaccination: propensity score-matched analysis with influenza vaccination.
Vaccine. 2024;46:126676. PubMed
ERBS G, Jakobsen JT, Schmidt ST, Christensen D, et al Retinoic acid-adjuvanted vaccine induces antigen-specific secretory IgA in the
gut of newborn piglets.
Vaccine. 2024;46:126672. PubMedAbstract available
TANG E, Ray I, Arnold BF, Acharya NR, et al Recombinant zoster vaccine and the risk of dementia.
Vaccine. 2024;46:126673. PubMedAbstract available
NAZARENO AL, Wood JG, Muscatello DJ, Homaira N, et al Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV)
vaccination in Australia: A dynamic and economic modelling analysis.
Vaccine. 2024;46:126651. PubMedAbstract available
MALTEZOU HC, Poland GA, de Lejarazu RO Influenza vaccination for children in Europe: The health of every child matters.
Vaccine. 2024 Dec 27:126675. doi: 10.1016/j.vaccine.2024.126675. PubMed
SAHA R, Lo M, De P, Deb AK, et al Epidemiology of viral gastroenteritis in children and genetic diversity of
rotavirus strains in Kolkata, West Bengal after introduction of rotavirus
vaccine.
Vaccine. 2024;45:126637. PubMedAbstract available
ZHANG J, Zhang L, Li J, Ma J, et al Moderate effectiveness of influenza vaccine in outpatient settings: A
test-negative study in Beijing, China, 2023/24 season.
Vaccine. 2024;46:126662. PubMedAbstract available
MA Y, Dong C, Kim JK, Zhu W, et al Impact of influenza immune imprinting on immune responses to subsequent
vaccinations in mice.
Vaccine. 2024;46:126670. PubMedAbstract available
CHO JY, Lee H, Wannaadisai W, Vietri J, et al Systematic literature review of cost-effectiveness analyses of adult 15- and
20-valent pneumococcal vaccines.
Vaccine. 2024;46:126656. PubMedAbstract available
AI L, Gao Z, Lv H, Zhang J, et al Immunogenicity and safety of live attenuated influenza vaccine in children aged
3-17 years in China.
Vaccine. 2024;46:126653. PubMedAbstract available
BEERENS D Navigating the future of vaccination strategies: Insights from the 17(th) annual
vaccine congress.
Vaccine. 2024;46:126634. PubMed
ZHANG Y, Zhao K, Liu Y, Xu J, et al An oral probiotic vaccine loaded by Lactobacillus casei effectively increases
defense against GCRV infection in grass carp.
Vaccine. 2024;45:126660. PubMedAbstract available
GRIMES DR Tortured confessions? Potentially erroneous statistical inferences may underpin
misleading claims of harms in reanalyses of COVID-19 and HPV vaccines.
Vaccine. 2024 Dec 25:126657. doi: 10.1016/j.vaccine.2024.126657. PubMedAbstract available
SAVULESCU C, Prats-Uribe A, Brolin K, Uuskula A, et al Relative effectiveness of the second booster COVID-19 vaccines against laboratory
confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study
(1 October 2022-2 May 2023).
Vaccine. 2024;45:126615. PubMedAbstract available
KILANY WH, Zain El-Abideen MA, Hisham I, Van Gaver D, et al Laboratory safety and immunogenicity evaluation of live attenuated avian
infectious bronchitis GI-23 virus vaccine.
Vaccine. 2024;45:126659. PubMedAbstract available
PEREZ-SAUCEDO D, Castro-Perea NV, Ruiz-Cruz A, Bustos-Jaimes I, et al Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus
virus-like particles.
Vaccine. 2024;45:126663. PubMedAbstract available
SHELDENKAR A, Ling TP, Schulz PJ, Chen MI, et al Trust in government vaccine recommendations during the Covid-19 pandemic in
Singapore: A longitudinal survey study.
Vaccine. 2024;45:126643. PubMedAbstract available
BARAL R, Fleming JA, Barros I, Cofie P, et al What will it take? Perspectives from five low- and middle-income countries on
opportunities and challenges of introducing new maternal vaccines.
Vaccine. 2024;45:126654. PubMedAbstract available
CAMPANELLA S, Volpe T, Safar Y, Lunsky Y, et al "They need to speak a language everyone can understand": Accessibility of
COVID-19 vaccine information for Canadian adults with intellectual and
developmental disabilities.
Vaccine. 2024;45:126618. PubMedAbstract available
WERTHNER Q, Faehrmann L, Och K, Bragazzi NL, et al Client satisfaction, safety, and insights from a three-season survey on influenza
vaccinations delivered at community pharmacies in Germany.
Vaccine. 2024;45:126650. PubMedAbstract available
GOMEZ JA, Pannunzio ME, Karwala P, Nocita F, et al Impact on meningococcal disease of different vaccination strategies with 4CMenB
and MenACWY-CRM197 in infants and adolescents in Argentina.
Vaccine. 2024;45:126589. PubMedAbstract available
TANAKA H, Takahashi Y, Matsumoto S, Matsuyama M, et al Shorter incubation period in symptomatic measles patients who had no history of
measles vaccination.
Vaccine. 2024;45:126652. PubMedAbstract available
LIEBERMANN E, Kornides M, Matsunaga M, Lim E, et al Corrigendum to "Use of social media and its influence on HPV vaccine hesitancy:
US National Online Survey of mothers of adolescents, 2023".
Vaccine. 2024;45:126640. PubMed
SERPA GONCALVES M, de Oliveira MM, Andrade RS, de Oliveira LF, et al Systematic review on the effectiveness of Brucella abortus S19 and RB51 vaccine
strains in field studies.
Vaccine. 2024;45:126649. PubMedAbstract available
FRAIHA ALS, da Silva Santos BSA, Aguilar NR, Gallinari GC, et al Immunization and challenge trials in a murine model using different inactivated
recombinant vaccines against H1N1 swine influenza virus circulating in Brazil.
Vaccine. 2024;45:126638. PubMedAbstract available
WANG J, Tonnies T, Brinks R Seasonal influenza vaccination coverage and the social determinants of influenza
vaccination among people over 50 with diabetes in Europe: Analyzing
population-based SHARE data for the 2019-2020 and 2021-2022 influenza seasons.
Vaccine. 2024;45:126646. PubMedAbstract available
KASSAM P, El-Zein M, Tota JE, Tellier PP, et al HPV vaccination and anal HPV infection in gay, bisexual, and other men who have
sex with men.
Vaccine. 2024;45:126644. PubMedAbstract available
DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al Corrigendum to Assessment of the Bnt162b2 covid-19 vaccine immune response in
Brazilian indigenous adolescents. Vaccine Volume 43, Part 1, 1 January 2025,
126494.
Vaccine. 2024;45:126630. PubMed
YANG J, Yao YL, Lv XY, Geng LH, et al The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing
assisted reproductive technology: A prospective cohort study.
Vaccine. 2024;45:126635. PubMedAbstract available
NUZHATH T, Yang Y, Couture MC, Gu NY, et al Structural equation modeling to evaluate the adult vaccine hesitancy scale for
vaccines recommended during pregnancy.
Vaccine. 2024;45:126568. PubMedAbstract available
BIAN S, Cai Q, Wang S, Xie Y, et al Evaluation of the toxoplasma Urm1 gene deletion mutant (PruDeltaUrm1) as a promising
vaccine candidate against toxoplasmosis in mice.
Vaccine. 2024;45:126632. PubMedAbstract available
SINGER R, Hubotter I, Holzner F, Genedl C, et al School vaccination programmes to increase HPV vaccination coverage - Experiences
from Bremen, Germany.
Vaccine. 2024;45:126636. PubMedAbstract available
SUN JW, Dodge LE, Kim EJ, Zhou L, et al Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in
the United States.
Vaccine. 2024;45:126629. PubMedAbstract available
PERRIER Q, Noble J, Bonadona A, Augier C, et al Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of
solid organ transplants.
Vaccine. 2024;45:126617. PubMedAbstract available
MOGHTADERI A, Callaghan T, Luo Q, Motta M, et al Evidence on trends in uptake of childhood vaccines and association with COVID-19
vaccination rates.
Vaccine. 2024;45:126631. PubMedAbstract available
WILLIAMS JTB, Ritger C, Holliman BD, Huebschmann AG, et al Staff and caregivers' perceptions of digital storytelling to increase influenza
vaccine confidence in an urban safety-net healthcare system.
Vaccine. 2024;45:126572. PubMedAbstract available
LIMA JLC, da Silva AB, Cabral AS, de Miranda FM, et al Changes in population genetic structure of serotype 19A Streptococcus pneumoniae
after universal childhood use of the 10-valent pneumococcal conjugate vaccine in
Brazil.
Vaccine. 2024;45:126588. PubMedAbstract available
BAINBRIDGE S, Mappi T, Cleaveland S, Chubwa C, et al Field vaccination of locally-owned cattle against malignant catarrhal fever under
environmentally challenging conditions in Tanzania.
Vaccine. 2024;45:126587. PubMedAbstract available
KARACHALIOU M, Espinosa A, Farre X, Blay N, et al Mental illness and antibody responses after COVID-19 vaccination in a prospective
population-based study in Catalonia.
Vaccine. 2024;45:126591. PubMedAbstract available
SLAMANIG S, Lemus N, Lai TY, Singh G, et al A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5
variant vaccine reduces disease and transmission in animals against
matched-variant challenge.
Vaccine. 2024;45:126586. PubMedAbstract available
ENDER E, Joshi A, Snyder M, Kumar S, et al Seroconversion following PPSV23 vaccination in children with type 1 diabetes
mellitus.
Vaccine. 2024;45:126592. PubMedAbstract available
MASSEY PM, Murray RM, Kostizak K, Lo WJ, et al Exploring the ethics of using fictional stories for health education on social
media to share information and emotions about the HPV vaccine: A cross-sectional
study with interdisciplinary health experts.
Vaccine. 2024 Dec 10:126575. doi: 10.1016/j.vaccine.2024.126575. PubMedAbstract available
HOMSI MR, Davey-Rothwell MA, Alonge O, Caniza MA, et al Knowledge, attitudes, and practices of healthcare providers regarding vaccinating
children with cancer in Latin America and the Caribbean.
Vaccine. 2024;45:126578. PubMedAbstract available
MASEMOLA NM, Burnett RJ, Makamba-Mutevedzi PC, Schonfeldt M, et al Vaccine stock-outs: A preventable health facility obstacle contributing to missed
vaccinations in South African children.
Vaccine. 2024;45:126583. PubMedAbstract available
ESKENAZI B, Rauch S, Elsiwi B, Bornman R, et al Undernutrition and antibody response to measles, tetanus and Haemophilus
Influenzae type b (Hib) vaccination in pre-school south African children: The
VHEMBE birth cohort study.
Vaccine. 2024 Dec 7:126564. doi: 10.1016/j.vaccine.2024.126564. PubMedAbstract available
BODY A, Lal L, Srihari S, MacIntyre CR, et al Comprehensive humoral and cellular immune responses to COVID-19 vaccination in
adults with cancer.
Vaccine. 2024 Dec 7:126547. doi: 10.1016/j.vaccine.2024.126547. PubMedAbstract available
CUNNINGHAM-ERVES J, Sanderson M, Jin SW, Davis J, et al Predictors of HPV vaccination coverage among adolescents in Tennessee during the
COVID-19 pandemic: A cross-sectional study.
Vaccine. 2024 Dec 7:126581. doi: 10.1016/j.vaccine.2024.126581. PubMedAbstract available
XIA M, Huang P, Vago FS, Jiang W, et al Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza
viruses elicited high HA1-specific antibody responses and protected mice against
mortality caused by influenza virus challenges.
Vaccine. 2024 Dec 7:126585. doi: 10.1016/j.vaccine.2024.126585. PubMedAbstract available
SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al Vaccine safety surveillance in South Africa through COVID-19: A journey to
systems strengthening.
Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535. PubMedAbstract available
KAPLAN BS, Souza CK, Kimble JB, Brand MW, et al A neuraminidase-based inactivated influenza virus vaccine significantly reduced
virus replication and pathology following homologous challenge in swine.
Vaccine. 2024 Dec 6:126574. doi: 10.1016/j.vaccine.2024.126574. PubMedAbstract available
LIEBERMANN E, Kornides M, Matsunaga M, Lim E, et al Use of social media and its influence on HPV vaccine hesitancy: US National
Online Survey of mothers of adolescents, 2023.
Vaccine. 2024 Dec 5:126571. doi: 10.1016/j.vaccine.2024.126571. PubMedAbstract available
HODGSON D, Sanchez-Ovando S, Carolan L, Liu Y, et al Quantifying the impact of pre-vaccination titre and vaccination history on
influenza vaccine immunogenicity.
Vaccine. 2024 Dec 4:126579. doi: 10.1016/j.vaccine.2024.126579. PubMedAbstract available
HSIAO A, Lewis N, Hansen J, Timbol J, et al Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type
invasive pneumococcal disease in older adults.
Vaccine. 2024;44:126543. PubMedAbstract available
MATTHEWS RL, Khan N, Beckman B, Sharma S, et al Immune profile diversity is achieved with synthetic TLR4 agonists combined with
the RG1-VLP vaccine in mice.
Vaccine. 2024 Dec 3:126577. doi: 10.1016/j.vaccine.2024.126577. PubMedAbstract available
MOUSTAFA DA, Lou E, Schafer-Kestenman ME, Mateu-Borras M, et al Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective
protein antigen.
Vaccine. 2024;42:126476. PubMedAbstract available
TANG A, Zhu M, Zhu J, Zhang D, et al The recombinant feline herpesvirus 1 expressing feline Calicivirus VP1 protein is
safe and effective in cats.
Vaccine. 2024;42:126468. PubMedAbstract available
TONG K, Hernandez EM, Basore K, Fremont DH, et al Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic
neutralizing antibody in mice.
Vaccine. 2024;42:126405. PubMedAbstract available
WU R, Chen Z, Yang X, Chen Y, et al Investigating the characteristics of mumps outbreaks in Fujian Province, China.
Vaccine. 2024;42:126415. PubMedAbstract available
FOTAKIS EA, Picasso E, Sacco C, Petrone D, et al Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in
preventing severe COVID-19 cases in Italy (October 2023-March 2024).
Vaccine. 2024;42:126375. PubMedAbstract available
PRY JM, McCullough K, Lai KW, Lim E, et al Defining long COVID using a population-based SARS-CoV-2 survey in California.
Vaccine. 2024;42:126358. PubMedAbstract available
CHUN J, Yoon D, Nowakowska A, Lee HD, et al Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector
enhance the immune breadth against SARS-CoV-2 variants of concern.
Vaccine. 2024;42:126355. PubMedAbstract available
CANETTI M, Barda N, Lustig Y, Weiss-Ottolenghi Y, et al Risk factors and correlates of protection against XBB SARS-CoV-2 infection among
health care workers.
Vaccine. 2024;42:126308. PubMedAbstract available
November 2024
PICHE-RENAUD PP, Drover SSM, Austin PC, Morris SK, et al COVID-19 vaccine effectiveness against severe omicron-related outcomes in
children aged 5 to 11 years in Ontario: A Canadian immunization research network
(CIRN) study.
Vaccine. 2024 Nov 30:126539. doi: 10.1016/j.vaccine.2024.126539. PubMedAbstract available
GONG S, Beukema M, De Vries-Idema J, Huckriede A, et al Assessing human B cell responses to influenza virus vaccines and adjuvants in a
PBMC-derived in vitro culture system.
Vaccine. 2024;44:126563. PubMedAbstract available
ANABE D, Terasjarvi JT, Barkoff AM, Knuutila A, et al Association of baseline cytokines with antibody concentrations after
diphtheria-tetanus-acellular pertussis booster vaccination in Finnish children.
Vaccine. 2024 Nov 30:126573. doi: 10.1016/j.vaccine.2024.126573. PubMedAbstract available
GRIGAS J, Spancerniene U, Simanavicius M, Pautienius A, et al Adaptive immune response to a wild boar-derived recombinant hepatitis e virus
capsid protein challenge in pigs.
Vaccine. 2024 Nov 30:126561. doi: 10.1016/j.vaccine.2024.126561. PubMedAbstract available
COSMA C, Radi A, Cattano R, Zanobini P, et al Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A
scoping review of the literature.
Vaccine. 2024;44:126559. PubMedAbstract available
NYIKA P, Yankey D, Elam-Evans LD, Meyer S, et al Human papillomavirus vaccination coverage among adolescent boys and girls in the
United States: A birth year cohort analysis of the National Immunization
Survey-Teen, 2016-2022.
Vaccine. 2024;44:126560. PubMedAbstract available
FLORES D, Luna EM The effectiveness of vaccines against COVID-19 in Mexico: A time series approach.
Vaccine. 2024;44:126565. PubMedAbstract available
BHAT N, Vodicka E, Clifford A, Ananth KB, et al The evidence base for rotavirus vaccination in India: Current status, future
needs.
Vaccine. 2024;44:126551. PubMedAbstract available
THIEM VD, Anh DD, Ha VH, Van Thom N, et al Safety and immunogenicity of an inactivated recombinant Newcastle disease virus
vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2
trial.
Vaccine. 2024;44:126542. PubMedAbstract available
WANG Q, Yang L, Li L, Xiu S, et al Investigating parental perceptions of respiratory syncytial virus (RSV) and
attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.
Vaccine. 2024;44:126570. PubMedAbstract available
EDELSTEIN M, Shibli H, Bornstein J Differences in knowledge, attitudes and intentions towards HPV vaccination among
young adults from diverse socio-cultural groups in Israel: A cross-sectional
study.
Vaccine. 2024;44:126548. PubMedAbstract available
BORYS D, Smulders R, Haranaka M, Nakano T, et al Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal
vaccine candidate in healthy, pneumococcal vaccine-naive Japanese adults: A phase
1 randomized dose-escalation trial.
Vaccine. 2024;44:126545. PubMedAbstract available
LINK EK, Tscherne A, Sutter G, Smith ER, et al A Brighton collaboration standardized template with key considerations for a
benefit/risk assessment for a viral vector vaccine based on a non-replicating
modified vaccinia virus Ankara viral vector.
Vaccine. 2024;43. PubMedAbstract available
PITTS PJ, Poland GA Addressing vaccine misinformation: The critical need for complete product
information disclosure.
Vaccine. 2024;44:126558. PubMed
KASAIJA PD, Kabi F, Semakula J, Kyakuwa I, et al One-year follow-up evaluation of approved Subolesin anti-tick vaccine in Uganda.
Vaccine. 2024;44:126562. PubMedAbstract available
GEMANDER N, Kemlin D, Depickere S, Kelkar NS, et al COVID-19 vaccine responses are influenced by distinct risk factors in naive and
SARS-CoV-2 experienced hemodialysis recipients.
Vaccine. 2024;44:126544. PubMedAbstract available
BLUKACZ A, Obach A, Vasquez P, Campana C, et al Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and
middle-income countries: A systematic review of qualitative evidence and thematic
synthesis.
Vaccine. 2024;44:126546. PubMedAbstract available
AMODIO D, Angelidou A, Cotugno N, Sherman AC, et al Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from
the fourth international precision vaccines conference.
Vaccine. 2024;43. PubMedAbstract available
CHOI YJ, Jung J, Kang M, Choi MJ, et al The risk of pregnancy-related adverse outcomes after COVID-19 vaccination:
Propensity score-matched analysis with influenza vaccination.
Vaccine. 2024;44:126506. PubMedAbstract available
DEAN NE, Halloran ME, Zarnitsyna VI Poor vaccine responders mask the true trend in vaccine effectiveness against
progression to severe disease.
Vaccine. 2024;43. PubMedAbstract available
CASTILLO-ZUNINO F, Hester KA, Keskinocak P, Nazzal D, et al Associations between family planning, healthcare access, and female education and
vaccination among under-immunized children.
Vaccine. 2024;44:126540. PubMedAbstract available
GLESER D, Cohen M, Kenigswald G, Kedmi M, et al Optimizing protocols for the 919 strain-based bovine ephemeral fever virus
vaccine (Ultravac(R), Zoetis): Evaluation of dose-dependent effectiveness and
long-term immunity.
Vaccine. 2024;43. PubMedAbstract available
REED NS, Brewer CC, Akintunde G, Blackie FF, et al Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa
virus disease and vaccines.
Vaccine. 2024;43. PubMedAbstract available
TSAI Y, Leung J, Anderson TC, Zhou F, et al Herpes zoster vaccination among Medicare beneficiaries with and without
prescription drug coverage.
Vaccine. 2024;43. PubMedAbstract available
LEE M, Qin C, Lee Y, Deng J, et al COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron
surge in South Korea and China.
Vaccine. 2024;43. PubMedAbstract available
WANTUCH PL, Knoot CJ, Marino EC, Harding CM, et al Klebsiella pneumoniae bioconjugate vaccine functional durability in mice.
Vaccine. 2024;43. PubMedAbstract available
DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian
indigenous adolescents.
Vaccine. 2024;43. PubMedAbstract available
COULTER FJ, Messer WB Breakthroughs and insights: A comprehensive review of yellow fever vaccine
breakthrough infection across 8 decades.
Vaccine. 2024;43. PubMedAbstract available
SUFFEL AM, Carreira H, Walker J, Grint D, et al The association of maternal mental health with vaccination coverage and
timeliness in early childhood - A historical cohort study in England using
electronic health records.
Vaccine. 2024;43. PubMedAbstract available
HUNG CT, Wang LM, Hung YC Trends and characteristics of herpes zoster vaccination among older adults with
asthma in the United States, 2008-2023: Findings from self-reported national
surveys.
Vaccine. 2024;43. PubMedAbstract available
MEELDIJK A, Vandeberg L, Akkermans R, Hautvast J, et al How text message reminders increase COVID-19 booster vaccine uptake: Two
randomized controlled trials.
Vaccine. 2024;43. PubMedAbstract available
MAO J, Kang HJ, Eom GD, Yoon KW, et al Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like
particles co-expressing M2e5x or N2.
Vaccine. 2024;43. PubMedAbstract available
MARSZALEK M, Hawking MKD, Gutierrez A, Firman N, et al Improving the timeliness and equity of preschool childhood vaccinations: Mixed
methods evaluation of a quality improvement programme in primary care.
Vaccine. 2024;43. PubMedAbstract available
VASQUEZ WF, Trudeau JM Americans' willingness to give to global immunization programs: Political
heterogeneity in preferences for program management and response to priming
communications.
Vaccine. 2024;42:126126. PubMedAbstract available
KIRK B, Bush C, Toyip A, Mues KE, et al Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2
among adults aged >/= 65 years in the United States.
Vaccine. 2024;42:126113. PubMedAbstract available
BONNIN FA, Talarico LB, Ferolla FM, Acosta PL, et al Antibody levels against respiratory syncytial virus fusion protein conformations
and lack of association with life-threatening infection in previously healthy
infants.
Vaccine. 2024;42:126119. PubMedAbstract available
TOMATIS C, Ferrer MF, Aquila S, Thomas PD, et al Baculovirus surface display of a chimeric E-NS1 protein of YFV protects against
YFV infection.
Vaccine. 2024;42:126045. PubMedAbstract available
LEE YS, Cheong MS, Lee J, Bang EK, et al Immunogenicity and protection of a triple repeat domain III mRNA vaccine against
Zika virus.
Vaccine. 2024;43. PubMedAbstract available
PARK JY, Senevirathne A, Lee JH Development of a candidate vaccine against severe fever with thrombocytopenia
syndrome virus using Gn/Gc glycoprotein via multiple expression vectors delivered
by attenuated Salmonella confers effective protection in hDC-SIGN transduced
mice.
Vaccine. 2024;43. PubMedAbstract available
FURUICHI M, Ohnishi T, Yaginuma M, Yamada Y, et al Live-attenuated vaccine failure after liver transplantation: A 20-year cohort
study.
Vaccine. 2024;43. PubMedAbstract available
KIM SS, Garcia Quesada M, Prasad PV, Nelson KN, et al Challenges of using the test-negative design to measure vaccine effectiveness of
multi-pathogen combination vaccines targeting one syndrome.
Vaccine. 2024 Nov 12:126520. doi: 10.1016/j.vaccine.2024.126520. PubMed
BERTHOUD TK, Ahmed T, Nadia W, Petrov I, et al A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which
correlate with anti HBs antibody titers: An investigation into the immunological
mechanisms contributing to high anti-HBs titers.
Vaccine. 2024;43. PubMedAbstract available
LAMBACH P, Silal S, Sbarra AN, Koh M, et al Report from the World Health Organization's immunization and vaccines-related
implementation research advisory committee (IVIR-AC) meeting, virtual gathering,
10-13 September 2024.
Vaccine. 2024;43. PubMedAbstract available
LOCKMAN A, Callaghan T, Blackburn CC, Colwell B, et al Vaccine spillover effects in Africa: A cross-national study of vaccine spillover
and confidence in Kenya, Nigeria, and South Africa.
Vaccine. 2024;43. PubMedAbstract available
JASTORFF A, Gymnopoulou E, Salas J, Merrall E, et al Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18
to 59 years with and without at-risk comorbidities for severe respiratory
syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
Vaccine. 2024;43. PubMedAbstract available
WIJDICKS EFM Fatal ascending paralysis after typhoid vaccine: Guillain and Barre's description
of the very first case.
Vaccine. 2024;42:126443. PubMedAbstract available
CHOE S, Park GN, Kim KS, Shin J, et al Immunogenicity of a classical swine fever bait vaccine (Flc-LOM- BE(rns)) in
hybrid-wild boars.
Vaccine. 2024;43. PubMedAbstract available
REGAN AK, Couture MC, Callaghan T, Agnew B, et al Modification and validation of a vaccine hesitancy scale for adolescent COVID-19
vaccination.
Vaccine. 2024;43. PubMedAbstract available
LOPEZ-MACIAS C, Torres M, Armenta-Copca B, Wacher NH, et al Phase II study on the safety and immunogenicity of single-dose intramuscular or
intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle
disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
Vaccine. 2024;43. PubMedAbstract available
PERALTA ALVAREZ MP, Downward K, White A, Harris SA, et al Intravenous BCG vaccination in non-human primates induces superior serum antibody
titers with enhanced avidity and opsonizing capacity compared to the intradermal
route.
Vaccine. 2024;42:126444. PubMedAbstract available
GWAK E, Choe SA, Bolormaa E, Choe YJ, et al Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19
vaccinations in South Korea.
Vaccine. 2024;43. PubMedAbstract available
GOKTUNA PT, Cokcaliskan C Concurrent use of the foot-and-mouth disease and other vaccines in livestock.
Vaccine. 2024;43. PubMedAbstract available
DE LUCA C, Hess M Vaccination strategies to protect chickens from fowl adenovirus (FAdV)-induced
diseases: A comprehensive review.
Vaccine. 2024;43. PubMedAbstract available
DILANGE L, El Belghiti FA, Demiguel V, Anselem O, et al Pertussis vaccination coverage in women at two months postpartum and associated
factors in France, National Perinatal Survey 2021.
Vaccine. 2024;43. PubMedAbstract available
PETERSON J, Drazan D, Moughan B, Maguire JD, et al Randomized trial showing persistence of hSBA titers elicited by a pentavalent
meningococcal MenABCWY vaccine for up to 4 years following a primary series and
safety and immunogenicity of a booster dose.
Vaccine. 2024;43. PubMedAbstract available
MATTES F, Dratva J, Schmelzer S, Wagner A, et al The association between service experience in vaccination centers and expectation
confirmation as a driver of future vaccination intentions: Results from a survey
among users of a Swiss mass COVID-19 vaccination center.
Vaccine. 2024;43. PubMedAbstract available
AGUIRRE-CAMACHO A, Hidalgo B, Rash JA Exposure to objective/sensationalist information moderates associations between
psychological factors and COVID-19 anti-vaccination attitudes: An experimental
study.
Vaccine. 2024;43. PubMedAbstract available
ANGULO M, Angulo C Trained immunity-based vaccines: A vision from the one health initiative.
Vaccine. 2024;43. PubMedAbstract available
WILLIAMS E, Echeverri Tribin F, Carreno JM, Krammer F, et al Proteomic signatures of vaccine-induced and breakthrough infection-induced host
responses to SARS-CoV-2.
Vaccine. 2024;43. PubMedAbstract available
LEWIS NM, Harker EJ, Leis A, Zhu Y, et al Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness
analyses - IVY Network, September 1, 2022-March 30, 2023.
Vaccine. 2024;43. PubMedAbstract available
DENG Y, Hayes KN, Zhao Y, Chachlani P, et al Variation in the time to complete the primary COVID-19 vaccine series by race,
ethnicity, and geography among older US adults.
Vaccine. 2024;43. PubMedAbstract available
STEFFENS MS, Bolsewicz KT, King C, Bullivant B, et al Australian parents' experiences with adolescent age-based vaccinations during the
COVID-19 pandemic.
Vaccine. 2024;43. PubMedAbstract available
LE MARCHAND C, Singson JRC, Clark A, Shah D, et al Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status
in California.
Vaccine. 2024;43. PubMedAbstract available
KERFUA SD, Haydon DT, Wilsden G, Ludi A, et al Corrigendum to "Evaluation of commercial quadrivalent foot-and-mouth disease
vaccines against east African virus strains reveals limited immunogenicity and
duration of protection" [Vaccine 42 (1-12) (2024) 126325].
Vaccine. 2024;43. PubMed
DELARUELLE K, Lermytte E, Bockstal M, Vuolanto P, et al Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of
preventive practices.
Vaccine. 2024;43. PubMedAbstract available
KIM SA, Maeda M, Murata F, Fukuda H, et al Effect of COVID-19 vaccination on the risk of developing post-COVID conditions:
The VENUS study.
Vaccine. 2024;43. PubMedAbstract available
THOBARI JA, Watts E, Carvalho N, Haposan JH, et al Cost effectiveness analysis of rotavirus vaccination in Indonesia.
Vaccine. 2024;43. PubMedAbstract available
CHARLAND K, Quach C, Papenburg J, Pierce L, et al Parental decisions regarding the vaccination of children and adolescents against
SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and
children in Montreal, Canada.
Vaccine. 2024;43. PubMedAbstract available
WARIRI O, Utazi CE, Okomo U, Dotse-Gborgbortsi W, et al Multi-level determinants of timely routine childhood vaccinations in The Gambia:
Findings from a nationwide analysis.
Vaccine. 2024;43. PubMedAbstract available
October 2024
ZACHARIA MM, Ziema SA, Abanga WA, Kyeremeh RA, et al RTS, S malaria vaccination among children aged 24-59 months in the Sunyani
Municipality, Ghana; 2023.
Vaccine. 2024;42:126490. PubMedAbstract available
KASAMATSU A, Yahata Y, Fukushima W, Sakamoto H, et al Estimating influenza vaccine effectiveness among older adults using an integrated
administrative database and the implications of potential bias: A
population-based cohort study in Japan.
Vaccine. 2024;42:126488. PubMedAbstract available
HOFSTETTER AM, Klein EJ, Strelitz B, Selvarangan R, et al On-time childhood vaccination before and during the COVID-19 pandemic in seven
communities: Findings from the New Vaccine Surveillance Network.
Vaccine. 2024;42:126455. PubMedAbstract available
MOSCHESE V, Graziani S, Spadea A, D'Amore M, et al Vaccinations in children of non-European origin: The Vax4globe survey.
Vaccine. 2024;42:126466. PubMedAbstract available
SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens
and induce dual immunity in mice.
Vaccine. 2024;42:126463. PubMedAbstract available
MACINTYRE CR, Akhtar Z, Moa A Corrigendum to "Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine
42/26 (2024) 126450]".
Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486. PubMed
WHITE TM, Lazarus JV, Rabin KH, Ratzan SC, et al Emerging global patterns of COVID-19 vaccine information fatigue in 23 countries
in 2023.
Vaccine. 2024;42:126475. PubMedAbstract available
LEIS AM, Wagner A, Flannery B, Chung JR, et al Evaluation of test-negative design estimates of influenza vaccine effectiveness
in the context of multiple, co-circulating, vaccine preventable respiratory
viruses.
Vaccine. 2024;42:126493. PubMedAbstract available
EBERHARDT J, Al-Qerem W, Ling J Comparing COVID-19 booster vaccine acceptance in the United Kingdom, Germany,
Austria, and Jordan: The role of protection motivation theory, conspiracy
beliefs, social media use and religiosity.
Vaccine. 2024;42:126474. PubMedAbstract available
GAM PH, Dung NM, Aziz JMA, Makram AM, et al Vaccine for hand, foot, and mouth disease (HFMD): A call to action.
Vaccine. 2024 Oct 27:126491. doi: 10.1016/j.vaccine.2024.126491. PubMed
MAURE C, Khazhidinov K, Kang H, Auzenbergs M, et al Chikungunya vaccine development, challenges, and pathway toward public health
impact.
Vaccine. 2024;42:126483. PubMedAbstract available
MCGREGOR R, Paterson A, Lavender B, Hooker C, et al The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023:
Impact of vaccination and infection.
Vaccine. 2024;42:126482. PubMedAbstract available
VIELOT NA, Ballard CAP, St Jean DT, Page S, et al Documenting human papillomavirus vaccine refusal among adolescents in electronic
health records: A mixed methods study.
Vaccine. 2024;42:126467. PubMedAbstract available
LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al Exploring the delivery of adult vaccination outside of primary care settings: A
mixed methods scoping review.
Vaccine. 2024;42:126458. PubMedAbstract available
HO TC, Chuang SC, Hung KC, Chang CC, et al Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination.
Vaccine. 2024;42:126470. PubMedAbstract available
LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al Exploring the attitudes and practices of adult service users and providers
towards vaccination in non-primary care settings: A mixed methods scoping review.
Vaccine. 2024;42:126472. PubMedAbstract available
MOHD HISHAM AA, Mat Yassim AS, Suppian R, Azlan M, et al Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2
homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month
prospective study in Malaysia.
Vaccine. 2024;42:126471. PubMedAbstract available
JORDAN E, Jenkins V, Silbernagl G, Chavez MPV, et al A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows
moderate protection against disease caused by RSV in older adults in a phase 3
clinical study.
Vaccine. 2024;42:126427. PubMedAbstract available
VALENCIA-HERNANDEZ AM, Zhao G, Miranda-Hernandez S, Segura-Cerda CA, et al A second-generation recombinant BCG strain combines protection against murine
tuberculosis with an enhanced safety profile in immunocompromised hosts.
Vaccine. 2024;42:126291. PubMedAbstract available
ROWE M, Collier AY, Barouch DH Insights from an observational translational research program during the COVID-19
pandemic: Four years of experience.
Vaccine. 2024;42:126306. PubMedAbstract available
PHAM-HUY A, Bowes J, Russell K, Amira A, et al Short- and long-term outcomes of cardiac adverse events following COVID-19
immunization managed in a Canadian pediatric center.
Vaccine. 2024;42:126090. PubMedAbstract available
KILIC G, Debisarun PA, Alaswad A, Baltissen MP, et al Seasonal variation in BCG-induced trained immunity.
Vaccine. 2024;42:126109. PubMedAbstract available
SHANMUGASUNDARAM D, Viswanathan R, Winter AK, Agarwal A, et al Rubella immunity among pregnant women and the burden of congenital rubella
syndrome (CRS) in India, 2022.
Vaccine. 2024;42:126077. PubMedAbstract available
SINTAYEHU K, Shaum A, Bonger ZT, Dagnachew Zeleke E, et al Applicability of selected Brighton Collaboration case definitions in low-resource
settings: A prospective hospital-based active surveillance in Addis Ababa,
Ethiopia.
Vaccine. 2024;42:126079. PubMedAbstract available
GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al The 2020 immunization programme landscape: Piloting an assessment metric to
evaluate the maturity of national immunization programmes across the life course.
Vaccine. 2024;42 Suppl 4:125541. PubMedAbstract available
NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A
population-based study using electronic health records in Singapore.
Vaccine. 2024;42:126462. PubMedAbstract available
ESSALIM S, Tachet C, Demingo S, Bruel S, et al Vaccination during febrile illness, what do we know? A systematic-narrative
hybrid review of the literature and international recommendations.
Vaccine. 2024;42:126473. PubMedAbstract available
DARKO DM, Seaneke SK, Karikari-Boateng E, Nkansah E, et al Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A
cohort event monitoring study.
Vaccine. 2024;42:126460. PubMedAbstract available
AB RAHMAN N, King TL, Peariasamy KM, Sivasampu S, et al Risk of major adverse cerebro-cardiovascular events following BNT162b2,
CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled
case-series study.
Vaccine. 2024;42:126465. PubMedAbstract available
SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an
integrated health system.
Vaccine. 2024;42:126440. PubMedAbstract available
BREWER SE, Cataldi JR, Perreira C, Nederveld A, et al "But then that's another barrier": A qualitative study of parent and provider
perspectives on rural versus urban disparities in adolescent vaccination.
Vaccine. 2024;42:126456. PubMedAbstract available
WICKLINE MM, Carpenter PA, Harris JR, Iribarren SJ, et al Vaccine hesitancy and routine revaccination among adult HCT survivors in the
United States: A convergent mixed methods analysis.
Vaccine. 2024;42:126374. PubMedAbstract available
PAPAILIOU S, Soldatou A, Marmarinos A, Avgeris M, et al Seroprevalence of diphtheria, tetanus and pertussis antibodies and Tdap
vaccination in pregnant women in Greece - A cross- sectional study.
Vaccine. 2024;42:126435. PubMedAbstract available
HARRACHE A, Saker K, Mokdad B, Generenaz L, et al Anti-RBD IgG dynamics following infection or vaccination.
Vaccine. 2024;42:126464. PubMedAbstract available
SMOK-KALWAT J, Gozdz S, Macek P, Wasinski P, et al FTIR monitoring of the 13-valent pneumococcal conjugate vaccine for lung cancer
patients: Changes in amides vibrations correlated with biochemical assays.
Vaccine. 2024;42:126459. PubMedAbstract available
AREFAINE M, Johannessen A, Teklehaymanot T, Mihret A, et al A prospective, multicenter study of hepatitis B birth-dose vaccine with or
without hepatitis B immunoglobulin in preventing mother-to-child transmission of
hepatitis B virus in Ethiopia.
Vaccine. 2024;42:126461. PubMedAbstract available
MA SH, Chen TL, Ou WF, Chao WC, et al The risk of postherpetic neuralgia in COVID-19 vaccination-associated herpes
zoster: A retrospective cohort study using TriNetX.
Vaccine. 2024;42:126451. PubMedAbstract available
EVIATAR T, Ziv A, Oved A, Miller-Barmak A, et al Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in
children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic
diseases: A prospective multicenter study.
Vaccine. 2024;42:126426. PubMedAbstract available
ESHRAGHISAMANI R, Facciuolo A, De Buck J Oral paratuberculosis vaccine efficacy and mucosal immunity in cattle.
Vaccine. 2024;42:126447. PubMedAbstract available
NAZARENO AL, Newall AT, Muscatello DJ, Hogan AB, et al Modelling the epidemiological impact of maternal respiratory syncytial virus
(RSV) vaccination in Australia.
Vaccine. 2024;42:126418. PubMedAbstract available
BERENDSEN MLT, Bles P, de Bree LCJ, Jensen KJ, et al Bacillus Calmette-Guerin vaccination induces a trained innate immunity phenotype
in adults over 50 years of age: A randomized trial in Guinea-Bissau.
Vaccine. 2024;42:126439. PubMedAbstract available
DUBE E, Gagnon D, Pelletier C, Comeau JL, et al Enhancing HPV vaccine uptake in girls and boys - A qualitative analysis of
Canadian school-based vaccination programs.
Vaccine. 2024;42:126425. PubMedAbstract available
TRAVILL DI, Machalek DA, Rees H, Mbulawa Z, et al High prevalence of human papillomavirus (HPV) in unvaccinated adolescent girls in
South Africa, particularly those living with HIV.
Vaccine. 2024;42:126442. PubMedAbstract available
TYAGI A, Bajaj SS, Nayeu EN, Stanford FC, et al No person left behind: Understanding vaccine hesitancy in low- and middle-income
countries.
Vaccine. 2024 Oct 16:126446. doi: 10.1016/j.vaccine.2024.126446. PubMed
SANO K, Kurosawa T, Horikawa K, Kimura Y, et al Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5
monovalent vaccination in Japan.
Vaccine. 2024;42:126452. PubMedAbstract available
NUZHATH T, Colwell B, Callaghan T, Hotez P, et al Pediatric COVID-19 vaccine hesitancy among pregnant and post-partum women: A
mixed-method study.
Vaccine. 2024;42:126420. PubMedAbstract available
LI J, Li X, Liu F, Jiang S, et al Development and characterization of HCMV recombinant subunit vaccines based on
T-cell epitopes.
Vaccine. 2024;42:126454. PubMedAbstract available
EIDEN AL, Drakeley S, Modi K, Mackie D, et al Attitudes and beliefs of healthcare providers toward vaccination in the United
States: A cross-sectional online survey.
Vaccine. 2024;42:126437. PubMedAbstract available
PHADKE VK, Gromer DJ, Rebolledo PA, Graciaa DS, et al Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with
inactivated, purified chick embryo cell rabies vaccine in healthy adults.
Vaccine. 2024;42:126441. PubMedAbstract available
COCKERILL R, Horney JA, Penta SC, Silver A, et al Factors associated with COVID-19 vaccination or intent to be vaccinated across
three U.S. states.
Vaccine. 2024;42:126457. PubMedAbstract available
TOP KA, Shulha HP, Muller MP, Valiquette L, et al Participant-reported neurological events following immunization in the Canadian
National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study.
Vaccine. 2024;42:126445. PubMedAbstract available
HSIEH HC, Chen CC, Liu WC, Wu SC, et al Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a
subunit after primary mRNA vaccination in mice.
Vaccine. 2024;42:126448. PubMedAbstract available
TASKIN T, Roncancio AM, Cano MA, Valente M, et al Cancer fatalism is associated with HPV vaccine uptake among Hispanic emerging
adult women in the US.
Vaccine. 2024;42:126417. PubMedAbstract available
MASON LMK, Betancur E, Riera-Montes M, Lienert F, et al MVA-BN vaccine effectiveness: A systematic review of real-world evidence in
outbreak settings.
Vaccine. 2024;42:126409. PubMedAbstract available
SEDAGHAT M, Karami B, Najafi F, Shadmani FK, et al Gender differences in adverse effects following the second dose of AstraZeneca
COVID-19 vaccine: a cross-sectional study among healthcare workers.
Vaccine. 2024;42:126424. PubMedAbstract available
LITAO L, Feng C, Hongyu Z, Wenbin C, et al Field production efficiency investigation of broilers immunized with a turkey
herpesvirus vector vaccine expressing hemagglutinin from H9N2 subtype avian
influenza virus.
Vaccine. 2024;42:126436. PubMedAbstract available
SCHULTZE A, Martin I, Messina D, Bots S, et al Corrigendum to "A comparison of four self-controlled study designs in an analysis
of COVID-19 vaccines and myocarditis using five European databases" [Vaccine 42
(12) (2024) 3039-3048].
Vaccine. 2024 Oct 12:126438. doi: 10.1016/j.vaccine.2024.126438. PubMed
BAMOUH Z, Semmate N, Mouahid M, Kerbal I, et al Safety and efficacy of 9R live attenuated vaccine against fowl typhoid in
partridge's species.
Vaccine. 2024;42:126413. PubMedAbstract available
MOUCHERAUD C, Ochieng E, Ogutu V, Chang LC, et al Intervention-amenable factors associated with lack of HPV vaccination in Kenya:
Results from a large national phone survey.
Vaccine. 2024;42:126410. PubMedAbstract available
WANG J, Gan Y, Yuan T, Huang Y, et al Protection against Mycoplasma hyorhinis infection in commercial pigs via
immunization with inactivated vaccines prepared with homologous or heterologous
strains.
Vaccine. 2024;42:126421. PubMedAbstract available
GERA S, Hoq M, Danchin M, Tuckerman J, et al Association between parental vaccine hesitancy and geographical coverage for
childhood vaccination: A cross-sectional study.
Vaccine. 2024;42:126422. PubMedAbstract available
DOYON-PLOURDE P, Farley R, Krishnan R, Tunis M, et al Direct quantitative comparison of benefits and risks of COVID-19 vaccines used in
National Immunization Technical Advisory Groups Guidance during the first two
years of the pandemic.
Vaccine. 2024;42:126406. PubMedAbstract available
MYLONA E, Pereira-Dias J, Keane JA, Karkey A, et al Phenotypic variation in the lipopolysaccharide O-antigen of Salmonella Paratyphi
A and implications for vaccine development.
Vaccine. 2024;42:126404. PubMedAbstract available
TAAFFE J, Ostrowsky JT, Mott J, Goldin S, et al Advancing influenza vaccines: A review of next-generation candidates and their
potential for global health impact.
Vaccine. 2024;42:126408. PubMedAbstract available
MWAMBA G, Gibson EM, Toko C, Tunda C, et al Effective integration of COVID-19 vaccination with routine immunization: A case
study from Kinshasa, DRC.
Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392. PubMedAbstract available
PASCOE KM, Bishop S, Ci X, Ramirez M, et al Factors that shape COVID-19 pediatric vaccine decision-making in rural
agricultural communities: A qualitative study.
Vaccine. 2024;42:126389. PubMedAbstract available
HOJO-SOUZA NS, de Castro JT, Rivelli GG, Azevedo PO, et al SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows
high efficacy in experimental models challenged with SARS-CoV-2 variants of
concern.
Vaccine. 2024;42:126394. PubMedAbstract available
TAHA, Eskandari S, Slesarenko VA, Haselhorst T, et al Refinement and optimisation of Neisseria gonorrhoeae NHBA and MetQ vaccine
candidates.
Vaccine. 2024;42:126416. PubMedAbstract available
ALANSARI KDH, Buhl C, Thabit AK, Badr AF, et al Validation of the Arabic translation of the vaccination attitudes examination
(VAX) scale.
Vaccine. 2024;42:126411. PubMedAbstract available
PERCIO J, Kobayashi CD, Silva RMA, Marinho AKBB, et al Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) -
Brazil, march 1, 2023-march 11, 2024.
Vaccine. 2024;42:126407. PubMedAbstract available
EARP M, Meng L, Black CL, Carter RJ, et al Using regression tree analysis to examine demographic and geographic
characteristics of COVID-19 vaccination trends over time, United States, May
2021-April 2022, National Immunization Survey Adult COVID Module.
Vaccine. 2024;42:126372. PubMedAbstract available
REN J, Gao Q, Zhou X, Chen L, et al Identification of gene and protein signatures associated with long-term effects
of COVID-19 on the immune system after patient recovery by analyzing single-cell
multi-omics data using a machine learning approach.
Vaccine. 2024;42:126253. PubMedAbstract available
BARBOSA TN, Ferreira MRA, Scholl NR, Pegoraro HG, et al Iridaea cordata lipid extract associated with the rCP01850 protein of C.
pseudotuberculosis elicited a Th1 immune response in immunized sheep.
Vaccine. 2024;42:126220. PubMedAbstract available
SPENCER CLINTON JL, Hoornweg TE, Tan J, Peng R, et al The EEHV1A gH/gL complex elicits humoral and cell-mediated immune responses in
mice.
Vaccine. 2024;42:126227. PubMedAbstract available
RAMIREZ MA, Loaiza RA, Martinez-Balboa Y, Bruneau N, et al Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust
antiviral immunity.
Vaccine. 2024;42:126203. PubMedAbstract available
IQBAL I, Shahid S, Kanwar S, Kabir F, et al Pneumococcal carriage and changes in serotype distribution post- PCV13
introduction in children in Matiari, Pakistan.
Vaccine. 2024;42:126238. PubMedAbstract available
GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al Evaluation of the potential impact and cost-effectiveness of respiratory
syncytial virus (RSV) prevention strategies for infants in Argentina.
Vaccine. 2024;42:126234. PubMedAbstract available
BROWN L, Bingham J, Pulliam J, Mthombothi Z, et al Estimation of the poliovirus type 2 immunity gap in South Africa.
Vaccine. 2024;42:126062. PubMedAbstract available
HOWARD LUDLAM A, Paynter J, Goodyear-Smith F, Petousis-Harris H, et al Pertussis epidemiology in adults: Retrospective analysis of pertussis incidence
and association with comorbidities among adult populations in Aotearoa New
Zealand, using national administrative datasets.
Vaccine. 2024;42:126048. PubMedAbstract available
LANGER S, Holzapfel S, August L, Badura A, et al Parental knowledge and attitudes to infant immunization in the context of RSV:
All about confidence?
Vaccine. 2024;42:126050. PubMedAbstract available
RUSSELL FA, Trim L, Bryan E, Fisher MA, et al Stability and antigenicity of Chlamydia muridarum major outer membrane protein
antigen at body temperature.
Vaccine. 2024;42:126047. PubMedAbstract available
NAHAR UJ, Wang J, Shalash AO, Lu L, et al Self-assembled monovalent lipidated mannose ligand as a standalone nanoadjuvant.
Vaccine. 2024;42:126060. PubMedAbstract available
WEGMAN AD, Kalimuddin S, Marques ETA, Adams LE, et al Proceedings of the dengue endgame summit: Imagining a world with dengue control.
Vaccine. 2024;42:126071. PubMedAbstract available
COLOMBATTI OLIVIERI MA, Cuerda MX, Moyano RD, Gravisaco MJ, et al Superior protection against paratuberculosis by a heterologous prime-boost
immunization in a murine model.
Vaccine. 2024;42:126055. PubMedAbstract available
GARLAND SM, Bhatla N, Woo YL IPVS STATEMENT on HPV vaccination: No longer supply constraints: Towards
achieving WHO vaccine targets.
Vaccine. 2024;42:126400. PubMedAbstract available
GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al Corrigendum to "Evaluation of the potential impact and cost-effectiveness of
respiratory syncytial virus (RSV) prevention strategies for infants in Argentina"
[Vaccine. Volume 42, Issue 23, 3 October 2024, 126234].
Vaccine. 2024 Oct 2:126402. doi: 10.1016/j.vaccine.2024.126402. PubMed
MIRANDA FM, da Silva LD, Fortuna LBDP, Silva AB, et al Long-term predominance in childhood colonization of the multidrug-resistant
lineage 6C/ST386 of Streptococcus pneumoniae after universal immunization with
the 10-valent pneumococcal conjugate vaccine in Brazil.
Vaccine. 2024;42:126414. PubMedAbstract available
CHOI YJ, Song JY, Wie SH, Choi WS, et al Real-world effectiveness of influenza vaccine over a decade during the 2011-2021
seasons-Implications of vaccine mismatch.
Vaccine. 2024;42:126381. PubMedAbstract available
PATRICK-SMITH M, Emary K, Hodgson SH, Thomas TM, et al Roles and responsibilities of participants, researchers, and the media in the
communication of vaccine trials: Experience from the United Kingdom's first
COVID-19 vaccine trial.
Vaccine. 2024;42:126391. PubMedAbstract available
KANG S, Chung E, Hong C, Aziz AB, et al Raising the case of hepatitis E: Report from the 2nd international HEV symposium.
Vaccine. 2024;42:126398. PubMedAbstract available
September 2024
TEUFEL LU, Taks EJM, van Gemert J, Neacsu M, et al Interleukin 38 reduces antigen-presentation capacity and antibody production
after vaccination.
Vaccine. 2024;42:126396. PubMedAbstract available
FLETCHER MA, Vojicic J, Daigle D, Taysi B, et al National recommendations for adult pneumococcal vaccination in countries of the
WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and
Western Pacific.
Vaccine. 2024;42:126390. PubMedAbstract available
MOTTA M, Motta G, Stecula D Conceptual debates in the study of canine & feline vaccine hesitancy: A response
to Haeder 2023.
Vaccine. 2024 Sep 28:126397. doi: 10.1016/j.vaccine.2024.126397. PubMed
SPASENOSKA D, Bloem P, Akaba H, Kahn AL, et al Using human papillomavirus (HPV) vaccine in controlled temperature chain (CTC): A
solution looking for a problem? Or a solution to problems that are not
systematically documented?
Vaccine. 2024 Sep 28:126399. doi: 10.1016/j.vaccine.2024.126399. PubMed
LYU X, Liu X, Hong H Validation of the Chinese version of the vaccine conspiracy beliefs scale during
COVID-19 pandemic and its correlates.
Vaccine. 2024;42:126395. PubMedAbstract available
SOTOODEH A, Hedberg P, Granath F, Alfven T, et al Sociodemographic determinants of COVID-19 vaccination in adolescents in
Stockholm, Sweden.
Vaccine. 2024;42:126388. PubMedAbstract available
SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al Corrigendum to "Immunogenicity during 6 months after SARS-CoV-2 infection is
significantly different depending on previous COVID-19 vaccine regimens and a
booster dose received" [Vaccine 42 (22) (2024) 126025].
Vaccine. 2024 Sep 27:126403. doi: 10.1016/j.vaccine.2024.126403. PubMed
ARCIDIACO S, Schreiber P, Poincelot L, Loukeri S, et al Vaccines efficacy against infection with circulating feline calicivirus after one
single injection: Comparison of Leucofeligen FeLV/RCP and Purevax RCPFeLV
vaccines.
Vaccine. 2024;42:126393. PubMedAbstract available
BARBIERI E, Cocchio S, Furlan P, Scamarcia A, et al A population database analysis to estimate the varicella vaccine effectiveness in
children < 14 years in a high vaccination coverage area from 2004 to 2022.
Vaccine. 2024;42:126387. PubMedAbstract available
DECEUNINCK G, Brousseau N, Lefebvre B, Quach C, et al Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to
prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian
immunization research network (CIRN) study.
Vaccine. 2024;42:126379. PubMedAbstract available
ENGLAND A, Sung J, Deulofeu M, Soler LF, et al Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2
vaccine (Bimervax(R)) by HIPRA.
Vaccine. 2024;42:126386. PubMedAbstract available
DANZELLE C, Cunha P, Noleto PG, Gilbert FB, et al Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis.
Vaccine. 2024;42:126385. PubMedAbstract available
TAN M, Zhang R, Shen T, Li A, et al Systematic evaluation of the induction of efficient neutralizing antibodies by
recombinant multicomponent subunit vaccines against monkeypox virus.
Vaccine. 2024;42:126384. PubMedAbstract available
WEITZMAN ER Social complexity of a fentanyl vaccine to prevent opioid overdose conference
proceedings: Radcliffe institute for advanced study conference proceedings.
Vaccine. 2024 Sep 23:126324. doi: 10.1016/j.vaccine.2024.126324. PubMedAbstract available
LAZARUS R, Harris R, Thirard R, Baos S, et al Comparison of assays used to detect antibody response in COVID-19 vaccine trials:
Results from of a UK multi-Centre randomised controlled trial to determine the
immunogenicity responses of COVID-19 vaccines administered concomitantly with
seasonal inf
Vaccine. 2024;42:126369. PubMedAbstract available
AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al The impact of coronavirus pandemic shutdowns on immunization completion in
Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering
healthcare system.
Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383. PubMedAbstract available
BERNADIN O, Cochin M, Driouich JS, Laprie C, et al Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate
AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer
Programme.
Vaccine. 2024;42:126378. PubMedAbstract available
LUI L, Requia WJ, Dos Santos F, Albert CE, et al Determining factors associated with vaccination coverage in the first year of
life in Brazil (2013-2022).
Vaccine. 2024;42:126382. PubMedAbstract available
LAEMMLE-RUFF I, Fryk JJ, Shenton P, Clothier HJ, et al Detailed review of mortality reported following COVID-19 vaccination in Victoria,
Australia: 2021-2023.
Vaccine. 2024;42:126368. PubMedAbstract available
SHARMA H, Parekh S, Pujari P, Shewale S, et al A randomized, active-controlled, multi-centric, phase-II clinical study to assess
safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine
(HEXASIIL(R)) in Indian toddlers.
Vaccine. 2024;42:126380. PubMedAbstract available
WEE LE, Malek MIBA, Tan J, Chiew C, et al Risk of death and cardiovascular events following COVID-19 vaccination or
positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.
Vaccine. 2024;42:126356. PubMedAbstract available
GOLDIN S, Brooks D, Jorgensen P, Wijesinghe P, et al Seasonal influenza vaccination: A global review of national policies in 194 WHO
member states in 2022.
Vaccine. 2024;42:126274. PubMedAbstract available
IMRAN M, Mills C, McDermott KW, Dean A, et al Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in
older adults with risk factors for influenza complications during the
2019-2020 U.S. influenza season.
Vaccine. 2024;42:126316. PubMedAbstract available
CHOI KY, El-Hamdi N, McGregor A T cell inducing vaccine against cytomegalovirus immediate early 1 (IE1) protein
provides high level cross strain protection against congenital CMV.
Vaccine. 2024;42:126357. PubMedAbstract available
CANDEIAS C, Almeida ST, Paulo AC, Simoes AS, et al Streptococcus pneumoniae carriage, serotypes, genotypes, and antimicrobial
resistance trends among children in Portugal, after introduction of PCV13 in
National Immunization Program: A cross-sectional study.
Vaccine. 2024;42:126219. PubMedAbstract available
ROELS S, Bruckner M, Sadoff J, Cardenas V, et al Pre- and post-Ad26.COV2.S booster dose antibody levels predict COVID-19 disease
risk.
Vaccine. 2024;42:126159. PubMedAbstract available
SHEN AK, Gutu V, Druc A, Ebama M, et al An evaluation of the National Influenza Vaccination Program in the Republic of
Moldova, 2023-2024.
Vaccine. 2024;42:126322. PubMedAbstract available
WITTESAELE C, Toska E, Cluver L, Weiss HA, et al Vaccine coverage and timeliness among children of adolescent mothers: A
community-based study in the eastern cape, South Africa.
Vaccine. 2024;42:126318. PubMedAbstract available
MEANEY-DELMAN D, Carroll S, Polen K, Jatlaoui TC, et al Planning for the future of maternal immunization: Building on lessons learned
from the COVID-19 pandemic.
Vaccine. 2024;42 Suppl 3. PubMedAbstract available
JONES-JACK N, El Kalach R, Yassanye D, Link-Gelles R, et al Advancing public health informatics during the COVID-19 pandemic: Lessons learned
from a public-private partnership with pharmacies.
Vaccine. 2024;42 Suppl 3:125667. PubMedAbstract available
MAHAPATRA B, Singh A, Banerjee A, Sirohi S, et al A squalene oil emulsified MPL-A and anti-CD200/CD300a antibodies adjuvanted
whole-killed Leishmania vaccine provides durable immunity against L. donovani
parasites.
Vaccine. 2024;42:126373. PubMedAbstract available
WADA YA, Mazlan M, Noordin MM, Mohd-Lila MA, et al Rabies epidemiology in Malaysia (2015-2023): A cross-sectional insights and
strategies for control.
Vaccine. 2024;42:126371. PubMedAbstract available
KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax
study.
Vaccine. 2024;42:126320. PubMedAbstract available
HEINS MJ, Spreeuwenberg P, Caini S, Hooiveld M, et al Measuring the impact of influenza vaccination in the Netherlands using
retrospective observational primary care, hospitalisation and mortality data.
Vaccine. 2024;42:126244. PubMedAbstract available
LAMBACH P, Silal S, Sbarra AN, Crowcroft NS, et al Report from the World Health Organization's immunization and vaccines-related
implementation research advisory committee (IVIR-AC) ad hoc meeting, 28 June - 1
July 2024.
Vaccine. 2024;42:126307. PubMedAbstract available
SHIU EYC, Cheng SMS, Martin-Sanchez M, Au NYM, et al Durability for 12 months of antibody response to a booster dose of monovalent
BNT162b2 in adults who had initially received 2 doses of inactivated vaccine.
Vaccine. 2024;42:126317. PubMedAbstract available
ARTETA-ACOSTA C, Villena R, Hormazabal JC, Fernandez J, et al Whole-genome sequencing of Neisseria meningitidis collected in Chile from
pediatric patients during 2016-2019 and coverage vaccine prediction.
Vaccine. 2024;42:126311. PubMedAbstract available
VAN HEESBEEN R, Bastian AR, Omoruyi E, Rosen J, et al Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF
protein vaccine in adults aged 60 years and older: A randomized, double-blind,
placebo-controlled, phase 2a study.
Vaccine. 2024;42:126273. PubMedAbstract available
KERFUA SD, Haydon DT, Wilsden G, Ludi A, et al Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against
east African virus strains reveals limited immunogenicity and duration of
protection.
Vaccine. 2024;42:126325. PubMedAbstract available
CHANG JY, Chang M, Huang S, Bosco J, et al COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during
the early pandemic in New York City.
Vaccine. 2024;42:126260. PubMedAbstract available
PHAM M, Pichichero M Modeling conjugate vaccine and natural induced antibody correlates of protection
for pneumococcal colonization and acute otitis media infection in young children.
Vaccine. 2024;42:126295. PubMedAbstract available
BAFFOUR AWUAH G, Tanaka LF, Eberl M, Donnachie E, et al Analysis of health claims data on vaccination coverage in older adults in
Bavaria, Germany: Influenza, pneumococcus and herpes zoster.
Vaccine. 2024;42:126354. PubMedAbstract available
RABOBA JL, Rahajamanana VL, Rakotojoelimaria HE, Masembe YV, et al Monovalent rotavirus vaccine effectiveness and long-term impact among children
<5 years old in Antananarivo, Madagascar, 2010-2022.
Vaccine. 2024;42:126321. PubMedAbstract available
ABARA WE, Modaressi S, Fireman B, Klein NP, et al Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: A
retrospective study.
Vaccine. 2024;42:126312. PubMedAbstract available
KING LM, Lewnard JA Health-economic burden attributable to novel serotypes in candidate 24- and
31-valent pneumococcal conjugate vaccines.
Vaccine. 2024;42:126310. PubMedAbstract available
GAUDOUEN H, Tattevin P, Thibault V, Menard G, et al Determinants of influenza and COVID vaccine uptake in healthcare workers: A
cross-sectional survey during the post-pandemic era in a network of academic
hospitals in France.
Vaccine. 2024;42:126272. PubMedAbstract available
REGAN AK, Sullivan SG, Arah OA Maternal influenza vaccination and associated risk of fetal loss: A claims-based
prospective cohort study.
Vaccine. 2024;42:126256. PubMedAbstract available
WANG C, Damiano RJ, Ruebush LE, Engelen MPKJ, et al A randomized, triple-blinded, placebo-controlled clinical trial evaluating immune
responses of Typhim Vi and PPSV23 vaccines in healthy adults: The PREP study.
Vaccine. 2024;42:126292. PubMedAbstract available
PETRI E, Biswal S, Lloyd E, Tricou V, et al Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301
clinical trial.
Vaccine. 2024;42:126309. PubMedAbstract available
BLASCO A, Royuela A, Garcia-Gomez S, Gomez-Lozano N, et al Association of SARS-CoV-2 immunoserology and vaccination status with myocardial
infarction severity and outcome.
Vaccine. 2024;42:126305. PubMedAbstract available
RAMIREZ OR, Farraye FA, Hayney MS, Caldera F, et al Inadvertent live vaccine administration in adult patients with inflammatory bowel
disease on immunosuppressive therapy.
Vaccine. 2024;42:126319. PubMedAbstract available
WOO EJ, Miller ER, Stroud E Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse
Event Reporting System (2003-2024).
Vaccine. 2024;42:126290. PubMedAbstract available
GROOM HC, Biel FM, Crane B, Sun E, et al Disparities in COVID-19 vaccination receipt by race, ethnicity, and social
determinants of health among a large patient population in a network of
community-based healthcare centers.
Vaccine. 2024;42:126288. PubMedAbstract available
HOXIE I, Vasilev K, Clark JJ, Bushfield K, et al A recombinant N2 neuraminidase-based CpG 1018(R) adjuvanted vaccine provides
protection against challenge with heterologous influenza viruses in mice and
hamsters.
Vaccine. 2024;42:126269. PubMedAbstract available
HUTTON DW, Prosser LA, Rose AM, Mercon K, et al Cost-effectiveness of vaccinating adults aged 60 years and older against
respiratory syncytial virus.
Vaccine. 2024;42:126294. PubMedAbstract available
SCHLEY K, Whichello C, Hauber B, Krucien N, et al Preferences of US adolescents and parents for vaccination against invasive
meningococcal disease.
Vaccine. 2024;42:126264. PubMedAbstract available
POH XY, Torres-Ruesta A, Yoong T, Wong N, et al Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants:
Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Vaccine. 2024;42:126275. PubMedAbstract available
CUI Y, Cibichakravarthy B, Tang X, Alameh MG, et al Salp14 epitope-based mRNA vaccination induces early recognition of a tick bite.
Vaccine. 2024;42:126304. PubMedAbstract available
KIM C, Dunphy C, Duggar C, Pike J, et al Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program
in the United States, December 20, 2020-May 31, 2021.
Vaccine. 2024;42:126287. PubMedAbstract available
BONNER C, Taba M, Fajardo MA, Batcup C, et al Using health literacy principles to improve understanding of evolving evidence in
health emergencies: Optimisation and evaluation of a COVID-19 vaccination
risk-benefit calculator.
Vaccine. 2024;42:126296. PubMedAbstract available
KARUNAKARAN KP, Yu H, Jiang X, Chan QWT, et al Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface
lipoprotein Mpt83 as a T cell antigen useful for vaccine development.
Vaccine. 2024;42:126266. PubMedAbstract available
LIU S, van Dijk LLA, den Hartog Y, Hoek R, et al mRNA-based COVID-19 vaccination of lung transplant recipients with prior
SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
Vaccine. 2024;42:126250. PubMedAbstract available
BOTTON J, Bertrand M, Jabagi MJ, Duranteau L, et al Risk of heavy menstrual bleeding following COVID-19 vaccination: A nationwide
case-control study.
Vaccine. 2024;42:126252. PubMedAbstract available
HOU X, Li N, Zhang H, Liu W, et al Hepatitis B virus infection and vaccination among people who use drugs in Xi'an,
China.
Vaccine. 2024;42:126259. PubMedAbstract available
RICHMOND P, Nolan T, McGirr A, Napier-Flood F, et al Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant
compared with Boostrix in healthy adults and adolescents.
Vaccine. 2024;42:126251. PubMedAbstract available
COLEMAN BL, Gutmanis I, Bondy SJ, Harrison R, et al Canadian health care providers' and education workers' hesitance to receive
original and bivalent COVID-19 vaccines.
Vaccine. 2024;42:126271. PubMedAbstract available
August 2024
LI G, Ren T, Zhang H, Ti J, et al Persistence of immunity in children aged 2 months and 7 months - 5 years old
after primary immunization with 13-valent pneumococcal conjugate vaccine.
Vaccine. 2024;42:126209. PubMedAbstract available
VIETRI J, Maculaitis MC, Cappelleri JC, Yu H, et al Preferences for a Clostridioides difficile vaccine among adults in the United
States.
Vaccine. 2024;42:126261. PubMedAbstract available
KELLY M, Janardhanan J, Wagh C, Verma S, et al Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is
immunogenic and provides protection against virulent challenge.
Vaccine. 2024;42:126263. PubMedAbstract available
MACKAY H, Gretton JD, Chyderiotis S, Elliott S, et al Confidence and barriers: Analysis of factors associated with timely routine
childhood vaccination in Canada during the COVID-19 pandemic.
Vaccine. 2024;42:126236. PubMedAbstract available
AIZAWA Y, Sato I, Abe Y, Sasagawa F, et al Impact of the emergence of severe acute respiratory syndrome coronavirus 2
omicron variants on routine childhood immunization in Japan.
Vaccine. 2024;42:126137. PubMedAbstract available
MAI W, Shen J, Ma F, Zhu J, et al Specific humoral immune response and XBB variants re-infection risk of
hemodialysis patients after Omicron BA.5 infection in China.
Vaccine. 2024;42:126108. PubMedAbstract available
EYAWO O, Ugoji UC, Pan S, Oyibo P, et al Predictors of the willingness to accept a free COVID-19 vaccine among households
in Nigeria.
Vaccine. 2024;42:126225. PubMedAbstract available
CHI X, Han F, Jiang Y, Cao L, et al Characterization of a triple-type chimeric vaccine against human papillomavirus
types 18, 45, and 59.
Vaccine. 2024;42:126245. PubMedAbstract available
BRESEE JS, Lafond KE The partnership for international vaccine initiatives: The importance and
opportunity to develop influenza vaccination programs in low- and middle-income
countries.
Vaccine. 2024 Aug 29:126255. doi: 10.1016/j.vaccine.2024.126255. PubMed
NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al How has post-implementation surveillance of high-coverage vaccination with
HPV16/18-AS04 vaccine in England added to evidence about its cross-protective
effects?
Vaccine. 2024;42:126215. PubMedAbstract available
FOURIE KR, Jeffery A, Chand D, Choudhary P, et al Vaccination with a Lawsonia intracellularis subunit water in oil emulsion vaccine
mitigated some disease parameters but failed to affect shedding.
Vaccine. 2024;42:126254. PubMedAbstract available
HARADA Y, Takahashi H, Fujimoto T, Horikoshi F, et al Evaluation of a qualified MDCK cell line for virus isolation to develop
cell-based influenza vaccine viruses with appropriate antigenicity.
Vaccine. 2024;42:126242. PubMedAbstract available
DONG R, Luo Z, Shao J, Xue H, et al Understanding hepatitis E vaccination intention among women of childbearing-age:
A theory-based cross-sectional study.
Vaccine. 2024;42:126258. PubMedAbstract available
LLABRE MM, Timpano KR, Broos HC, Leite RO, et al Lessons from a longitudinal community-based investigation of adherence to
guidelines and intent to vaccinate during the COVID-19 pandemic.
Vaccine. 2024;42:126265. PubMedAbstract available
PETRI FAM, Malcher CS, Mechler-Dreibi ML, Panneitz AK, et al Shedding reduction and immunity modulation in piglets with an inactivated
Mycoplasma hyopneumoniae vaccine encapsulated in nanostructured SBA-15 silica.
Vaccine. 2024;42:126268. PubMedAbstract available
PATHER S, Charpentier N, van den Ouweland F, Rizzi R, et al A Brighton Collaboration standardized template with key considerations for a
benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
Vaccine. 2024;42:126165. PubMedAbstract available
KANU FA, Freeland C, Nwokoro UU, Mohammed Y, et al Evaluation of interventions to improve timely hepatitis B birth dose vaccination
among infants and maternal tetanus vaccination among pregnant women in Nigeria.
Vaccine. 2024;42:126222. PubMedAbstract available
FERREIRA-SILVA SN, Soares MEM, Vasconcelos R, Barbieri C, et al COVID-19 vaccine hesitancy: Meaning relations between responses in an
epidemiological study and twitter messages.
Vaccine. 2024;42:126247. PubMedAbstract available
HUANG X, Yang S, Zhao J, Yang J, et al Generation and evaluation of Salmonella entericaserovar Choleraesuis mutant
strains as a potential live-attenuated vaccine.
Vaccine. 2024;42:126262. PubMedAbstract available
GUZMAN RUIZ L, Zollner AM, Hoxie I, Kuchler J, et al Enhancing NA immunogenicity through novel VLP designs.
Vaccine. 2024;42:126270. PubMedAbstract available
ADAMS K, Diallo D, Tadount F, Mouajou V, et al Evaluation of the decision-making process underlying the initial off-label use of
vaccines: A scoping review.
Vaccine. 2024;42:126246. PubMedAbstract available
SINGH D, Damasevicius R, Kumar V, Bagnoli F, et al Editorial: ML-driven vaccine against COVID-19: Developmental challenges and
foresight.
Vaccine. 2024;42:126267. PubMed
EVANS I, Jury S, Morrison A, Best E, et al Onward transmission of measles virus among vaccinated cases in a large community
outbreak in Auckland, New Zealand, 2019.
Vaccine. 2024;42:126257. PubMedAbstract available
VIELOT NA, Kelly NK, Ludema C, Rosenberg M, et al Patterns and predictors of COVID-19 vaccination among young adults at 44 US
sites: Secondary analysis of a randomized, controlled, open-label trial, March -
December 2021.
Vaccine. 2024;42:126237. PubMedAbstract available
UNAGAMI K, Yoshikawa M, Egawa H, Ohfuji S, et al Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid
organ transplant recipients: Prospective cohort study.
Vaccine. 2024;42:126221. PubMedAbstract available
SHINJOH M, Yaginuma M, Yamaguchi Y, Tamura K, et al Effectiveness of inactivated influenza vaccine in children during the 2023/24
season: The first season after relaxation of intensive COVID-19 measures.
Vaccine. 2024;42:126241. PubMedAbstract available
ADAMS L, Prasinou AK, Hadley L, Ramsay M, et al Estimating the potential number of cases prevented by infant/ toddler
immunisation with a MenACWY vaccine.
Vaccine. 2024;42:126240. PubMedAbstract available
OGAR CK, Gilbert HN, Bloem LT, Leopold C, et al Patient-reported outcomes of adverse events after COVID-19 vaccination in
Nigeria: A mixed methods study.
Vaccine. 2024;42:126196. PubMedAbstract available
SKIRROW H, Lewis C, Haque H, Choudary-Salter L, et al 'Why did nobody ask us?': A mixed-methods co-produced study in the United Kingdom
exploring why some children are unvaccinated or vaccinated late.
Vaccine. 2024;42:126172. PubMedAbstract available
POURAKBARI B, Ashraf Talesh S, Mahmoudi S, Sotoudeh M, et al Measles immunity status in Iranian infants and children and outbreak concerns:
Time for reconsidering the vaccination schedule?
Vaccine. 2024;42:126243. PubMedAbstract available
CHEN Z, Gou Q, Yuan Y, Zhang X, et al Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in
a murine model of pneumonia.
Vaccine. 2024;42:126217. PubMedAbstract available
ESPOSITO GL, Fassio F, Girardi D, Picasso E, et al "REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis
against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised
patients (REALISE).
Vaccine. 2024;42:126208. PubMedAbstract available
SANFTENBERG L, Bader F, Rottenkolber M, Sebastiao M, et al Associations of mental health with vaccination readiness in informal caregivers
and the vaccination status of their care recipients during the Covid-19 pandemic
- A cross sectional analysis.
Vaccine. 2024;42:126218. PubMedAbstract available
CASEY RM, Najjengo MS, Lubega I, Sekiziyivu AB, et al Adverse events following immunization (AEFI) with fractional one-fifth and
one-half doses of yellow fever vaccine compared to full dose in children
9-23 months old in Uganda, 2019-2020 - Preliminary report.
Vaccine. 2024;42:126197. PubMedAbstract available
WANDERA EA, Kurokawa N, Mutua MM, Muriithi B, et al Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific
gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted
time-series analysis.
Vaccine. 2024;42:126210. PubMedAbstract available
HERNANDEZ-BERNAL F, Noa-Romero E, Quintana-Guerra J, Chavez-Chong CO, et al Efficacy and safety of Abdala COVID-19 subunit vaccine in children and
adolescents: An open-label, single-arm, phase 2 trial (MENIQUE).
Vaccine. 2024;42:126223. PubMedAbstract available
SNIDER CJ, Zaman K, Estivariz CF, Aziz AB, et al Assessing the mucosal intestinal and systemic humoral immunity of sequential
schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine
for essential immunization in Bangladesh: An open-label, randomized controlled
trial.
Vaccine. 2024;42:126216. PubMedAbstract available
HADLEY L, Soeters HM, Cooper LV, Fernandez K, et al Modelling control strategies for pneumococcal meningitis outbreaks in the African
meningitis belt.
Vaccine. 2024;42:125983. PubMedAbstract available
IHENETU G, Aylin P, Novov V, Skirrow H, et al Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19
in pregnancy: Retrospective cohort study.
Vaccine. 2024 Aug 13:126214. doi: 10.1016/j.vaccine.2024.126214. PubMedAbstract available
FINN MB, Penfound TA, Salehi S, Ogega CO, et al Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.
Vaccine. 2024;42:126205. PubMedAbstract available
VALDES I, Suzarte E, Lazo L, Cobas K, et al Addition of nucleotide adjuvants enhances the immunogenicity of a recombinant
subunit vaccine against the Zika virus in BALB/c mice.
Vaccine. 2024 Aug 12:126213. doi: 10.1016/j.vaccine.2024.126213. PubMedAbstract available
GLEASON A, Kumar CK, Klein E, Laxminarayan R, et al Effect of rotavirus vaccination on the burden of rotavirus disease and associated
antibiotic use in India: A dynamic agent-based simulation analysis.
Vaccine. 2024;42:126211. PubMedAbstract available
CAMERON RL, Palmer TJ, Cuschieri K, Kavanagh K, et al Assessing real world vaccine effectiveness: A review of Scotland's approach to
monitoring human papillomavirus (HPV) vaccine impact on HPV infection and
cervical disease.
Vaccine. 2024;42:126177. PubMedAbstract available
NASIR S, Anwer F, Ishaq Z, Saeed MT, et al VacSol-ML(ESKAPE)(:) Machine learning empowering vaccine antigen prediction for
ESKAPE pathogens.
Vaccine. 2024;42:126204. PubMedAbstract available
JOB MJ, Kim D, Acosta F, Valera S, et al Attitudes of pregnant women in the Dominican Republic towards a future maternal
Group B Streptococcus vaccine.
Vaccine. 2024;42:126169. PubMedAbstract available
WALDEN J, Stanek JR, Young J, Griffith MM, et al Influenza vaccine uptake among youth with sickle cell disease who are seen in
clinic before and after the COVID-19 pandemic.
Vaccine. 2024;42:126212. PubMedAbstract available
GRAF DD, Westphal L, Hallgreen CE The life cycle of vaccines evaluated by the European Medicines Agency.
Vaccine. 2024;42:126186. PubMedAbstract available
BAJPAI D, Bose S, Saxena N, Kulkarni B, et al Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients.
Vaccine. 2024 Aug 8:126206. doi: 10.1016/j.vaccine.2024.126206. PubMedAbstract available
BLOODWORTH S, Singleton D, Perkins E, Radford A, et al Temporal trends and factors associated with vaccination uptake in dogs and cats
from 2016 to 2022 in the United Kingdom.
Vaccine. 2024;42:126185. PubMedAbstract available
O'MAHONY E, Sherman SM, Marlow R, Bedford H, et al UK paediatricians' attitudes towards the chicken pox vaccine: The SPOTTY study.
Vaccine. 2024;42:126199. PubMedAbstract available
GOMEZ-ACEBO I, Barquin-Ruiz A, Llorente S, Alonso-Molero J, et al The impact of the COVID-19 pandemic on childhood vaccination rates and the role
of sociodemographic factors: A cohort study.
Vaccine. 2024;42:126207. PubMedAbstract available
D'SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al Understanding structural inequities in Covid-19 vaccine access and uptake among
disability, transgender and gender-diverse communities in India.
Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174. PubMedAbstract available
GAO Y, Yang X, Li X, Chen H, et al Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion
inactivated influenza vaccine in healthy population aged 9-59 years: A
randomized, double-blind, controlled, phase IV clinical trial.
Vaccine. 2024;42:126182. PubMedAbstract available
BUTLER AM, Newland JG, Sahrmann JM, O'Neil CA, et al Characterizing timeliness of recommended vaccinations among privately-insured
children in the United States, 2009-2019.
Vaccine. 2024;42:126179. PubMedAbstract available
GEORGE G, Strauss M, Lansdell E, Nota P, et al Factors associated with COVID-19 vaccine uptake among south African health care
workers.
Vaccine. 2024;42:126181. PubMedAbstract available
BOKEL J, Martins-Goncalves R, Grinsztejn E, Mendes-de-Almeida DP, et al Anti-PF4 positivity and platelet activation after Ad26.COV2.S vaccination in
Brazil.
Vaccine. 2024 Aug 5:126175. doi: 10.1016/j.vaccine.2024.126175. PubMedAbstract available
BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al Identifying psychological predictors of SARS-CoV-2 vaccination: A machine
learning study.
Vaccine. 2024;42:126198. PubMedAbstract available
AUGELLO M, Wagenhauser I, Krone M, Dauby N, et al Should SARS-CoV-2 serological testing be used in the decision to deliver a
COVID-19 vaccine booster? A pro-con assessment.
Vaccine. 2024 Aug 2:126184. doi: 10.1016/j.vaccine.2024.126184. PubMedAbstract available
MCCARRON M, Marcenac P, Yau TS, Lafond KE, et al Healthcare personnel acceptance and recommendations for influenza vaccine in
twelve low- and middle-income countries: A pooled analysis from 2018 to 2020.
Vaccine. 2024 Aug 2:125670. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WOOLFORK MN, Haire K, Farinu O, Ruffin J, et al A health equity science approach to assessing drivers of COVID-19 vaccination
coverage disparities over the course of the COVID-19 pandemic, United States,
December 2020-December 2022.
Vaccine. 2024 Aug 1:126158. doi: 10.1016/j.vaccine.2024.126158. PubMedAbstract available
JIANG M, Zhang H, Yao X, Wang Y, et al Immunization-related stress and stress-related responses of mucosal versus
intramuscular COVID-19 vaccination among adults in China.
Vaccine. 2024 Aug 1:126150. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
July 2024
ABIL OZ, Liu S, Yeh YW, Wu Y, et al A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant
activity of S100A4-A damage-associated molecular pattern molecule.
Vaccine. 2024 Jul 31:126151. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al Corrigendum to "COVID-19 vaccine hesitancy among older adult Thai Muslim people:
A case-control study" [Vaccine 2023;41(41):6048-6054].
Vaccine. 2024 Jul 31:126180. doi: 10.1016/j.vaccine.2024.126180. PubMed
SANGWE CN, Budzi MN, Shifu IN, Ghangha JG, et al The use of community-oriented primary care (COPC) model to generate vaccine
demand: The case of a remote fishing community in Cameroon.
Vaccine. 2024 Jul 31:126173. doi: 10.1016/j.vaccine.2024.126173. PubMedAbstract available
DE WEERDT L, Herzog SA, Van Damme P, Maertens K, et al Timing of pertussis vaccination during pregnancy: Evidence and implementation - A
systematic review.
Vaccine. 2024;42:126152. PubMedAbstract available
GUO S, Li Z, Zheng M, Wu F, et al Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin
strains) simultaneously administrated with other vaccines for primary and booster
immunization in Jiangxi Province, China.
Vaccine. 2024;42:126183. PubMedAbstract available
MATSUMOTO N, Sasaki A, Kadowaki T, Mitsuhashi T, et al Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an
Omicron surge in Japan.
Vaccine. 2024;42:126156. PubMedAbstract available
BESBASSI H, Elias G, Meysman P, Jansens H, et al Modeling antigen-specific T cell dynamics following Hepatitis B Vaccination
indicates differences between conventional and regulatory T cell dynamics.
Vaccine. 2024;42:126148. PubMedAbstract available
ASUPOTO O, Li X, Hemberg JL, Emerson A, et al COVID-19 and influenza vaccine uptake in women with criminal-legal system
involvement.
Vaccine. 2024 Jul 30:126176. doi: 10.1016/j.vaccine.2024.126176. PubMedAbstract available
ELYASS J, Desalegn A, Trinh NTH, Orangzeb S, et al Individual and familial factors associated with mRNA COVID-19 vaccine uptake in
pregnancy: A large-scale registry-based linkage study.
Vaccine. 2024 Jul 29:126171. doi: 10.1016/j.vaccine.2024.126171. PubMedAbstract available
GE Y, Lu Y, Allen JD, Einav T, et al Pre-existing immunity to influenza aids ferrets in developing stronger and
broader H3 vaccine-induced antibody responses.
Vaccine. 2024 Jul 29:126149. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TAHSIN A, Bhattacharjee P, Al Saba A, Yasmin T, et al Genetic and epigenetic analyses of IFN-gamma gene proximal promoter region underlying
positive correlation between persistently high anti-SARS-CoV-2 IgG and IFN-gamma
among COVID-19 vaccinated Bangladeshi adults.
Vaccine. 2024 Jul 29:126157. doi: 10.1016/j.vaccine.2024.126157. PubMedAbstract available
GEBRETEKLE GB, Yeung MW, Ximenes R, Cernat A, et al Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of
respiratory syncytial virus disease in Canadian infants.
Vaccine. 2024 Jul 29:126164. doi: 10.1016/j.vaccine.2024.126164. PubMedAbstract available
WILLIS DE, Moore R, Selig JP, Shafeek Amin N, et al Pediatric HPV vaccination: Provider recommendations matter among hesitant
parents.
Vaccine. 2024 Jul 29:126166. doi: 10.1016/j.vaccine.2024.126166. PubMedAbstract available
MOTAGHI S, Pullenayegum E, Morgan RL, Loeb M, et al The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator
in children.
Vaccine. 2024 Jul 28:126122. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SULEMAN A, Vicente P COVID-19 vaccination reluctance across Europe: Lessons for the future.
Vaccine. 2024 Jul 27:126168. doi: 10.1016/j.vaccine.2024.126168. PubMedAbstract available
REN J, Huang Z, Tian J, Li Z, et al Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A
cost-effectiveness analysis.
Vaccine. 2024 Jul 27:126162. doi: 10.1016/j.vaccine.2024.126162. PubMedAbstract available
WILLIS DE, Moore R, Purvis RS, McElfish PA, et al Hesitant but vaccinated: Lessons learned from hesitant adopters.
Vaccine. 2024 Jul 27:126135. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JENA D, Ghosh A, Jha A, Prasad P, et al Impact of vaccination on SARS-CoV-2 evolution and immune escape variants.
Vaccine. 2024 Jul 26:126153. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ATAULLAHJAN A, Piche-Renaud PP, Shahrbabak EK, Fadaleh SA, et al Weighing the risks and benefits: Parental perspectives on COVID-19 vaccines for
5- to 11-year-old children.
Vaccine. 2024 Jul 26:126154. doi: 10.1016/j.vaccine.2024.126154. PubMedAbstract available
WILLIAMS LR, Emary KRW, Phillips DJ, Hay J, et al Implementation and adherence to regular asymptomatic testing in a COVID-19
vaccine trial.
Vaccine. 2024 Jul 26:126167. doi: 10.1016/j.vaccine.2024.126167. PubMedAbstract available
BILGIN GM, Munira SL, Lokuge K, Glass K, et al Mathematical modelling of the 100-day target for vaccine availability after the
detection of a novel pathogen: A case study in Indonesia.
Vaccine. 2024 Jul 26:126163. doi: 10.1016/j.vaccine.2024.126163. PubMedAbstract available
KHANAFER N, Oudot S, Maligeay M, Planckaert C, et al A quick access to information on influenza burden and prevention in Lyon
university hospital: A prospective QR code-based information campaign in
2022-2023.
Vaccine. 2024 Jul 26:126160. doi: 10.1016/j.vaccine.2024.126160. PubMedAbstract available
JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al Effectiveness of mRNA booster doses in preventing infections and hospitalizations
due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare
workers, Spain.
Vaccine. 2024;42:4011-4021. PubMedAbstract available
JOHNSTON C, Scheele S, Bachmann L, Boily MC, et al Vaccine value profile for herpes simplex virus.
Vaccine. 2024;42. PubMedAbstract available
MARTIN LB, Tack B, Marchello CS, Sikorski MJ, et al Vaccine value profile for invasive non-typhoidal Salmonella disease.
Vaccine. 2024;42. PubMedAbstract available
LAWAL S, St-Jean M, Hu Y, Bakos B, et al Assessing sociodemographic disparities in HPV vaccine uptake among grade 6 and 9
students in the Vancouver Coastal Health region.
Vaccine. 2024 Jul 25:126147. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SILVER ER, Fink L, Baylis KR, Faust RA, et al Challenging the 'acceptable option': Public health's advocacy for continued care
in the case of pediatric vaccine refusal.
Vaccine. 2024 Jul 23:126144. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YAMEY G, McDade KK, Anderson RM, Bartsch SM, et al Vaccine value profile for schistosomiasis.
Vaccine. 2024 Jul 23:126020. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WAGENHAUSER I, Almanzar G, Forg FB, Stein A, et al Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of
basic immunity show similar immunogenicity regarding long-term spike-specific
cellular immunity in healthcare workers.
Vaccine. 2024 Jul 20:126132. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZOU GQ, Li K, Yan C, Li YQ, et al Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for
enhanced COVID-19 subunit vaccine immunogenicity.
Vaccine. 2024 Jul 20:126145. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al Evaluation of combination vaccines targeting transmission of Plasmodium
falciparum and P. vivax.
Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SANADA T, Honda T, Kohara M Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2
mRNA vaccination.
Vaccine. 2024 Jul 19:126146. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHAU M, Kaufman J, Holland P, Danchin M, et al Co-designing an intervention to improve the childhood catch-up vaccination
process for migrant parents in Australia.
Vaccine. 2024 Jul 18:S0264-410X(24)00745-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BAUER BU, Herms TL, Jahnke R, Ossowski N, et al Control of Coxiella burnetii shedding in a dairy goat herd by annual offspring
vaccination.
Vaccine. 2024 Jul 18:S0264-410X(24)00787-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WASSIL J, Sisti M, Fairman J, Rankin B, et al A phase 2, randomized, blinded, dose-finding, controlled clinical trial to
evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal
conjugate vaccine (VAX-24) in healthy adults 65 years and older.
Vaccine. 2024 Jul 17:S0264-410X(24)00786-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ANDERSON S, Kuter BJ, Brien K, Bauerle Bass S, et al Perceptions of vaccine requirements among students at four Pennsylvania
universities.
Vaccine. 2024 Jul 17:S0264-410X(24)00801-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JIN CHOI S, Lee W, Cheol Kim S, Jo HY, et al Longitudinal multiomic profiling and corticosteroid modulation of the immediate
innate immune response to an adenovirus-vector vaccine.
Vaccine. 2024 Jul 17:S0264-410X(24)00774-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SANTIBANEZ TA, Black CL, Zhou T, Srivastav A, et al Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.
Vaccine. 2024 Jul 16:S0264-410X(24)00802-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HU TH, Tou CY, Lee YH, Chang HH, et al Knowledge gap of human monkeypox among high-risk individuals receiving
preexposure vaccination in Taiwan.
Vaccine. 2024 Jul 16:S0264-410X(24)00753-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JIN F, Zhu L, Wang Y, Qin G, et al Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing
the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell)
with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024)
26059].
Vaccine. 2024 Jul 16:S0264-410X(24)00791-6. doi: 10.1016/j.vaccine.2024. PubMed
LIU G, Pang Y, Lv M, Lu M, et al Effectiveness of influenza vaccination on hospitalization outcomes among older
patients with diabetes.
Vaccine. 2024 Jul 16:S0264-410X(24)00806-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
STEENACKERS K, Hanning N, Bruckers L, Desombere I, et al Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine
schedules in healthy adults: The IMCOVAS randomized clinical trial.
Vaccine. 2024 Jul 16:S0264-410X(24)00773-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LUNA-MUSCHI A, Carmo Borges I, Dos Santos Barboza A, de Faria E, et al Duration of vaccine protection against breakthrough infections during five
COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac.
Vaccine. 2024 Jul 16:S0264-410X(24)00752-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TAKAHASHI Y, Tanaka H, Taniguchi C, Ogata T, et al Efficiency of indirect protection of COVID-19 vaccination and interactions
between indirect and direct protection on household transmission.
Vaccine. 2024 Jul 16:S0264-410X(24)00749-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HATFIELD K, Wiegand R, Reddy S, Patel A, et al Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among
residents of US nursing homes, November 2022 - March 2023.
Vaccine. 2024 Jul 16:S0264-410X(24)00754-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ALTAWALBEH SM, Wateska AR, Patricia Nowalk M, Lin CJ, et al Corrigendum to "Cost-effectiveness of an in-development adult-formulated
21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older"
[Vaccine 42 (2024) 3024-3032].
Vaccine. 2024 Jul 15:S0264-410X(24)00789-8. doi: 10.1016/j.vaccine.2024. PubMed
STEFANIZZI P, Di Lorenzo A, Capodiferro L, Moscara L, et al Increasing vaccination coverage among healthcare workers: Active call and
mandatory laws. Data from a large general hospital in Southern Italy.
Vaccine. 2024 Jul 15:S0264-410X(24)00739-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FISMAN DN, Simmons AE, Tuite AR Case-cohort design as an efficient approach to evaluating COVID-19 vaccine
effectiveness, waning, heterologous immune effect and optimal dosing interval.
Vaccine. 2024 Jul 13:S0264-410X(24)00797-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JAJOU R, Lieber T, van Puijenbroek EP, Mulder E, et al GP consultations for menstrual disorders after COVID-19 vaccination - A
self-controlled cohort study based on routine healthcare data from the
Netherlands.
Vaccine. 2024 Jul 13:S0264-410X(24)00793-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DULL PM, Achilles SL, Ahmed R, Barnabas RV, et al Meeting report: Considerations for trial design and endpoints in licensing
therapeutic HPV16/18 vaccines to prevent cervical cancer.
Vaccine. 2024 Jul 13:S0264-410X(24)00741-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VERANI JR, Omondi D, Odoyo A, Odiembo H, et al Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya:
Nasopharyngeal carriage among children in a rural and an urban site six years
after introduction.
Vaccine. 2024 Jul 13:S0264-410X(24)00782-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MIAO Q, Nguyen W, Zhu J, Liu G, et al A getah virus-like-particle vaccine provides complete protection from viremia and
arthritis in wild-type mice.
Vaccine. 2024 Jul 13:S0264-410X(24)00799-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LE BAGOUSSE-BERNARD A, Dussart C, Pin P, Tazarourte K, et al Mass COVID-19 vaccination center: Optimizing the vaccination pathway during a
12 month timeframe.
Vaccine. 2024 Jul 12:S0264-410X(24)00742-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HUANG WT, Law B, Tran H, Schonborn L, et al Validation of the newly proposed Brighton Collaboration case definition for
vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DANELIAN G, Burton L, Bayley T, Sanchez-Marroquin A, et al The impact and cost-effectiveness of pneumococcal immunisation strategies for the
elderly in England.
Vaccine. 2024;42:3838-3850. PubMedAbstract available
AGARWAL S, Harsukhbhai Chandpa H, Naskar S, Lal Meena C, et al Dominant B cell-T cell epitopes instigated robust immune response in-silico
against Scrub Typhus.
Vaccine. 2024;42:3899-3915. PubMedAbstract available
BUCHHORN DE FREITAS S, Clair Pinto Seixas Neto A, Aparecido Panagio L, Pereira Soares M, et al Hypothetical adhesin CAM87009.1 formulated in alum or biogenic silver
nanoparticles protects mice from lethal infection by multidrug-resistant
Acinetobacter baumannii.
Vaccine. 2024;42:3802-3810. PubMedAbstract available
LI J, Gong L, Li J, Gong Z, et al Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in
response to breakthrough infection by booster.
Vaccine. 2024;42:3751-3755. PubMedAbstract available
SARTORI AL, Buffarini R, Machado da Silva A, Amaral de Andrade Leao O, et al Child COVID-19 vaccine uptake among participants of the 2015 Pelotas (Brazil)
Birth Cohort Study.
Vaccine. 2024 Jul 11:S0264-410X(24)00746-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LAMBACH P, Silal S, Sbarra AN, Koh M, et al Corrigendum to "Report from the World Health Organization's immunization and
vaccines-related implementation research advisory committee (IVIR-AC) meeting,
virtual gathering, 26 February-1 March 2024" [Vaccine 42(15) (2024) 3379-3383].
Vaccine. 2024 Jul 11:S0264-410X(24)00743-6. doi: 10.1016/j.vaccine.2024. PubMed
HOEVE CE, Huiberts AJ, de Gier B, Andeweg SP, et al COVID-19 vaccination-induced antibody responses and waning by age and comorbidity
status in a large population-based prospective cohort study.
Vaccine. 2024 Jul 11:S0264-410X(24)00783-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MILLER E, Michel A, Singh P, Limaye R, et al Countering vaccine misinformation: Designing a learning resource for healthcare
workers in eight countries.
Vaccine. 2024 Jul 11:S0264-410X(24)00732-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GARCIA S, Shin M, Gill M, He Z, et al Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to
inform health messaging interventions in community-based settings.
Vaccine. 2024 Jul 11:S0264-410X(24)00792-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BOLIO A, Waheed DE, Mugo N, Garland SM, et al Overview of CHIC symposia series: Summary of Africa and South Asia symposia.
Vaccine. 2024;42 Suppl 2:S9-S15. PubMedAbstract available
NDIAYE C, Kyesi F, Masupha T, Ranyali M, et al Integrating HPV vaccine service delivery with adolescent health programmes -
Experiences and perspectives from selected countries in Africa.
Vaccine. 2024;42 Suppl 2:S45-S48. PubMedAbstract available
SIDIBE A, Kouassi KS, Ekra D, Bloem P, et al Accelerating and broadening multisectoral partnerships for introducing and
rebuilding HPV vaccination programmes.
Vaccine. 2024;42 Suppl 2:S41-S44. PubMed
WAHEED DE, Bolio A, Kyesi F, Miano CW, et al Routine HPV vaccination: Reflection on delivery strategies based on countries'
experiences.
Vaccine. 2024;42 Suppl 2:S37-S40. PubMedAbstract available
KOUASSI KS, Chisupa E, Clarke A, Massenon I, et al Pandemic-related resilience in HPV vaccination programmes - Perspectives from
selected countries in Africa on what it will take to vaccinate 90 % of girls by
2030.
Vaccine. 2024;42 Suppl 2:S33-S36. PubMedAbstract available
NJOGU R, Deb Roy A, Bagudu Z, Borda H, et al Effective communication by health care workers to promote HPV vaccination:
Lessons learned from Kenya, India, and Nigeria.
Vaccine. 2024;42 Suppl 2:S27-S32. PubMedAbstract available
WAHEED DE, Mumba M, Alfred D, Bogale M, et al Identifying key challenges and optimizing approaches for training of health care
professionals for HPV vaccination programmes.
Vaccine. 2024;42 Suppl 2:S22-S26. PubMedAbstract available
STANLEY M, Schuind A, Muralidharan KK, Guillaume D, et al Evidence for an HPV one-dose schedule.
Vaccine. 2024;42 Suppl 2:S16-S21. PubMedAbstract available
BORDA H, Bloem P, Akaba H, Guillaume D, et al Status of HPV disease and vaccination programmes in LMICs: Introduction to
special issue.
Vaccine. 2024;42 Suppl 2:S1-S8. PubMedAbstract available
GHARPURE R, Longley AT, Takamiya M, Hidle A, et al Typhoid conjugate vaccine perceptions and coverage among children and adults:
Findings from a post-campaign coverage survey - Harare, Zimbabwe, 2019.
Vaccine. 2024 Jul 10:S0264-410X(24)00727-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WEITZMAN ER, Pierce SE, Blakemore LM, Murdock A, et al Need for strategic communications and stakeholder engagement to advance
acceptability of an overdose preventing vaccine targeting fentanyl.
Vaccine. 2024 Jul 10:S0264-410X(24)00722-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZOU M, Lei C, Huang D, Liu L, et al Application of plant-derived products as adjuvants for immune activation and
vaccine development.
Vaccine. 2024 Jul 9:S0264-410X(24)00756-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SANCHEZ-GONZALEZ G, Luna-Casas G, Mascarenas C, Macina D, et al Corrigendum to "Pertussis in Mexico from 2000 to 2019: A real-world study of
incidence, vaccination coverage, and vaccine effectiveness" [Vaccine 41(41)
(2023) 6105-6111].
Vaccine. 2024 Jul 8:S0264-410X(24)00726-6. doi: 10.1016/j.vaccine.2024. PubMed
JITENDER, Vikram Kumar B, Singh S, Verma G, et al Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine
antigen and confers near-complete protection against SARS-CoV-2 infection in
Hamster.
Vaccine. 2024 Jul 8:S0264-410X(24)00740-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BANG JY, Kim YJ, Seo YJ, Hong SH, et al Reduced cell-mediated immune response in hyperglycemic NOD mice following
influenza vaccination.
Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KORCHINSKI I, Marquez C, McClymont E, Av-Gay G, et al Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in
pregnancy: A prospective cohort study.
Vaccine. 2024 Jul 8:S0264-410X(24)00785-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WACHINGER J, Renosa MDC, Endoma V, Landicho-Guevarra J, et al Routines, disruptions, revised decisions: A biographical analysis of vaccination
trajectories among Filipino caregivers.
Vaccine. 2024 Jul 6:S0264-410X(24)00736-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ARAUJO-CHAVERON L, Olivier C, Pellissier G, Bouvet E, et al Analyzing the 7C psychological antecedents of vaccine acceptance throughout the
COVID-19 pandemic among healthcare sector workers in France: A repeated
cross-sectional study (CappVac-Cov).
Vaccine. 2024 Jul 6:S0264-410X(24)00744-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023
autumnal campaigns in Europe: results from the VEBIS primary care test-negative
design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
Vaccine. 2024 Jul 5:S0264-410X(24)00730-8. doi: 10.1016/j.vaccine.2024. PubMed
NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al Cost-effectiveness of recombinant influenza vaccine compared with standard dose
influenza vaccine in adults 18-64 years of age.
Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MESHRAM R, Kolte B, Gacche R Reverse vaccinology approach for identification of epitopes from E1 protein as
peptide vaccine against HCV: A proof of concept.
Vaccine. 2024 Jul 5:S0264-410X(24)00747-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KOUTSOUMPLI G, Stasiukonyte N, Hoogeboom BN, Daemen T, et al An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C
virus vaccines.
Vaccine. 2024 Jul 3:S0264-410X(24)00659-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KAFADAR AH, Sabatini S, Jones KA, Dening T, et al Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy
in the United Kingdom: A systematic review and meta-analysis.
Vaccine. 2024 Jul 2:S0264-410X(24)00733-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZHANG D, Jiang Y, Wang M, Zhao J, et al A novel costimulatory molecule gene-modified leukemia cell-derived exosome
enhances the anti-leukemia efficacy of DC vaccine in mouse models.
Vaccine. 2024 Jul 2:S0264-410X(24)00738-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HOULE SKD, Waite NM, Vernon-Wilson E, Dolovich L, et al Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A
study among community pharmacists.
Vaccine. 2024 Jul 1:S0264-410X(24)00737-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
June 2024
GAO H, Zhang S, Chang H, Guo Y, et al Generation of a novel attenuated IBDV vaccine strain by mutation of critical
amino acids in IBDV VP5.
Vaccine. 2024 Jun 28:S0264-410X(24)00723-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ROOZEN GVT, Granger A, van Binnendijk RS, den Hartog G, et al Intradermal fractional dose vaccination as a method to vaccinate individuals with
suspected allergy to mRNA COVID-19 vaccines.
Vaccine. 2024 Jun 28:S0264-410X(24)00734-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BHELLA S, Wilkin AM, Hueniken K, Vijenthira A, et al COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent
vaccine doses in patients with hematologic malignancies.
Vaccine. 2024 Jun 28:S0264-410X(24)00715-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PLEY C, Kampmann B Opportunities and challenges to the development and deployment of vaccines for
pregnant women in Germany.
Vaccine. 2024 Jun 28:S0264-410X(24)00735-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KELLY JA, Walsh JL, Quinn K, Amirkhanian YA, et al Factors predicting primary and booster COVID-19 vaccination in a community sample
of African American men and women in the United States Midwest.
Vaccine. 2024 Jun 27:S0264-410X(24)00729-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JIN F, Zhu L, Wang Y, Qin G, et al Randomized, blind, controlled phase III clinical trial: Assessing the
immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a
4-dose regimen (2-1-1) in a 10-60 year-old demographic.
Vaccine. 2024 Jun 26:S0264-410X(24)00700-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GUTIERREZ MP, Huckaby AB, Yang E, Weaver KL, et al Antibody-mediated immunological memory correlates with long-term Lyme veterinary
vaccine protection in mice.
Vaccine. 2024 Jun 26:S0264-410X(24)00725-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
COULIBALY D, Douba A, N'Guessan K, N'Gattia AK, et al Intent to receive flu vaccine and influenza vaccination coverage among health
professionals during 2019, 2020 and 2021 campaigns in Cote d'Ivoire.
Vaccine. 2024 Jun 25:S0264-410X(24)00717-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YOO YM, Katz MA, Greenberg D, Marcenac P, et al Knowledge, attitudes, and practices associated with influenza vaccine uptake
among healthcare personnel in Israel during three influenza seasons, 2016-2019.
Vaccine. 2024 Jun 25:S0264-410X(24)00705-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HUSSEIN I, Mohamud H, Hussein A, Luomala O, et al "If the nurse tells me this is a good thing, I trust her completely" - Exploring
health system enablers of MMR vaccine uptake in the Finnish Somali community: A
mixed method study.
Vaccine. 2024 Jun 25:S0264-410X(24)00728-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VIANNA CM, Noronha TG, Camacho LAB, Andrade RC, et al Duration of post-vaccination immunity to yellow fever in volunteers ten years
after a dose-response study - A complementary study.
Vaccine. 2024 Jun 25:S0264-410X(24)00724-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHATZILENA A, Hyams C, Challen R, Marlow R, et al Winter 2022-23 influenza vaccine effectiveness against influenza-related
hospitalised aLRTD: A test-negative, case-control study.
Vaccine. 2024 Jun 24:S0264-410X(24)00713-8. doi: 10.1016/j.vaccine.2024. PubMed
LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or
heterologous COVID-19 booster vaccination: Results of a randomized, double-blind,
phase 2 trial.
Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LIN M, Deng JZ, Scapin G, Yuan Y, et al Quantitation and characterization of serotype 6A activation for pneumococcal
conjugate vaccine by cryo-EM and SEC methods.
Vaccine. 2024 Jun 24:S0264-410X(24)00709-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HELARY A, Botelho-Nevers E, Bonneton M, Khennouf L, et al Factors, motivations and barriers associated with eagerness to volunteer in
COVID-19 vaccine clinical trials in France: A mixed-method study.
Vaccine. 2024 Jun 22:S0264-410X(24)00662-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FITZPATRICK T, Yamoah P, Lacuesta G, Sadarangani M, et al Revaccination outcomes among adolescents and adults with suspected
hypersensitivity reactions following COVID-19 vaccination: A Canadian
immunization research network study.
Vaccine. 2024 Jun 22:S0264-410X(24)00719-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RIMAL RN, Ganjoo R, Jamison A, Parida M, et al Social norms, vaccine confidence, and interpersonal communication as predictors
of vaccination intentions: Findings from slum areas in Varanasi, India.
Vaccine. 2024 Jun 21:S0264-410X(24)00666-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
POVEDA-URKIXO I, Mena-Bueno S, Ramirez GA, Zabalza-Barangua A, et al Brucella melitensis Rev1Deltawzm: Placental pathogenesis studies and safety in
pregnant ewes.
Vaccine. 2024;42:3710-3720. PubMedAbstract available
MCDERMID P, Abdi I, Mustafa K, Blazek K, et al Examining the influence of community leaders and other community actors on
immunisation practices in Australia: A national cross-sectional study.
Vaccine. 2024;42:3647-3654. PubMedAbstract available
PISCHEL L, Martini BA, Yu N, Cacesse D, et al Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease
severity: A systematic review and meta-analysis.
Vaccine. 2024 Jun 20:S0264-410X(24)00694-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHU X, Ge S, Zuo Y, Cui J, et al Thoughts on the research of African swine fever live-attenuated vaccines.
Vaccine. 2024 Jun 20:S0264-410X(24)00693-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZHANG X, Monnat SM Watchful, skeptics, and system distrusters: Characteristics associated with
different types of COVID-19 vaccine hesitancy among U.S. working-age adults.
Vaccine. 2024 Jun 19:S0264-410X(24)00721-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CARLSON CJ, Garnier R, Tiu A, Luby SP, et al Strategic vaccine stockpiles for regional epidemics of emerging viruses: A
geospatial modeling framework.
Vaccine. 2024 Jun 19:S0264-410X(24)00690-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CARLOS GUILLERMO B, Tomas Alberto O, Julio I First vaccine confidence and access index in Argentina: Comparison of results
from 2019 to 2022.
Vaccine. 2024 Jun 19:S0264-410X(24)00711-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
AHMED T, Tauheed I, Hoque S, Sarower Bhuyan G, et al A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY
vaccine 'Ingovax ACWY' among Bangladeshi adults.
Vaccine. 2024 Jun 18:S0264-410X(24)00704-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHICHILI GR, Smulders R, Santos V, Cywin B, et al Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in
healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years"
[Vaccine 40 (2002) 4190-4198].
Vaccine. 2024 Jun 18:S0264-410X(24)00650-9. doi: 10.1016/j.vaccine.2024. PubMed
HOPKINS KL, Lihemo G, Underwood T, Sommers T, et al The second annual Vaccination Acceptance Research Network Conference (VARN2023):
Shifting the immunization narrative to center equity and community expertise.
Vaccine. 2024 Jun 18:S0264-410X(24)00655-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHENG TM, Chen YS, Wei KC, Chang YC, et al Assessment of the herpes zoster risk among renal transplant recipients
administered the influenza vaccine.
Vaccine. 2024 Jun 18:S0264-410X(24)00716-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LAEMMLE-RUFF I, Morgan HJ, Harris A, Abruzzo V, et al Guillain-Barre syndrome temporally associated with COVID-19 vaccines - Progress
over time.
Vaccine. 2024 Jun 17:S0264-410X(24)00714-X. doi: 10.1016/j.vaccine.2024. PubMed
YAZDAN PANAH M, Vaheb S, Mokary Y, Afshari-Safavi A, et al Comparing the consequences of COVID-19 vaccination between central nervous system
(CNS) demyelinating diseases and other neurological disorders.
Vaccine. 2024 Jun 16:S0264-410X(24)00702-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FERM J, Jaworski DC, Stoll I, Kleinhenz MD, et al Genetically modified live vaccine offers protective immunity against wild-type
Anaplasma marginale tick-transmission challenge.
Vaccine. 2024 Jun 15:S0264-410X(24)00710-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DESLAURIERS F, Hoq M, Kaufman J, Enticott J, et al Comparison of parent-reported motivators of non-vaccination for children
5-11 years old in Australia and Canada: Results of the iCARE study.
Vaccine. 2024 Jun 15:S0264-410X(24)00698-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WALTENBURG MA, Kainulainen MH, Whitesell A, Nyakarahuka L, et al Knowledge, attitudes, and practices and long-term immune response after
rVSVDeltaG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in
Uganda.
Vaccine. 2024 Jun 15:S0264-410X(24)00658-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GUL C, Gul A, Karakavuk T, Erkunt Alak S, et al A novel DNA vaccine encoding the SRS13 protein administered by electroporation
confers protection against chronic toxoplasmosis.
Vaccine. 2024 Jun 15:S0264-410X(24)00706-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JIANG X, Wang J, Li C, Yeoh EK, et al Relationship between parental acceptance of the COVID-19 vaccine and attitudes
towards measles vaccination for children: A cross-sectional study.
Vaccine. 2024 Jun 15:S0264-410X(24)00708-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
REY-ARES L, Ta A, Freigofaite D, Warren S, et al Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate
vaccine compared with lower-valent alternatives in Argentina.
Vaccine. 2024 Jun 14:S0264-410X(24)00670-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TING DK, Rosychuk RJ, Hau JP, Righolt CH, et al Leveraging a clinical emergency department dataset to estimate two-dose COVID-19
vaccine effectiveness and duration of protection in Canada.
Vaccine. 2024 Jun 14:S0264-410X(24)00699-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SONG T, Cao F, Huang X, Wu S, et al Augmenting vaccine efficacy: Tailored immune strategy with alum-stabilized
Pickering emulsion.
Vaccine. 2024 Jun 13:S0264-410X(24)00649-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WHITE MC, Osazuwa-Peters OL, Abouelella DK, Barnes JM, et al Trends and factors associated with receipt of human papillomavirus (HPV) vaccine
in private, public, and alternative settings in the United States.
Vaccine. 2024 Jun 13:S0264-410X(24)00663-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DAVEY SA, Hampson C, Christodoulaki ME, Gaffiero D, et al Investigating the predictors of COVID-19 vaccine decision-making among parents of
children aged 5-11 in the UK.
Vaccine. 2024 Jun 13:S0264-410X(24)00646-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HASSO-AGOPSOWICZ M, Sparrow E, Cameron AM, Sati H, et al The role of vaccines in reducing antimicrobial resistance: A review of potential
impact of vaccines on AMR and insights across 16 vaccines and pathogens.
Vaccine. 2024 Jun 13:S0264-410X(24)00676-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CARDOSO N, Eschbaumer M, Capozzo AV An IgG1 single-dilution avidity ELISA predicts cross-protection against
heterologous foot-and-mouth disease virus challenge after vaccination.
Vaccine. 2024 Jun 13:S0264-410X(24)00707-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EMILIE HARTVIG RASMUSSEN C, Odgaard Vedel J, Moller Jensen A, Da Silva Borges I, et al Implementation of the vaccination program in Guinea-Bissau: Coverage and missed
opportunities for BCG at birth.
Vaccine. 2024 Jun 12:S0264-410X(24)00697-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
QUIROGA R, Gastellu S, Fernandez B, Ottaviani R, et al The impact of COVID-19 childhood and adolescent vaccination on mortality in
Argentina.
Vaccine. 2024 Jun 12:S0264-410X(24)00665-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind,
placebo-controlled Phase 2a dose-finding study.
Vaccine. 2024;42:3536-3546. PubMedAbstract available
SHERMAN AC, van Haren SD, Borberg E, Swank Z, et al Heterologous SARS-CoV-2 booster vaccine for individuals with hematological
malignancies after a primary SARS-CoV-2 mRNA vaccine series.
Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MANANDHAR P, Katz J, Lama TP, Khatry SK, et al COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HOFFMAN E, Kahan T, Auerbach E, Brody H, et al Peer education as a strategy to promote vaccine acceptance: A randomized
controlled trial within New York community healthcare practices.
Vaccine. 2024 Jun 10:S0264-410X(24)00654-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
OTSUKI T, Akada S, Anami A, Kosaka K, et al Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV
illness in Japanese infants: Subset analysis from the pivotal randomized phase 3
MATISSE trial.
Vaccine. 2024 Jun 8:S0264-410X(24)00668-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BRADY K, Lee A, Bassler J, Young Pierce J, et al Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release
among mothers in Alabama.
Vaccine. 2024 Jun 8:S0264-410X(24)00673-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BADLIS S, Yu H, Klusaritz H, S L Tan A, et al Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in
Philadelphia: Lessons from the VaxUpPhillyFamilies program.
Vaccine. 2024 Jun 8:S0264-410X(24)00664-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al Immunogenicity during 6 months after SARS-CoV-2 infection is significantly
different depending on previous COVID-19 vaccine regimens and a booster dose
received.
Vaccine. 2024 Jun 7:S0264-410X(24)00652-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
R MUGALI R, Ip H, Zikusooka A, Vong L, et al Striving for equitable vaccination coverage: Leveraging rapid coverage and
community assessments during the COVID-19 pandemic to reach missed populations in
Cambodia.
Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JAYAWARDANA S, Esquivel M, Oreskovic T, Mossialos E, et al Gender differences in COVID-19 preventative measures and vaccination rates in the
United States: A longitudinal survey analysis.
Vaccine. 2024 Jun 7:S0264-410X(24)00671-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DE POUVOURVILLE G, Guyot E, Farge G, Belhassen M, et al Human Papillomavirus (HPV) vaccination coverage among French adolescents: A
claims data study.
Vaccine. 2024 Jun 7:S0264-410X(24)00667-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VILLENA R, Izquierdo G, Wilhelm J, Garcia C, et al Dynamics of multisystem inflammatory syndrome in children associated to COVID-19
in Chile: Epidemiologic trends during pandemic, before and after children
vaccination.
Vaccine. 2024 Jun 7:S0264-410X(24)00640-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YOUNES S, Nicolai E, Younes N, Pieri M, et al Comparable antibody levels in heterologous and homologous mRNA COVID-19
vaccination, with superior neutralizing and IgA antibody responses in mRNA
homologous boosting.
Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KANG DW, June Choe Y, Lee JY, Suk IA, et al Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for
the pediatric population in South Korea.
Vaccine. 2024 Jun 5:S0264-410X(24)00616-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in
Europe: Results from the VEBIS primary care test-negative design study, September
2023-January 2024.
Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KAWASUJI H, Morinaga Y, Tani H, Yamada H, et al Low pre-infection levels of neutralizing antibody in breakthrough infections
after bivalent BA.4-5 vaccine and practical application of dried blood spots.
Vaccine. 2024 Jun 4:S0264-410X(24)00656-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al Costs of in- and outpatient respiratory disease and the seasonal influenza
vaccination program in Armenia - 2020-2021.
Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FENG J, Du Y, Chen L, Su W, et al A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong
protective immune responses in animal models.
Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FABIANI M, Mateo-Urdiales A, Sacco C, Fotakis EA, et al Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent
(original/Omicron BA.4-5) mRNA vaccines in persons aged >/=60 years: Estimates over
calendar time and by time since administration during prevalent circulation of
different O
Vaccine. 2024 Jun 3:S0264-410X(24)00653-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
QUIAMBAO BP, Payumo RA, Roa C, Borja-Tabora CF, et al A phase 2b, Randomized, double blinded comparison of the safety and efficacy of
the monoclonal antibody mixture SYN023 and human rabies immune globulin in
patients exposed to rabies.
Vaccine. 2024 Jun 3:S0264-410X(24)00643-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BEJKO D, Ernst C, Vergison A, Stranges S, et al High vaccine effectiveness against severe COVID-19 outcomes and population
preventable fraction during the Omicron era in Luxembourg: A nationwide
retrospective risk factor analysis.
Vaccine. 2024 Jun 1:S0264-410X(24)00636-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
May 2024
KUPEK E Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
Vaccine. 2024;42:3437-3444. PubMedAbstract available
WOLFSCHMIDT-FIETKAU A, Goertz RS, Goertzen S, Schmid K, et al Immunity against vaccine-preventable diseases among pregnant employees in
Germany. A situation analysis before the introduction of the Measles Protection
Act.
Vaccine. 2024 May 31:S0264-410X(24)00604-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HE Q, Chen Y, Li Y, Cheng X, et al Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine
elicited a rapid and potent protective immunity against tetanus.
Vaccine. 2024 May 31:S0264-410X(24)00583-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
Vaccine. 2024 May 31:S0264-410X(24)00595-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
COMER D, Warner NZ, Noone C Human PapillomaVirus vaccination in gay and bi men: Predictors, dynamic norms,
and connectedness to the LGBT+ community.
Vaccine. 2024 May 31:S0264-410X(24)00639-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MANSFIELD LN, Kahn BZ, Kokitkar S, Kritikos KI, et al HPV vaccine standing orders and communication in primary care: A qualitative
study.
Vaccine. 2024 May 29:S0264-410X(24)00554-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NAKASE T, Brownwright T, Okunromade O, Egwuenu A, et al The impact of sub-national heterogeneities in demography and epidemiology on the
introduction of rubella vaccination programs in Nigeria.
Vaccine. 2024 May 28:S0264-410X(24)00589-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LUO H, Ma Y, Bi J, Li Z, et al Experimental and molecular dynamics simulation studies on the physical properties
of three HBc-VLP derivatives as nanoparticle protein vaccine candidates.
Vaccine. 2024 May 28:S0264-410X(24)00599-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BATOOL R, Yousafzai MT, Mir F, Muhammad S, et al Longevity of serologic responses following a single dose of typhoid conjugate
vaccine among children living with HIV in Pakistan: A prospective cohort study.
Vaccine. 2024 May 28:S0264-410X(24)00625-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BEGUM T, Efstathiou N, Bailey C, Guo P, et al Cultural and social attitudes towards COVID-19 vaccination and factors associated
with vaccine acceptance in adults across the globe: A systematic review.
Vaccine. 2024 May 27:S0264-410X(24)00600-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EOM J, Kim Y, Kim D, Lee E, et al Cost-benefit analysis of human adenovirus vaccine development in a Korean
military setting.
Vaccine. 2024 May 27:S0264-410X(24)00622-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MENA-BUENO S, Garrido V, Romero F, Zabalza-Barangua A, et al Rev1Deltawzm vaccine candidate is safe in young and adult sheep and protects against
Brucella ovis infection in rams.
Vaccine. 2024 May 27:S0264-410X(24)00605-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LUSTIG Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and
BA.5 mRNA COVID-19 vaccines.
Vaccine. 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VASHIST K, Yankey D, Elam-Evans LD, Mu Y, et al Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years,
National Immunization Surveys, 2019-2022.
Vaccine. 2024 May 27:S0264-410X(24)00596-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RENDUCHINTALA K, Arevalo M, Fonseca G, Haver MK, et al Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping
review.
Vaccine. 2024 May 27:S0264-410X(24)00602-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TREHARNE A, Patel Murthy B, Zell ER, Jones-Jack N, et al Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S.
jurisdictions.
Vaccine. 2024 May 25:S0264-410X(24)00603-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DOHERTY K, Bonnett L, Agbla SC, Beveridge NER, et al The effectiveness of revaccination with pneumococcal polysaccharide vaccine for
preventing pneumococcal disease in older adults in England: A population-based
cohort study.
Vaccine. 2024 May 24:S0264-410X(24)00618-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
OKOLI GN, Neilson CJ, Grossman Moon A, Kimmel Supron H, et al Exploration of individual socioeconomic and health-related characteristics
associated with human papillomavirus vaccination initiation and vaccination
series completion among adult females: A comprehensive systematic evidence review
with meta-analysis
Vaccine. 2024 May 24:S0264-410X(24)00601-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LYNETTE EJEZIE C, Cuccaro P, Savas LS, Shegog R, et al Regional differences in provider recommendation of HPV vaccines among
13-to-17 year old adolescents from 2019 to 2021.
Vaccine. 2024 May 24:S0264-410X(24)00581-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WU JY, Zhang W, Pu J, Liu Y, et al A randomized, double-blind, placebo-controlled phase I clinical trial of
rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged
18-49 years to assess safety and preliminary observation of immunogenicity.
Vaccine. 2024 May 24:S0264-410X(24)00559-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BAK J, Hasan Q, Kissa J, Mere MO, et al Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23:
How do we switch to a life course approach?
Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine
in multiple sclerosis patients under disease modifying therapies: A single-center
prospective study.
Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TSAMPALIEROS A, Zemek R, Barrowman N, Langlois MA, et al Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5
to 11 years.
Vaccine. 2024 May 23:S0264-410X(24)00588-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BENEDICT KPOZEHOUEN E, Raina Macintyre C, Tan TC Coverage of influenza, pneumococcal and zoster vaccination and determinants of
influenza and pneumococcal vaccination among adults with cardiovascular diseases
in community.
Vaccine. 2024 May 23:S0264-410X(24)00619-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EIBERG MF, Rezahosseini O, Bukan KB, Charlotte Arp B, et al Changes in vaccination uptake against pneumococcal disease, influenza, and
coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer
diagnosis.
Vaccine. 2024 May 23:S0264-410X(24)00566-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KANDASAMY R, Gurung M, Shrestha S, Gautam MC, et al Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage,
and carriage density in Nepalese children after PCV10 introduction: A pre-post
comparison study.
Vaccine. 2024 May 23:S0264-410X(24)00564-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YEGANEH N, Yin S, Moir O, Danza P, et al Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in
Los Angeles County, August 29, 2022 to January 1, 2023.
Vaccine. 2024 May 23:S0264-410X(24)00594-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CARNALLA M, Stern D, Arantxa Colchero M, Rangel-Moreno K, et al Who is getting COVID-19 boosters? A latent class analysis in a nationally
representative sample of Mexican adults 60 years and over.
Vaccine. 2024;42:3273-3276. PubMedAbstract available
RAMOS-DUARTE VA, Orlowski A, Jaquenod de Giusti C, Corigliano MG, et al Safe plant Hsp90 adjuvants elicit an effective immune response against
SARS-CoV2-derived RBD antigen.
Vaccine. 2024;42:3355-3364. PubMedAbstract available
PROSPER P, Rodriguez Puertas R, Guerin DMA, Branda MM, et al Computational method for designing vaccines applied to virus-like particles
(VLPs) as epitope carriers.
Vaccine. 2024 May 22:S0264-410X(24)00584-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZHOU H, Zhao W, Ma R, Zheng Y, et al Mixed methods examination of risk perception on vaccination intentions: The
perspective of doctor-patient communication.
Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZHANG WX, Zhang Y, Du J, Shi W, et al Effectiveness of momentary intervention on influenza vaccination among the
elderly in China: From willingness to action.
Vaccine. 2024 May 22:S0264-410X(24)00591-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PAN X, Guo X, Shi J Design of a novel multiepitope vaccine with CTLA-4 extracellular domain against
Mycoplasma pneumoniae: A vaccine-immunoinformatics approach.
Vaccine. 2024 May 21:S0264-410X(24)00568-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHIHANA R, Jin Kee J, Moodie Z, Huang Y, et al Factors associated with reactogenicity to an investigational HIV vaccine regimen
in HIV vaccine trials network 702.
Vaccine. 2024 May 21:S0264-410X(24)00598-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VAN DER PLAS JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, et al Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza
vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A
randomized, double-blind, controlled, ascending dose study in healthy adults and
elderly.
Vaccine. 2024 May 20:S0264-410X(24)00370-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MACHIDA M, Fukushima S, Saitoh A, Inoue S, et al Uptake among four indicated vaccines by adults aged 65 years and older in Japan,
2023.
Vaccine. 2024 May 20:S0264-410X(24)00592-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al COVID-19 vaccine acceptance and uptake among caregivers of children aged
5-11?years in Ontario, Canada: A cross-sectional survey.
Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GARG R, Liu Q, Van Kessel J, Asavajaru A, et al Efficacy of a stable broadly protective subunit vaccine platform against
SARS-CoV-2 variants of concern.
Vaccine. 2024 May 19:S0264-410X(24)00586-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TSUJII A, Takahashi K, Harada H, Kawashima S, et al Evaluation of the protective effect of the intranasal vaccines adjuvanted with
bacterium-like particles against intestinal infection.
Vaccine. 2024 May 18:S0264-410X(24)00582-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al Interchangeability of different COVID-19 vaccine platforms as booster doses: A
phase 3 study mimicking real-world practice.
Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YANG T, Tong F, Tang L, Li P, et al Repeated vaccination does not appear to significantly weaken the protective
effect of influenza vaccine in the elderly: A test-negative case-control study in
China.
Vaccine. 2024 May 17:S0264-410X(24)00593-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KIM S, Choi JK, Suh J, Park SH, et al The epidemiologic and economic impact of varicella and herpes zoster vaccination
in South Korea: A mathematical modelling study.
Vaccine. 2024 May 17:S0264-410X(24)00562-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GRIFFIN I, Berry I, Navarra T, Priyamvada L, et al Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of
participants from the District of Columbia (D.C.).
Vaccine. 2024 May 17:S0264-410X(24)00563-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GARCIA-VICENTE EJ, Rey-Casero I, Martin M, Perez A, et al Oral supplementation with postbiotics modulates the immune response produced by
myxomatosis vaccination in wild rabbits.
Vaccine. 2024 May 16:S0264-410X(24)00585-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
URAGUCHI K, Matsumoto N, Mitsuhashi T, Takao S, et al Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and
post-pneumococcal conjugate vaccine eras born in 2001 and 2010.
Vaccine. 2024 May 16:S0264-410X(24)00567-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NG'OMBE H, Bosomprah S, Phiri B, Muchimba M, et al Comparative analysis of cholera serum vibriocidal antibodies from Convalescent
and vaccinated adults in Zambia.
Vaccine. 2024 May 16:S0264-410X(24)00587-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
URQUIDI C, Sepulveda-Penaloza A, Valenzuela MT, Ponce A, et al Vaccine effectiveness in reducing COVID-19-related hospitalization after a
risk-age-based mass vaccination program in a Chilean municipality: A comparison
of observational study designs.
Vaccine. 2024 May 14:S0264-410X(24)00538-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MIRANDA-LOPEZ A, Gonzalez-Ortega O, Govea-Alonso DO, Betancourt-Mendiola L, et al Rational design and production of a chimeric antigen targeting Zika virus that
induces neutralizing antibodies in mice.
Vaccine. 2024 May 14:S0264-410X(24)00518-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against
SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KARIM S, Rehana Siddiqui A, Karim N, Pradhan NA, et al Role of rotavirus vaccine in reducing diarrheal episodes in infants visiting
private primary health care clinics in Karachi, Pakistan: A mixed-methods study.
Vaccine. 2024 May 13:S0264-410X(24)00558-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EJNAR HANSEN M, David Pickering S The role of religion and COVID-19 vaccine uptake in England.
Vaccine. 2024;42:3215-3219. PubMedAbstract available
MUTTUCUMARU R, Lau CL, Leeb A, Mills DJ, et al Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia.
Vaccine. 2024;42:3166-3171. PubMedAbstract available
LIU F, Li Z, Wang H, Cao Y, et al Effectiveness of the varicella vaccine in the real world, a matched case-control
study.
Vaccine. 2024 May 10:S0264-410X(24)00552-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DINH THIEM V, Van Anh PT, Van Men C, Hung DT, et al A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19
prevention during the Omicron-dominant period: A phase 3, randomised,
placebo-controlled clinical trial.
Vaccine. 2024 May 10:S0264-410X(24)00523-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among
healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and
BA.2 subvariants.
Vaccine. 2024 May 9:S0264-410X(24)00522-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHANI M, Hermesh I, Feldhamer I, Reges O, et al The association between BNT162b2 vaccinations and incidence of immune-mediated
comorbidities.
Vaccine. 2024 May 9:S0264-410X(24)00536-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LEE KY, Song KH, Lee KH, Baek JY, et al Persistent differences in the immunogenicity of the two COVID-19 primary vaccines
series, modulated by booster mRNA vaccination and breakthrough infection.
Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KIM DH, Lee SH, Kim J, Lee J, et al Efficacy of live and inactivated recombinant Newcastle disease virus vaccines
expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian
influenza in SPF chickens, Broilers, and domestic ducks.
Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LAURA SORIANO PEREZ M, Montironi I, Alejandro Funes J, Margineda C, et al Nanogel-Mediated antigen delivery: Biocompatibility, immunogenicity, and
potential for tailored vaccine design across species.
Vaccine. 2024 May 7:S0264-410X(24)00525-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BASKOL ELIK D, Yildirim C, Akyol Seyhan D, Aytac Erdem H, et al Evaluation of antibody responses in healthcare workers before & after
meningococcal vaccine and determination of meningococcal carriage rates.
Vaccine. 2024 May 7:S0264-410X(24)00540-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TIPPINS A, Acevedo JC, Palomeque FS, Coy KC, et al Strategies to strengthen COVID-19 vaccine uptake and improve vaccine equity in
U.S. Territories and Freely Associated States during the first six months of
vaccine rollout.
Vaccine. 2024 May 7:S0264-410X(24)00541-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DIONNE M, Etienne D, Witteman HO, Sauvageau C, et al Impact of interventions to improve HPV vaccination acceptance and uptake in
school-based programs: Findings of a pilot project in Quebec.
Vaccine. 2024 May 6:S0264-410X(24)00528-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CAO A, Ueta M, Uchibori M, Murakami M, et al Trust in governments, public health institutions, and other information sources
as determinants of COVID-19 vaccine uptake behavior in Japan.
Vaccine. 2024 May 6:S0264-410X(24)00520-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SONG H, Waheed Abdullah S, Yin S, Dong H, et al Virus-like particle-based multipathogen vaccine of FMD and SVA elicits balanced
and broad protective efficacy in mice and pigs.
Vaccine. 2024 May 6:S0264-410X(24)00530-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SOE P, Wong H, Naus M, Muller MP, et al mRNA COVID-19 vaccine safety among older adults from the Canadian National
Vaccine Safety Network.
Vaccine. 2024 May 6:S0264-410X(24)00535-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JEARANAIWITAYAKUL T, Sunintaboon P, Kittiayuwat A, Limthongkul J, et al Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects
mice from nasal infection and completely inhibits disease development.
Vaccine. 2024 May 6:S0264-410X(24)00519-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KOLAKOWSKA A, Marshall E, Krastinova E, Cros A, et al Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: A
prospective study in outpatient clinics in the Paris region.
Vaccine. 2024 May 6:S0264-410X(24)00516-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KIM J, Chang J Cross-protective efficacy and safety of an adenovirus-based universal influenza
vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix
protein 2.
Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LI H, Li Q, Hao Z, Zhang L, et al A recombinant IL-1beta vaccine attenuates bleomycin-induced pulmonary fibrosis in
mice.
Vaccine. 2024 May 6:S0264-410X(24)00531-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CROWE CL, Dreyfus J, Lanes S, Chung H, et al Variation in incidence rates of outcomes relevant to vaccine safety monitoring in
a US commercially insured population by case identification algorithm.
Vaccine. 2024 May 6:S0264-410X(24)00534-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MAJE BELLO A, Chaimongkolnukul K, Poomputsa K, Mekvichitsaeng P, et al Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based
tetravalent vaccine against four major enteroviruses causing hand, foot, and
mouth disease.
Vaccine. 2024 May 4:S0264-410X(24)00526-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ANDREJKO KL, Gierke R, Rowlands JV, Rosen JB, et al Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of
invasive pneumococcal disease among children in the United States between 2010
and 2019: An indirect cohort study.
Vaccine. 2024 May 3:S0264-410X(24)00499-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ADINUGROHO I, Stafford T, Bentall RP The correlation between conspiracy mentality and vaccine intentions is moderated
by social events: Evidence from longitudinal data during COVID-19 pandemic in the
UK.
Vaccine. 2024 May 3:S0264-410X(24)00510-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHRISTOU-ERGOS M, Bleicher K, Leask J Factors associated with vaccination intention and uptake over time in a sample of
older Australians.
Vaccine. 2024 May 3:S0264-410X(24)00508-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ESPARZA J Introduction of the smallpox vaccine in Napoleonic France, as recorded in
contemporary medals.
Vaccine. 2024 May 3:S0264-410X(24)00503-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHI XC, Gruber JF, Ondari M, Lloyd PC, et al Assessment of potential adverse events following the 2022-2023 seasonal influenza
vaccines among U.S. adults aged 65 years and older.
Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al Exploring the effect of clinical case definitions on influenza vaccine
effectiveness estimation at primary care level: Results from the end-of-season
2022-23 VEBIS multicentre study in Europe.
Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SEFAT KMSR, Kumar M, Kehl S, Kulkarni R, et al An intranasal nanoparticle vaccine elicits protective immunity against
Mycobacterium tuberculosis.
Vaccine. 2024 May 3:S0264-410X(24)00482-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients
with cardiovascular diseases.
Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BAGLIVO F, De Angelis L, Magri M, De Nicola I, et al The impact of COVID-19 vaccination campaign on pediatric vaccine uptake based on
parents' attitudes towards mandatory and recommended vaccination in Southern
Italy.
Vaccine. 2024 May 3:S0264-410X(24)00513-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay
for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MARINTHE G, Brown G, Cristea M, Kutlaca M, et al Predicting vaccination hesitancy: The role of basic needs satisfaction and
institutional trust.
Vaccine. 2024 May 3:S0264-410X(24)00507-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HU H, Ma F, Gong L, Wang Y, et al Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine
ZF2202-A in Chinese adults.
Vaccine. 2024 May 3:S0264-410X(24)00495-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LAMBACH P, Silal S, Sbarra AN, Koh M, et al Report from the World Health Organization's immunization and vaccines-related
implementation research advisory committee (IVIR-AC) meeting, virtual gathering,
26 February-1 March 2024.
Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ANGAITKAR P, Ram Janghel R, Prasad Sahu T An MCDM approach for Reverse vaccinology model to predict bacterial protective
antigens.
Vaccine. 2024 May 3:S0264-410X(24)00517-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DHALARIA P, Kumar P, Verma A, Priyadarshini P, et al Exploring landscape of measles vaccination coverage: A step towards measles
elimination goal in India.
Vaccine. 2024 May 3:S0264-410X(24)00511-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al Changes in depressive symptoms and antibody production following influenza
vaccination in adolescents and adults.
Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MASTROLEO I Use of experimental vaccines is ethically permissible during public health
emergencies.
Vaccine. 2024 May 1:S0264-410X(24)00504-8. doi: 10.1016/j.vaccine.2024. PubMed
April 2024
LV M, Du J, Xie MZ, Zhou Y, et al Protective effect of PCV13 against all-cause hospitalized pneumonia in children
in Beijing, China: real-world evidence.
Vaccine. 2024;42:3091-3098. PubMedAbstract available
WANG Z, Wang M, Wang F, Luo Y, et al Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer
membrane protein H (OmpH) demonstrated increased efficacy against infections
caused by different Pasteurella multocida serogroups in mouse models.
Vaccine. 2024;42:3075-3083. PubMedAbstract available
MAGALI P, Sophie M, Arnaud B, Pol L, et al Retrospective study on the health and economic burden of hospitalized patients
due to pneumonia and invasive pneumococcal infections in Belgium settings.
Vaccine. 2024;42:3018-3023. PubMedAbstract available
GRANT LR, Hanquet G, Sepulveda-Pachon IT, Theilacker C, et al Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and
antimicrobial resistance.
Vaccine. 2024;42:2983-2993. PubMedAbstract available
JI W, Zhou H, Li J, Britto CD, et al Distributions of candidate vaccine Targets, virulence Factors, and resistance
features of invasive group B Streptococcus using Whole-Genome Sequencing: A
Multicenter, population-based surveillance study.
Vaccine. 2024 Apr 30:S0264-410X(24)00498-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FLEARY SA, Shahn Z, Teasdale CA Effects of parental childhood cultural health environment on children's influenza
and COVID-19 vaccination status.
Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NIESSEN FA, Bruijning-Verhagen PCJL, Bonten MJM, Knol MJ, et al Vaccine effectiveness against COVID-19 related hospital admission in the
Netherlands by medical risk condition: A test-negative case-control study.
Vaccine. 2024 Apr 29:S0264-410X(24)00432-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GUDOORU K, Nguyen K, Le K, Sarabu V, et al Collective good and individual choice: Perceptions on COVID-19 vaccine mandate
among COVID-19 vaccinated individuals.
Vaccine. 2024 Apr 27:S0264-410X(24)00479-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DORJEE K, Namdon T, Topgyal S, Gyatso U, et al Association between Covishield vaccine and menstrual disturbance. Findings from a
cross-sectional study among participants of Zero TB cohort in India.
Vaccine. 2024 Apr 27:S0264-410X(24)00500-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PIASECKI AM, Hall DM, Zajac J, Miller SA, et al A programmatic update on COVID-19 vaccination in rural communities in the United
States.
Vaccine. 2024 Apr 25:S0264-410X(24)00469-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LUO G, Zeng Y, Sheng R, Zhang Z, et al Wa-VP4* as a candidate rotavirus vaccine induced homologous and heterologous
virus neutralizing antibody responses in mice, pigs, and cynomolgus monkeys.
Vaccine. 2024 Apr 25:S0264-410X(24)00483-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
XIE Z, Stallings-Smith S, Patel S, Case S, et al COVID-19 booster vaccine uptake and reduced risks for long-COVID: A
cross-sectional study of a U.S. adult population.
Vaccine. 2024 Apr 25:S0264-410X(24)00509-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al Authors' reply: Excess mortality in Cyprus during the COVID-19 vaccination
campaign.
Vaccine. 2024 Apr 25:S0264-410X(24)00506-1. doi: 10.1016/j.vaccine.2024. PubMed
FUJITA DM, da Silva Nali LH, da Costa RR, de Andrade Junior HF, et al Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.
Vaccine. 2024 Apr 24:S0264-410X(24)00435-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al Non-specific effects of the inactivated influenza vaccine. A test-negative study:
The inactivated influenza vaccine and SARS-CoV-2 infections.
Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SWITALSKI J, Miazga W, Wnuk K, Tatara T, et al Analyzing the dynamics of meningococcal vaccinations initiatives by local
government units in Poland (2017-2021) - Scope, challenges and recommendations.
Vaccine. 2024 Apr 22:S0264-410X(24)00472-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SONG S, Madewell ZJ, Liu M, Miao Y, et al A systematic review and meta-analysis on the effectiveness of bivalent mRNA
booster vaccines against Omicron variants.
Vaccine. 2024 Apr 22:S0264-410X(24)00476-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MUSA S, Merdrignac L, Skocibusic S, Nedic R, et al BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and
older during the Delta-dominant period in the Federation of Bosnia and
Herzegovina, a test-negative case-control study.
Vaccine. 2024 Apr 20:S0264-410X(24)00471-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WANG Y, Xu F, Yuan C, Zhang Y, et al Comparison of immune effects of porcine circovirus type 2d (PCV2d) capsid protein
expressed by Escherichia coli and baculovirus-insect cells.
Vaccine. 2024;42:2848-2857. PubMedAbstract available
MOHANTY S, Done N, Liu Q, Song Y, et al Incidence of pneumococcal disease in children =48 months old in the United
States: 1998-2019.
Vaccine. 2024;42:2758-2769. PubMedAbstract available
LIEVRE G, Sicsic J, Galmiche S, Charmet T, et al Are the 7C psychological antecedents associated with COVID-19 vaccine behaviours
beyond intentions? A cross-sectional study on at-least-one-dose and up-to-date
vaccination status, and uptake speed among adults in France.
Vaccine. 2024 Apr 19:S0264-410X(24)00438-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al Immunogenicity and protective efficacy of a multivalent herpesvirus vectored
vaccine against H9N2 low pathogenic avian influenza in chicken.
Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WON H, Kim JA, Jeong NY, Choi NK, et al Safety of concomitant administration of 23-valent polysaccharide pneumococcal
vaccine and influenza vaccine among the elderly.
Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines
among a convenience sample in Minnesota.
Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive
registry-based cohort study of over 800,000 individuals.
Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GAJEWSKA M, Lewtak K, Gorynski P, Piotrowicz M, et al Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations
after four years of its introduction into the Polish National Immunisation
Programme: Follow-up study.
Vaccine. 2024 Apr 18:S0264-410X(24)00433-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show
improved immunogenicity and neutralizing response in mice.
Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BEITARI S, Yi S, Sharma S, Yung R, et al Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in
inner city Vancouver, Canada: Insights into characteristics and clinical
outcomes.
Vaccine. 2024 Apr 17:S0264-410X(24)00477-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MUTSAERTS EAML, van Cranenbroek B, Madhi SA, Simonetti E, et al Impact of nutritional status on vaccine-induced immunity in children living in
South Africa: Investigating the B-cell repertoire and metabolic hormones.
Vaccine. 2024 Apr 17:S0264-410X(24)00448-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MATUR RV, Thuluva S, Gunneri S, Yerroju V, et al Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate
vaccine (PNEUBEVAX 14) administered to 6-8 weeks old healthy Indian Infants: A
single blind, randomized, active-controlled, Phase-III study.
Vaccine. 2024 Apr 17:S0264-410X(24)00362-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al Cost-effectiveness of high-dose influenza vaccination in the Netherlands:
Incorporating the impact on both respiratory and cardiovascular hospitalizations.
Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JI Y, Sui X, Miao W, Wang C, et al Erratum to "Immunogenicity of an adenovirus-vectored bivalent vaccine against
wild type SARS-CoV-2 and Omicron variants in a murine model" [Vaccine 42(6)
(2024) 1292-1299].
Vaccine. 2024 Apr 16:S0264-410X(24)00386-4. doi: 10.1016/j.vaccine.2024. PubMed
PEREIRA ET, Iasulaitis S, Greco BC Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and
ideological orientations in Brazil.
Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GEE J, Shimabukuro TT, Su JR, Shay D, et al Overview of U.S. COVID-19 vaccine safety surveillance systems.
Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LEE N, Hong Y, Kirkpatrick CE, Hu S, et al COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and
message framing among black and white participants.
Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al Understanding the views of adult migrants around catch-up vaccination for missed
routine immunisations to define strategies to improve coverage: A UK in-depth
interview study.
Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHEFFER R, Bucris E, Amitai Z, Indenbaum V, et al Measles outbreak associated with a preschool setting among partially vaccinated
children in the Tel Aviv District, Israel, October 2023.
Vaccine. 2024 Apr 15:S0264-410X(24)00427-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MELNIKOW J, Padovani A, Zhang J, Miller M, et al Patient concerns and physician strategies for addressing COVID-19 vaccine
hesitancy.
Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WONG IOL, Wong C, Mak N, Dai A, et al Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy
and uptake among Chinese adults in Hong Kong.
Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DAVIS BM, Blake I, Panicker G, Meites E, et al Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native
children aged 9-14 years at 5 years after vaccination.
Vaccine. 2024 Apr 15:S0264-410X(24)00447-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YAGI A, Ueda Y, Kimura T HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine
and to provide effective evaluation of the problem through social-medical and
behavioral-economic perspectives.
Vaccine. 2024 Apr 13:S0264-410X(24)00407-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection,
symptoms, and severity in the pre-omicron era: A time-dependent gradient.
Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BAKER J, Aliabadi N, Munjal I, Jiang Q, et al Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults
18-49 years of age: Results of a randomized phase 3 study.
Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NASKAR S, Harsukhbhai Chandpa H, Agarwal S, Meena J, et al Super epitope dengue vaccine instigated serotype independent immune protection
in-silico.
Vaccine. 2024 Apr 13:S0264-410X(24)00423-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YONEKAWA M, Watanabe T, Kogawara O, Yoshii C, et al Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in
healthy Japanese participants 1 year of age and older.
Vaccine. 2024 Apr 12:S0264-410X(24)00388-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LEE JS, Choi H, Shin SH, Hwang MJ, et al Characterization of Brighton Collaboration criteria for myocarditis and
pericarditis following COVID-19 vaccine in Korean adolescents.
Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NOLAN MB, Chrenka E, Walker P, Steiner A, et al COVID-19 vaccine uptake among non-US-born populations in the United States,
2020-2022.
Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al Despite mandated primary series, health care personnel still hesitant about
COVID-19 vaccine and immunizing children.
Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
AHERN S, Browne J, Murphy A, Teljeur C, et al An economic evaluation and incremental analysis of the cost effectiveness of
three universal childhood varicella vaccination strategies for Ireland.
Vaccine. 2024 Apr 11:S0264-410X(24)00441-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
OWUSU-EDUSEI K, Favre-Bulle A, Tsoumani E, Mutschler T, et al Evaluating the health and economic outcomes of a PCV15 vaccination program for
adults aged 65 years-and-above in Switzerland.
Vaccine. 2024 Apr 11:S0264-410X(24)00431-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PITTS PJ, Poland GA Addressing vaccine hesitancy: Learning from the successes and failures of the
COVID-19 pandemic.
Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024. PubMed
HUSETH-ZOSEL AL, Fuller H, Hicks A, Carson PJ, et al Reliance on sources of immunization information and vaccine uptake among older
adults in a rural state: The mediating role of trust.
Vaccine. 2024 Apr 10:S0264-410X(24)00444-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BLAKE JM, Thompson J, HogenEsch H, Ekenstedt KJ, et al Heritability and genome-wide association study of vaccine-induced immune response
in Beagles: A pilot study.
Vaccine. 2024 Apr 10:S0264-410X(24)00398-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
THAI H, Audet EC, Koestner R Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory
Perspective to a Global Health Crisis.
Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al A comparative analysis of knowledge, attitude, and practice (KAP) towards
influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior
to and during the COVID-19 pandemic.
Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EL BUSHRA HE, Haroun AAA, Dauod Altaf M, Gardiwal H, et al Early use of oral cholera vaccines as a prime control measure during outbreaks:
Necessary but not sufficient.
Vaccine. 2024 Apr 8:S0264-410X(24)00332-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al A survey of state and local practices encouraging pediatric COVID-19 vaccination
of children ages 6 months through 11 years.
Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WONODI C, Crowcroft N, Bose AS, Oteri J, et al Country ownership as a guiding principle for IA2030: A case study of the measles
and rubella elimination programs in Nepal and Nigeria.
Vaccine. 2024;42 Suppl 1:S107-S117. PubMedAbstract available
PATEL MK, Scobie HM, Serhan F, Dahl B, et al A global comprehensive vaccine-preventable disease surveillance strategy for the
immunization Agenda 2030.
Vaccine. 2024;42 Suppl 1. PubMedAbstract available
CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al The quest for more effective vaccine markets - Opportunities, challenges, and
what has changed with the SARS-CoV-2 pandemic.
Vaccine. 2024;42 Suppl 1:S64-S72. PubMedAbstract available
ARCHER H, McCoy SI, Sears D, Kwan A, et al Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a
California state Prison, May 2021.
Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial
of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S
formulated with AS02 adjuvant in healthy, malaria-naive adults.
Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHONG CY, Kam KQ, Zhang J, Bertoletti A, et al Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17-
year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination.
Vaccine. 2024 Apr 6:S0264-410X(24)00425-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BINTE HOSSAIN F, Muscatello D, Jayasinghe S, Jonnagaddala J, et al Uptake of pneumococcal vaccines in older Australian adults before and after
universal public funding of PCV13.
Vaccine. 2024 Apr 6:S0264-410X(24)00426-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al Estimating averted illnesses from influenza vaccination for children and pregnant
women - El Salvador, Panama, and Peru, 2011-2018.
Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SCHULTZE A, Martin I, Messina D, Bots S, et al A comparison of four self-controlled study designs in an analysis of COVID-19
vaccines and myocarditis using five European databases.
Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
STEFANIZZI P, Moscara L, Palmieri C, Martinelli A, et al Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in
high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
Vaccine. 2024 Apr 5:S0264-410X(24)00311-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NYBRU GLEDITSCH R, Skogset Ofitserova T, Aubrey White R, Karoline Raberg Kjollesdal M, et al Vaccine coverage among children born to immigrant parents in Norway, 2000-2020.
Vaccine. 2024 Apr 5:S0264-410X(24)00395-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NAKANO T, Hasegawa M, Endo M, Matsuda K, et al Immunogenicity and safety of adsorbed diphtheria-purified
pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate
combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants >/= 2 and < 43 months of
Age: A phase III, multicenter
Vaccine. 2024 Apr 5:S0264-410X(24)00394-3. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
BAUM HE, Thirard R, Halliday A, Baos S, et al Detection of SARS-CoV-2-specific mucosal antibodies in saliva following
concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ALTAWALBEH SM, Wateska AR, Nowalk MP, Lin CJ, et al Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal
conjugate vaccine in US adults aged 50 years or older.
Vaccine. 2024 Apr 4:S0264-410X(24)00404-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HEISLER-MACKINNON JA, Queen T, Yi Kong W, Kennedy KL, et al Identifying effective vaccine champions: Findings from a national survey of
primary care professionals.
Vaccine. 2024 Apr 3:S0264-410X(24)00403-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine
(IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3,
randomized, active-controlled, multicenter trial.
Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TEMBO G, Mayuni M, Kamng'ona R, Chimgoneko L, et al Poor association between 13-valent pneumococcal conjugate vaccine-induced serum
and mucosal antibody responses with experimental Streptococcus pneumoniae
serotype 6B colonisation.
Vaccine. 2024 Apr 2:S0264-410X(24)00360-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WU CY, Kao SE, Tseng YC, Hou JT, et al Pilot-scale production of a highly efficacious and stable monoglycosylated
influenza split virus vaccine.
Vaccine. 2024;42:2220-2228. PubMedAbstract available
LIU J, Qi Q, Liu Y, Ni P, et al A paired measles-rubella catch-up campaign in Sichuan China to stop an outbreak
and strengthen local immunization programs.
Vaccine. 2024;42:2155-2160. PubMedAbstract available
SU L, Zhou X, Peng W, Luo J, et al Investigation on the correlation factors of positive Streptococcus pneumoniae
antibody and IgG antibody level of Streptococcus pneumoniae in the elderly over
60 years old in Shenzhen.
Vaccine. 2024;42:2448-2454. PubMedAbstract available
HUBER A, Kovacs E, Horvath A, Sahin-Toth J, et al Prevalence, serogroup distribution and risk factors of Neisseria meningitidis
carriage in high school and university students in Hungary.
Vaccine. 2024;42:2271-2277. PubMedAbstract available
KIMBUGWE G, Vatrinet R, Mwanga JA, Kakuru R, et al Perceptions, attitudes, and willingness of healthcare and frontline workers to
participate in an Ebola vaccine trial in Uganda.
Vaccine. 2024 Apr 1:S0264-410X(24)00358-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
March 2024
GONG JD, Barnboym E, O'Mara M, Gurevich N, et al Self-reported determinants of COVID-19 vaccine acceptance among persons with and
without autoimmune disease.
Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al Effectiveness of COVID-19 vaccination against school absenteeism in children and
adolescents hospitalized with COVID-19.
Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PADENIYA TN, Hui BB, Wood JG, Regan DG, et al Review of mathematical models of Neisseria gonorrhoeae vaccine impact:
Implications for vaccine development.
Vaccine. 2024 Mar 30:S0264-410X(24)00380-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HUF SW, Grailey K, Crespo RF, Woldmann L, et al Testing the impact of differing behavioural science informed text message content
in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical
trial.
Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FUKUDA Y, Suzuki T, Iwata KI, Haruta K, et al Nanopore sequencing in distinguishing between wild-type and vaccine strains of
Varicella-Zoster virus.
Vaccine. 2024 Mar 27:S0264-410X(24)00333-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BRUUN N, Laursen MF, Carmelo R, Christensen E, et al Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic
cells and generate a potent antibody response in vivo.
Vaccine. 2024 Mar 26:S0264-410X(24)00364-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PARISI A, Nunez O, Lopez-Perea N, Masa-Calles J, et al Reduced pertussis disease severity in infants following the introduction of
pertussis vaccination of pregnant women in Spain, 2015-2019.
Vaccine. 2024 Mar 25:S0264-410X(24)00315-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WEYANT C, Hooda Y, Munira SJ, Lo NC, et al Cost-effectiveness and public health impact of typhoid conjugate vaccine
introduction strategies in Bangladesh.
Vaccine. 2024 Mar 25:S0264-410X(24)00322-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al Influenza vaccination accuracy among adults: Self-report compared with electronic
health record data.
Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al The early safety profile of simultaneous vaccination against influenza and
Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al Leveraging seasonal influenza health worker vaccination programmes for COVID-19
vaccine Introduction: A global qualitative analysis.
Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
DAHL BA, Tritter B, Butryn D, Dahlke M, et al Global VAX: A U.S. contribution to global COVID-19 vaccination efforts,
2021-2023.
Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PONNE S, Kumar R, Vanmathi SM, Brilhante RSN, et al Reverse engineering protection: A comprehensive survey of reverse
vaccinology-based vaccines targeting viral pathogens.
Vaccine. 2024 Mar 23:S0264-410X(24)00265-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MORGAN G, Casalino S, Chowdhary S, Frangione E, et al COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
STUREBORG R, Nichols J, Dhingra B, Yang J, et al Development and validation of VaxConcerns: A taxonomy of vaccine concerns and
misinformation with Crowdsource-Viability.
Vaccine. 2024 Mar 22:S0264-410X(24)00255-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CONDIE J, Northstone K, Major-Smith D, Halstead I, et al Exploring associations between the Big Five personality traits and cognitive
ability with COVID-19 vaccination hesitancy and uptake among mothers and
offspring in a UK prospective cohort study.
Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
COMES JDG, Doets K, Zegers T, Kessler M, et al Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens.
Vaccine. 2024 Mar 22:S0264-410X(24)00319-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
PRICE O, Dietze P, Maher L, Dore GJ, et al High COVID-19 vaccine uptake following initial hesitancy among people in
Australia who inject drugs.
Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HIRTH J, Ostovar-Kermani T, Gutierrez JA, Thompson EL, et al Effect of age at initiation of the human papillomavirus vaccine on the
association between race/ethnicity and completion of the vaccine series.
Vaccine. 2024 Mar 21:S0264-410X(24)00336-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZHANG Y, Wang Y, Li G, Zhao X, et al A randomized, blind, parallel controlled phase I clinical trial to evaluate the
safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide
vaccine in healthy people aged 2 years and older.
Vaccine. 2024 Mar 21:S0264-410X(24)00331-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al Higher educational attainment associated with higher confidence in influenza
vaccination in Norway.
Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZHAO Z, Meng Q, Sun TZ, Zhu B, et al Mannose modified targeted immersion vaccine delivery system improves protective
immunity against Infectious spleen and kidney necrosis virus in mandarin fish
(Siniperca chuatsi).
Vaccine. 2024 Mar 21:S0264-410X(24)00335-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al Differences in social media use by COVID-19 vaccination status.
Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SASI A, Dandotiya J, Kaushal J, Ganguly S, et al Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA
vaccines in adolescent/young adults with cancer: A prospective cohort study.
Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BROOKS SP, Sidhu K, Cooper E, Michelle Driedger S, et al The influence of health service interactions and local policies on vaccination
decision-making in immigrant women: A multi-site Canadian qualitative study.
Vaccine. 2024 Mar 20:S0264-410X(24)00299-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CRISTINA MARTINI RODRIGUES C, Caroline Ribeiro Sales A, Marli Christovam Sartori A, de Souza Azevedo A, et al Yellow fever neutralizing antibody seroprevalence proportion and titers in
previously vaccinated adults with chronic kidney disease.
Vaccine. 2024 Mar 20:S0264-410X(24)00316-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ARTIGAS-JERONIMO S, Villar M, Estrada-Pena A, Alberdi P, et al Subolesin knockdown in tick cells provides insights into vaccine protective
mechanisms.
Vaccine. 2024 Mar 19:S0264-410X(24)00278-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHENG Y, Shen R, Liu F, Li Y, et al Humoral and cellular immune responses induced by serogroup W135 meningococcal
conjugate and polysaccharide vaccines.
Vaccine. 2024 Mar 19:S0264-410X(24)00326-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al Transformative vaccination: A pentavalent shield against COVID-19 and influenza
with betulin-based adjuvant for enhanced immunity.
Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
GEHRT L, Englund H, Laake I, Nieminen H, et al Is vaccination against measles, mumps, and rubella associated with reduced rates
of antibiotic treatments among children below the age of 2 years? Nationwide
register-based study from Denmark, Finland, Norway, and Sweden.
Vaccine. 2024 Mar 19:S0264-410X(24)00313-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ANWARI P, Burnett E, Chavers TP, Samsor A, et al Post-marketing surveillance of intussusception after Rotarix administration in
Afghanistan, 2018-2022.
Vaccine. 2024;42:2059-2064. PubMedAbstract available
LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults
in United States commercial and Medicare claims databases, 2017-2020.
Vaccine. 2024;42:2004-2010. PubMedAbstract available
SOVIK WLM, Madsen AMR, Aaby P, Nielsen S, et al The association between BCG scars and self-reported chronic diseases: A
cross-sectional observational study within an RCT of Danish health care workers.
Vaccine. 2024;42:1966-1972. PubMedAbstract available
KWON KW, Choi HG, Choi HH, Choi E, et al Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase,
against Mycobacterium tuberculosis Beijing outbreak strains.
Vaccine. 2024;42:1941-1952. PubMedAbstract available
HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al Mucosal immunization with dual influenza/COVID-19 single-replication virus vector
protects hamsters from SARS-CoV-2 challenge.
Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al CHO cells for virus-like particle and subunit vaccine manufacturing.
Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WU J, Jiang L, Shao Q, Liu J, et al Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant
inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78
challenge.
Vaccine. 2024 Mar 18:S0264-410X(24)00325-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MEDENI V, Altiner OT, Medeni I Measles vaccination coverage and immunization status of nurses: An interventional
study in Turkiye.
Vaccine. 2024 Mar 18:S0264-410X(24)00324-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DANGOR Z, Benson N, Berkley JA, Bielicki J, et al Vaccine value profile for Klebsiella pneumoniae.
Vaccine. 2024 Mar 18:S0264-410X(24)00248-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
OPMEER L, Gazzoli I, Ballmann M, Willemsen M, et al High throughput AS LNA qPCR method for the detection of a specific mutation in
poliovirus vaccine strains.
Vaccine. 2024 Mar 18:S0264-410X(24)00130-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al COVID-19 vaccination in cancer patients: Immune responses one year after the
third dose.
Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FIERRO C, Weidenthaler H, Vidojkovic S, Schmidt D, et al Safety and immunogenicity of a novel trivalent recombinant MVA-based equine
encephalitis virus vaccine: A Phase 1 clinical trial.
Vaccine. 2024 Mar 16:S0264-410X(24)00296-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HARTMEIER PR, Ostrowski SM, Busch EE, Empey KM, et al Lymphatic distribution considerations for subunit vaccine design and development.
Vaccine. 2024 Mar 16:S0264-410X(24)00320-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
FIX J, Christopher Mast T, Smith K, Baker N, et al Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
COTTON SA, Subramanian A, Hughes TD, Huang Y, et al The effect of SARS-COV-2 variant on non-respiratory features and mortality among
vaccinated and non-fully vaccinated patients.
Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JUNEAU C, Fall E, Bros J, Le Duc-Banaszuk AS, et al Do boys have the same intentions to get the HPV vaccine as girls? Knowledge,
attitudes, and intentions in France.
Vaccine. 2024 Mar 14:S0264-410X(24)00256-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CAMERON DB, Grage L, Van Wyck R, Edwards A, et al Identifying trusted local sources and predicting behavior change pathways
according to COVID-19 vaccination status: Results of a 2022 statewide survey of
Alaskan adults.
Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MACKENZIE GA, Hossain I, Salaudeen R, Badji H, et al Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal
carriage in the Gambia: Population-based cross-sectional surveys.
Vaccine. 2024 Mar 14:S0264-410X(24)00225-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al Predicting intention to vaccinate against COVID-19 in older Syrian refugees in
Lebanon: Findings from a multi-wave study.
Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al The effect of a financial incentive on COVID-19 vaccination uptake, and
predictors of uptake, in people experiencing homelessness: A randomized
controlled trial.
Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SAKAUE T, Sugawara T, Mukasa K, Nohara M, et al Varicella outbreak at nursery school under routine immunization in Japan in 2017
and 2018 and vaccine effectiveness.
Vaccine. 2024 Mar 12:S0264-410X(24)00250-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHEUNG DH, Chen S, Fang Y, Sun F, et al Influences of mpox disease perceptions, sources and contents of information
exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex
with men in Hong Kong, China.
Vaccine. 2024 Mar 12:S0264-410X(24)00259-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHERMAN SM, Allerton-Price C, Lingley-Heath N, Lai J, et al UK healthcare professionals' attitudes towards the introduction of varicella
vaccine into the routine childhood vaccination schedule and their preferences for
administration.
Vaccine. 2024 Mar 12:S0264-410X(24)00274-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RUSS S, Myers C, Licherdell E, Bowden A, et al Sociodemographic and Occupational Characteristics Associated with Early and
Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MERDRIGNAC L, Ait El Belghiti F, Pandolfi E, Acosta L, et al Effectiveness of one and two doses of acellular pertussis vaccines against
laboratory-confirmed pertussis requiring hospitalisation in infants: Results of
the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015
- December 201
Vaccine. 2024 Mar 11:S0264-410X(24)00272-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHIJIA YAN A, Jay Sehgal N Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among
Parents/Guardians and vaccine uptake among children in the U.S.
Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SENPUKU K, Kataoka-Nakamura C, Kunishima Y, Hirai T, et al An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN
or AddaVax elicits potent protective immunity in mice.
Vaccine. 2024 Mar 11:S0264-410X(24)00303-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MORO PL, Carlock G, Fifadara N, Habenicht T, et al Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the
vaccine adverse event reporting System - United States, September 1, 2022 - March
31, 2023.
Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
HARRELL JE, Roy CJ, Gunn JS, McLachlan JB, et al Current vaccine strategies and novel approaches to combatting Francisella
infection.
Vaccine. 2024 Mar 8:S0264-410X(24)00264-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SU YW, Qiu YZ, Wang YH, Xu Y, et al Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2
mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A
randomised, double-blinded, active-controlled phase 1 trial.
Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LUISI M, Geana MV, Pei J Pandemic antecedents - Exploring predictivity and relationships between COVID-19
vaccine uptake and influenza, shingles, and HPV vaccination.
Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BROUSSEAU N, Angers-Goulet ME, Bastien R, Ye L, et al Vaccination during pregnancy and modulation of IgG response to pertussis vaccines
in infants: The impact of different vaccine formulations.
Vaccine. 2024 Mar 8:S0264-410X(24)00300-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli
filaments and the highly conserved M2e epitope confers protection against
influenza a virus in mice.
Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GHASEMIFAR S, Chabak O, Piri-Gharaghie T, Doosti A, et al PIRES2-EGFP/CTB-UreI vaccination activated a mixed Th1/Th2/Th17 immune system
defense towards Helicobacter pylori infection in the BALB/c mice model.
Vaccine. 2024 Mar 7:S0264-410X(24)00209-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
Expression of Concern: "Cross-protection against H7N9 influenza strains using a
live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages
108-116].
Vaccine. 2024;42:1851. PubMed
Expression of Concern: "Human COBRA 2 vaccine contains two major epitopes that
are responsible for eliciting neutralizing antibody responses against
heterologous clades of viruses" [Vaccine Volume 38, Issue 4, 22 January 2020,
Pages 830-839].
Vaccine. 2024;42:1850. PubMed
DE WAELE A, Hendrickx G, Valckx S, Dominguez A, et al The Vaccine Training Barometer: Assessing healthcare providers' confidence to
answer vaccine-related questions and their training needs.
Vaccine. 2024 Mar 7:S0264-410X(24)00254-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SIREK G, Ulysse S, Jacques Toussaint M, Nosamiefan C, et al A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian
Creole.
Vaccine. 2024 Mar 7:S0264-410X(24)00257-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GILBERT PB, Fong Y, Hejazi NS, Kenny A, et al Four statistical frameworks for assessing an immune correlate of protection
(surrogate endpoint) from a randomized, controlled, vaccine efficacy trial.
Vaccine. 2024 Mar 7:S0264-410X(24)00247-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MALDONADO I, Rodriguez Nino N, Valencia CF, Ortiz D, et al Evaluation of the safety profile of the quadrivalent vaccine against human
papillomavirus in the risk of developing autoimmune, neurological, and
hematological diseases in adolescent women in Colombia.
Vaccine. 2024 Mar 7:S0264-410X(24)00263-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZIBOLENOVA J, Malobicka E, Ulbrichtova R, Novak M, et al Probability of exposure to the wild measles virus in adult population -
Estimation from seroepidemiology and historical data.
Vaccine. 2024;42:1648-1655. PubMedAbstract available
HYAMS C, Lahuerta M, Theilacker C, King J, et al Surveillance of pneumococcal serotypes in adults hospitalised with acute lower
respiratory tract infection in Bristol, UK.
Vaccine. 2024;42:1599-1607. PubMedAbstract available
MENG L, Harris L, Shaw L, Lymon H, et al Social and demographic factors associated with receipt of a COVID-19 vaccine
initial booster dose and with interval between primary series completion and
initial booster dose uptake among persons aged >/= 12 years, United States, August
2021-October 2
Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KARRAS J, Harrison M, Steffens M, Abdi I, et al "COVID is a huge jigsaw puzzle that I am trying to make sense of myself":
Exploring the perceptions towards the COVID-19 vaccine communication strategy in
Australia amongst unvaccinated Australian adults.
Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
WONG WHS, Leung DL, Yip KM, So HK, et al Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less
than 3 years old during Omicron wave in Hong Kong.
Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country
cohort event monitoring study.
Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al Association of COVID-19 vaccination with duration of hospitalization in older
adults in Hong Kong.
Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria
vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BEAVIS AC, Dienger-Stambaugh K, Briggs K, Chen Z, et al A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in
mice.
Vaccine. 2024 Mar 4:S0264-410X(24)00227-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DUAN X, Zhang L, Ding L, Zhang C, et al Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease
profile of post-vaccination infection.
Vaccine. 2024 Mar 2:S0264-410X(24)00172-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZAMAN K, Schuind AE, Adjei S, Antony K, et al Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in
girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
Vaccine. 2024 Mar 1:S0264-410X(24)00251-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy
at point of care.
Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
February 2024
YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al Immunogenicity and safety of a quadrivalent recombinant influenza vaccine
manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind,
non-inferiority, randomized controlled trial.
Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KOHLI M, Maschio M, Lee A, Igarashi A, et al Projections of the incidence of COVID-19 in Japan and the potential impact of a
Fall 2023 COVID-19 vaccine.
Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al An overview of the COVID-19 pediatric vaccine program - The U.S. experience
vaccinating children ages 6 months through 17 years.
Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
LEVIN MJ, Ginde AA, Schmid DS, Lang N, et al Effect of high dose vitamin D supplementation on subsequent immune responses to
administration of the live herpes zoster vaccine to long-term care residents.
Vaccine. 2024 Feb 28:S0264-410X(24)00214-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MARINDA E, Mathentamo Q, Coulson N, Parker S, et al Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake
in Kwazulu-Natal, South Africa.
Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
OMAR ALI S, Dessart C, Parikh R Co-administration of the adjuvanted recombinant zoster vaccine with other adult
vaccines: An overview.
Vaccine. 2024 Feb 28:S0264-410X(24)00194-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GUO J, Chen X, Guo Y, Liu M, et al Real-world effectiveness of seasonal influenza vaccination and age as effect
modifier: A systematic review, meta-analysis and meta-regression of test-negative
design studies.
Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
ZHOU W, Guo X, Lu J, Lu X, et al Parental willingness to accept and pay human papillomavirus vaccine for boys aged
9-14 in a metropolis area of China: Evidence for developing a vaccination
strategy.
Vaccine. 2024 Feb 28:S0264-410X(24)00253-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JACKSON S, Kabir Z, Comiskey C Retrospective cohort study exploring the impact of universal Tuberculosis (TB)
vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
Vaccine. 2024 Feb 28:S0264-410X(24)00220-2. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al Intensification of integrated immunization services to recover routine
vaccination coverage and bring COVID-19 vaccine to the population of Iraq in
2022.
Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TANAKA M, Okubo R, Hoshi SL, Kondo M, et al Cost-effectiveness analysis of pertussis booster vaccination for adolescents in
Japan.
Vaccine. 2024 Feb 27:S0264-410X(24)00199-3. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
GIDENGIL C, Scherer AM, Parker AM, Gedlinske A, et al Lyme disease vaccine attitudes and intentions among parents of children aged 5-18
years in the United States.
Vaccine. 2024 Feb 27:S0264-410X(24)00105-1. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
YANG XY, Liu T, Jiang SC, Zhang ZW, et al Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human
muscle cells and neuroglial cells.
Vaccine. 2024;42:1259-1267. PubMedAbstract available
MUNDO ORTIZ A, Nasri B Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring
differences across the Health Region model.
Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KEGELE LIGNANI L, de Vasconcellos Carvalhaes de Oliveira R, Matos Dos Santos E, Antonio Bastos Camacho L, et al Neutralizing antibody titers against D8 genotype and persistence of measles
humoral and cell-mediated immunity eight years after the first dose of measles,
mumps, and rubella vaccine in Brazilian children.
Vaccine. 2024 Feb 26:S0264-410X(24)00219-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC Rabies vaccination of the Maxakali indigenous population.
Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023. PubMed
KRISTINSDOTTIR I, Haraldsson A, Thors V Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of
influenza in pregnant women and their infants.
Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al The association between influenza vaccination uptake and influenza and
pneumonia-associated deaths in the United States.
Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
BIJUKCHHE SM, Gurung M, Pokhrel B, Shakya M, et al Immune responses to typhoid conjugate vaccine in a two dose schedule among
Nepalese children <2 years of age.
Vaccine. 2024 Feb 22:S0264-410X(24)00156-7. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al Influenza vaccine effectiveness against hospitalizations associated with
influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November
2023.
Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al Audiovestibular adverse events following COVID-19 vaccinations.
Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for
data collection, analysis, and presentation of immunisation safety data.
Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024. PubMedAbstract available
DREYFUS J, Munnangi S, Bengtsson C, Correia B, et al Background incidence rates of health outcomes in populations at risk for Lyme
disease using US administrative claims data.
Vaccine. 2024;42:1094-1107. PubMedAbstract available
PREVOT-MONSACRE P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, et al What is the relevancy of a surveillance of mumps without a systematic laboratory
confirmation in highly immunized populations? Epidemiology of suspected and
biologically confirmed mumps cases seen in general practice in France between
2014 and 2020.
Vaccine. 2024;42:1065-1070. PubMedAbstract available
November 2023
ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al Childhood vaccination coverage and regional differences in Swiss birth cohorts
2012-2021: Are we on track?
Vaccine. 2023;41:7226-7233. PubMedAbstract available
FLANDES X, Hansen CA, Palani S, Abbas K, et al Vaccine value profile for Chikungunya.
Vaccine. 2023 Nov 7:S0264-410X(23)00915-5. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
HOTEZ PJ, Bottazzi ME, Kaye PM, Lee BY, et al Neglected tropical disease vaccines: hookworm, leishmaniasis, and
schistosomiasis.
Vaccine. 2023;41 Suppl 2. PubMed
UGHASORO MD, Nnakenyi I, Echendu N, Akpeh JO, et al Neutralizing anti-polio antibody titre in newborn babies in post-polio
eradication period in Nigeria.
Vaccine. 2023;41:6820-6823. PubMedAbstract available
DO LAH, Le NTN, Mahmud S, Mulholland K, et al Impact and cost-effectiveness of strategies to prevent respiratory syncytial
virus (RSV) disease in Vietnam: A modelling study.
Vaccine. 2023;41:6782-6790. PubMedAbstract available
October 2023
CORSTEN C, Vang ZM, Gold I, Goldenberg MJ, et al Understanding COVID-19 vaccine hesitancy in Canada.
Vaccine. 2023 Oct 27:S0264-410X(23)01260-4. doi: 10.1016/j.vaccine.2023. PubMedAbstract available
LI J, Shi LW, Li K, Huang LR, et al Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18
vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A
randomized, double-blind, non-inferiority clinical trial.
Vaccine. 2023;41:7212-9. PubMedAbstract available
MULLER T, Wallace RM, Freuling CM Rabies importation in dogs and reduction of waiting period - The fear for
scientifically justified changes.
Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023. PubMed